

# Quality indicators of Clinical Cancer Care (QC<sub>3</sub>) in colorectal cancer

Journal:	BMJ Open
Manuscript ID:	bmjopen-2013-002818
Article Type:	Research
Date Submitted by the Author:	01-Mar-2013
Complete List of Authors:	Bianchi, Valentina; Cantonal Institute of Pathology, Ticino Cancer Registry Spitale, Alessandra; Cantonal Institute of Pathology, Ticino Cancer Registry Mazzucchelli, Luca; Cantonal Institute of Pathology, Clinical Pathology Ortelli, Laura; Cantonal Institute of Pathology, Ticino Cancer Registry Bordoni, Andrea; Cantonal Institute of Pathology, Ticino Cancer Registry
<b>Primary Subject Heading</b> :	Qualitative research
Secondary Subject Heading:	Oncology
Keywords:	QUALITATIVE RESEARCH, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Gastrointestinal tumours < ONCOLOGY, Gastrointestinal tumours < GASTROENTEROLOGY



## **Original Article**

## Quality indicators of Clinical Cancer Care (QC<sub>3</sub>) in colorectal cancer

Valentina Bianchi<sup>1</sup>, Alessandra Spitale<sup>1</sup>, Luca Mazzucchelli<sup>2</sup>, Laura Ortelli<sup>1</sup>, Andrea Bordoni<sup>1</sup> and the QC<sub>3</sub> CRC Working Group<sup>3</sup>

<sup>1</sup>Cantonal Institute of Pathology, Ticino Cancer Registry, 6600 Locarno, Switzerland <sup>2</sup>Cantonal Institute of Pathology, Clinical Pathology, 6600 Locarno, Switzerland <sup>3</sup>Members of the QC<sub>3</sub> Colorectal Working Group are listed in the Appendix

## Running title: Quality indicators of clinical care in colorectal cancer

#### **Corresponding author:**

Valentina Bianchi, M.D., Cantonal Institute of Pathology, Ticino Cancer Registry, , Via in Selva 24, 6600 Locarno, Switzerland - e-mail: <u>valentina.bianchi-galdi@ti.ch</u>; phone: +41 91 8160826; fax: +41 91 8160829

*Key words:* quality of cancer care, colorectal cancer, quality indicators, cancer registry, population-based study

## Word count: 2811

## ABSTRACT

**Objectives:** Assessing the quality of cancer care (QoCC) has become increasingly important to providers, regulators and purchasers of care worldwide. Aim of this study was to develop evidence-based quality indicators (QI) for colorectal cancer (CRC) to be applied in a population-based setting.

**Design:** A comprehensive evidence-based literature search was performed to identify the initial list of QI, which were then selected and developed using a two-step modified Delphi process involving two multidisciplinary expert panels with expertise in colorectal cancer care, quality of care and epidemiology.

Setting: The  $QC_3$  population-based project, which involve all the public and private hospitals and clinics present on the territory of Canton Ticino (South Switzerland).

**Participants:** Ticino Cancer Registry, The Colorectal Cancer Working Group (CRC-WG) and the external academic Advisory Board (AB).

**Main outcome measures:** Set of quality indicators (QI) which encompass the whole diagnostictreatment process of colorectal cancer.

**Results:** Of the 149 QI emerged from 181 sources of literature, 104 were selected during the inperson meeting of the CRC-WG. During the Delphi process, the CRC-WG shortened the list to 89 QI. The AB finally validated 27 QI according to the phase of care: diagnosis (N=6), pathology (N=3), treatment (N=16), and outcome (N=2).

**Conclusions:** Using the validated Delphi methodology, including literature review of the evidence and integration of expert opinions from local clinicians and international experts we were able to develop a list of QI to assess QoCC for CRC. This will hopefully guarantee feasibility of data retrieval, acceptance and translation of QI into the daily clinical practice to improve QoCC. Moreover, evidence-based selected QI allow to assess immediate changes and improvements in the diagnostic-therapeutic process that could be translated in a short-term benefit for patients with a possible gaining both in overall and disease-free survival.

## **ARTICLE SUMMARY**

## **Article focus**

- Quality of Cancer care (QoCC) studies on specific quality indicators (QI) developed worldwide since the late '90s showed both a continuous improvement of oncologic care provided by the clinical structures involved and an increased availability of specialized care in the considered areas.
- This study aims to define evidence-based QI for colorectal cancer care (CRC), in order to favour the evaluation of the oncologic diagnostic-therapeutic process, which can be followed by the definition of standards of care for each QI, in terms of minimum and target requirements.

## Key messages

- QI should be defined, developed and tested with scientific evidence-based rigor in a careful and transparent manner, taking into account their degree of relevancy, validity, reliability and feasibility.
- The selected CRC QI can be applied in a population-based setting, implying the inclusion of the elderly, considering age an extremely important determinant of treatment.

## Strengths and limitations of this study

- To develop the CRC QI we used a formal iterative process, the RAND/UCLA Appropriateness Methodology widely diffused and validated within other QoCC research. The selected QI are representative of the main steps of the diagnostic-therapeutic process.
- Due to the evidence that research studies demonstrated that single-discipline panels select different indicators than do multidisciplinary panels and to maximize the applicability of CRC QI, we constituted two panels of experts, a local Working Group and an external national/international academic Advisory Board, which could offer a multidisciplinary perspective on practice and who can guarantee that the selected QI and their results will be comparable with national and international data.

• The possible limitation of the current work is the level of evidence found in the literature. However this situation is common to many aspects of health care, and it was the reason that the expert panel methodology was developed – specifically, to identify the processes that are most likely to be valid measures of quality when the highest level of evidence is not available

to been to liek only

#### **BMJ Open**

## INTRODUCTION

Research on QoCC performed during the last decade has demonstrated that the increase in knowledge on treatments with proven efficacy do not directly translate into optimal delivery of such treatments to patients. Moreover, accumulating evidence suggests that underuse and overuse of care may occur for patients with cancer.[1-2] In addition to survival analysis, to evaluate and compare quality of care at the population-based level, the assessment of QoCC has become increasingly important to providers, regulators and purchasers of care to growing demand for services, rising costs, constrained resources and evidence of variation in clinical practice.[3]

QoCC studies and structured programmes on specific quality indicators (QI) have been developed worldwide since the late '90s, showing both a continuous improvement of oncologic care provided by the clinical structures involved and an increased availability of specialized care in the considered areas. Most of these studies have been implemented at the regional level on a territory with uniform legislative, health and geographical characteristics, increasing the likelihood of recruitment of involved clinicians.[1, 4-7]

So far, in Switzerland no population-based study on QoCC with a prospective design has been implemented. In addition to the yearly renewed international guidelines for each type of cancer, there is still the need to evaluate the real conditions of care in the community. Population-based Cancer Registry data are therefore essential to describe and reflect real world and routine care as well as to provide regular feedback to healthcare workers and decision makers about the management of a disease in the daily practice and those treatments that are routinely prescribed and/or effective in all patient groups.[8] Moreover, Cancer Registries represent an independent observatory, thus assuring a fair evaluation service, avoiding any conflicts of interest.

We, therefore, implemented the  $QC_3$  project, focusing on QoCC about the diagnosis-treatment process in colon-rectum, prostate, uterus, ovary and lung cancers in the territory of Canton Ticino (South Switzerland).

### **BMJ Open**

Colorectal cancer (CRC) is an important health issue worldwide. It is the most common malignancy in Europe (excluding non-melanoma skin cancers) and the second most common in terms of cancerrelated mortality.[9] In Switzerland, CRC is the second and third most frequent tumour in women and men, respectively. About 4000 CRC cases are diagnosed annually, corresponding to a European age-standardized incidence rate equal to 49.4 and 30.6 cases per 100'000 inhabitants in men and women, respectively, and representing the 11% of all tumours.[10-12] CRC is the third leading cancer cause of death in Switzerland, with approximately 1600 deaths/year, corresponding to a European age-standardized mortality rate equal to 18.5 and 10.6 cases per 100'000 inhabitants in men and women, respectively. With a 5-year survival probability equal to 60%, Switzerland is the country with the most favourable prognosis in Europe.[13] A recent Swiss report with follow up to 2009 show an additional 5 year survival increase to 62%.[11] The aims of the QC<sub>3</sub> study are the following: 1) to define evidence-based QoCC indicators for the

tumour localizations above cited, in order to favour an improvement of the short-term oncologic diagnostic-therapeutic process; 2) to define and implement at the regional level standards of care for each QoCC measure, in terms of minimum and target requirements. In the present report we will describe the initial part of the  $QC_3$  project, meaning the process followed to identify the panel of specific QoCC indicators for the CRC, as well as the list of QoCC indicators identified and approved both by a dedicated Working Group of local health care providers and by an external independent academic Advisory Board.

#### **BMJ Open**

## MATERIAL AND METHODS

The QC<sub>3</sub> project is a prospective, descriptive study on the QoCC to be implemented in a populationbased setting; it is performed by the Ticino Cancer Registry on a 3-year time period (2011-2013) on the territory of Canton Ticino (South Switzerland). In this paper we focus on the initial part of the project: the identification of the CRC quality indicators which will be used to evaluate the QoCC about CRC in our region.

Quality indicators (QI) for CRC were developed involving a local expert panel, named QC<sub>3</sub> Colorectal Working Group (CRC-WG). Elected members, selected on the basis of their expertise and on their daily clinical involvement in CRC care, were contacted to have their interest confirmed in being involved. The final QC<sub>3</sub> CRC-WG encompassed two pathologists, four gastroenterologists, two oncologists, three surgeons, two radiologists, two radiation oncologists and one nuclear medicine specialist, for a total of 15 panellists all working in the public or in the private hospitals and clinics of Canton Ticino (see Appendix 1).

Published studies and references were identified through a comprehensive search on PubMed/MEDLINE. For each of the identified candidate indicators, we performed a systematic literature review to identify the highest level of evidence supporting the validity of that quality indicator for articles published from 1990 onwards. The reference list of the included articles were also examined to identify any additional article that had not been identified in the MEDLINE search. We included all the peer-reviewed articles, but case reports, letters, abstracts or editorials. If evidence at the highest level were limited or absent, then lower levels of evidence were evaluated. For example, if data were not available from randomized controlled trials, cohort or case-control studies, case series and expert opinion or clinical guidelines were reviewed.

The initial QI list emerged from 181 sources of literature, and it was proposed to the CRC-WG in the context of an in-person meeting held at the very beginning of the process. The list was then left to the QC<sub>3</sub> CRC-WG's evaluation for a period of two weeks. The participants were asked to provide a whole opinion with written comments about those QI considered pertinent for the assessment of

## BMJ Open

CRC care quality, to suggest additional QI not already included in the list and to delete those QI considered not suitable. In order to make the selection and evaluation easier, the QI were subdivided in chapters recalling the Donabedian's and the National Initiative for Cancer Care Quality schemes: diagnosis and staging, pathology, treatment, follow-up, outcome.[2, 14]

## **Delphi Round 1**

The QI selection was done by using a 2-step modified Delphi process.[15] The initial list of QI, reanalyzed by the QC<sub>3</sub> CRC-WG, was formatted as a questionnaire, where for each indicator was specified the numerator, the denominator and the sources of evidence from which it was extracted. The questionnaire was distributed by regular mail to the QC<sub>3</sub> CRC-WG, so to maintain it anonymous, along with a stamped, addressed return envelope and an attached letter with the deadline date of two weeks from the receipt and the instruction for voting. Respondents were asked to rate each QI adopting the RAND Appropriateness Methodology (scale 1 to 9, 1 = extremely inappropriate; 9 = extremely appropriate), according to selection criteria of relevance, scientific soundness (validity, reliability, comparability) and feasibility (precise definition and specification, data feasibility, reliability of data collection).[16-18] Each QI was judged as validated if it reached a strong consensus for acceptance ( $\geq$ 70% of the QC<sub>3</sub> CRC-WG rated the QI with a vote  $\geq$ 7), discarded if it reached a strong consensus for exclusion ( $\geq$ 70% of the QC<sub>3</sub> CRC-WG rated the QI with a votes  $\leq$  3) and in stand-by if there was an unclear consensus (4  $\leq$  votes  $\leq$  6), which implies an eventual in-person meeting.

### Delphi Round 2

The Delphi Round 2 questionnaire was performed with the same modalities of the first round and enclosed the frequency distribution of round 1 votes, allowing the panellists to eventually alter their responses, in the light of colleagues' assessments.[16]

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

#### **BMJ Open**

The list of selected QI derived from the two Delphi rounds was then submitted to an independent external national/international academic multidisciplinary Advisory Board (AB), in order to get an additional evaluation on the suitability of QI as "quality" indexes according to the criteria shown in the previous paragraph. The intent was to achieve at least one health professional for each specialty. The AB included one pathologist, one gastroenterologist, two oncologists, two surgeons, one radiologist, one radiation oncologist, one nuclear medicine specialist and one epidemiologist, for a total of 10 experts in CRC care (see Acknowledgements); all the panellists are daily involved in the CRC care and they had been contacted with the same modalities of the QC<sub>3</sub> CRC WG. The selected QI as well as the corresponding literature sources were distributed to the AB as an electronic form where their opinion about QI were expressed both as megatrends (i.e. response yes/no to the suitability of each QI) and as eventual additional comments. We considered every single QI as finally approved by the AB if it achieved  $\geq$  70% of the agreement (i.e.  $\geq$  70% of respondents should have answered "yes") and if no doubtful comments about the QI had been expressed.

# RESULTS

The QI selection process began in January 2011 and ended in December 2011.

Participation of CRC-WG members throughout the process was high: 15 (100%) participated to the in-person meeting, 12 (80%) completed both the Delphi round 1 and 2. The Delphi Round 1 questionnaire respondent time were in the range of 18 to 60 days, while for the Round 2, the delay time was in the range of 8 to 55 days; these delays and the time for recruitment of the AB influence the long time spent for this part of the project.

The Figure 1 summarizes the entire process used to select QI for CRC care. The literature search produces 181 citations dealing with CRC QoCC. From this search, we initially selected a total of 149 QI, which were proposed to the CRC-WG in the context of the initial in-person meeting. The following discussion and revision reduced the list to 104 QI before the modified Delphi process started; these QI were divided into the following areas: diagnosis and staging, pathology, treatment, follow-up and outcome. After the whole Delphi process the list was shortened to 89 QI, distributed as following: diagnosis and staging (N=16), pathology (N=20), treatment (N=38), follow-up (N=10), and outcome (N=5). The QI finally underwent to the AB's evaluation; this last step, according to the procedure described in the Methods, shortened the final list to 27 QI (Tab.1): diagnosis (N=6), pathology (N=3); treatment (N=16), follow-up (N=0), and outcome (N=2).

#### **BMJ Open**

## DISCUSSION

In the preliminary phase of the  $QC_3$  project shown in this paper we developed a panel of evidencebased CRC QI which are suitable to be implemented in a population-based setting.

To develop the QC<sub>3</sub> QI we used a formal iterative process, the RAND/UCLA Appropriateness Methodology widely diffused and validated within other QoCC research.[16-17] Due to the evidence that research studies demonstrated that single-discipline panels select different indicators than do multidisciplinary panels and to maximize the applicability of QC<sub>3</sub> CRC QI, we constituted a working group which could offer a multidisciplinary perspective on practice, including specialists, professionals, clinicians and researchers coming from both public and private hospitals.[19-25] Moreover, we have used a further validation step enrolling an independent national/international academic AB. This choice was due to the aim of measuring QoCC within a Swiss region, and of obtaining results which will be comparable with national and international data. We believe that the expertise and multidisciplinary representativeness of the QC<sub>3</sub> CRC-WG and of the AB will surely increase quality, acceptance and translation of QI into the daily clinical practice.

The selected QI are representative of the main steps of the diagnostic-therapeutic process. The diagnosis QI reflect the importance of a pre-operative evaluation and staging, reliable evaluation of the tumour localization and local invasion, and particularly for the rectal cancers, of a feasible and effective surgery. The pathology QI reflect the importance of a good communication between clinicians and pathologists in terms of patient's anamnesis and consequent evaluation of the effectiveness of a neo-adjuvant therapy; moreover, there is a need of standardization of the pathologic report following the international guidelines (e.g. take at least three samples of tumour during the macroscopy), not leaving any items unexplained or implicit. The treatment QI cover the general issues of surgery such as emergency, postoperative mortality and a multidisciplinary discussion of the clinical case; furthermore, they focus on the debate of the retrieved lymph nodes, on the timing between radiotherapy and surgery, on the adjuvant chemotherapy and on the attitude towards the metastatic patients. The two main items of the outcome chapter refers to the overall and

## **BMJ Open**

disease free survival. Concerning the QI about follow-up, AB did not finally include any of them. Indeed, although the follow-up procedures are suggested by several international guidelines, they are based on level II-III evidence and controversies remain regarding selection of optimal strategies for following up patients after potentially curative colorectal cancer surgery. [26-29]

The first limitation of the current work is the level of evidence found in the literature. For some indicators, strong evidence of their validity was not available from RCTs. However this situation is common to many aspects of health care, and it was the very reason that the expert panel methodology was developed – specifically, to identify the processes that are most likely to be valid measures of quality when the highest level of evidence is not available.[16, 30-31] Secondly, we may have missed some studies during the literature search and, consequently, some QI has not been proposed to the QC<sub>3</sub> CRC-WG since the beginning of the QI revision process. However, this limitation should have been overcome by the fact that the members of the QC<sub>3</sub> CRC-WG were likely to be very familiar with the literature, and had the opportunity to suggest other QI based on their experience. [7, 19-20, 32] Thus we integrated the best research evidence with clinical expertise, as reported by Sackett et al. [33] A further limit could be the feasibility of measuring QI in terms of data collection and calculation, which is immediately the next step. Actually, the QI selected by both the QC<sub>3</sub> CRC-WG and the AB represent an ideal set of criteria to measure the quality of CRC care; at the same time they both were concerned about the feasibility, validity and reliability of clinical data collection, necessary for the calculation of each single QI. This is the reason why most of the identified  $QC_3$  QI are common to many QoCC studies. In addition, we performed a retrospective preliminary pilot collection on the detailed and necessary incidence data of CRC occurred in 2011, realising that the measurement of most QI is feasible, whereas for some selected QI the retrieving of variables should be additionally tested. [34-35] Only the definitive results will give us the proportion of missing information, whose magnitude will be assessed.

The selected QC<sub>3</sub> CRC QI will be applied in a population-based setting, where age is an extremely important determinant of treatment. The elderly are rarely included in the randomized clinical trials

Page 13 of 29

#### **BMJ Open**

with the consequence of a possible "underuse of treatment".[18, 36-37] At a broad European level, national audit registries in surgical oncology have led to improvements with a great impact and they offered the possibility, as for our project, to perform research on patients that are usually excluded from clinical trials such as elderly and co-morbid patients.[38-39] Evidence suggests that the relative benefits of treatment for the elderly are similar to those seen for cancer patients in general, though decision making for treatment becomes more complex as life expectancy, co-existing illnesses, and functional status all need to be considered.[18, 36-37] Applying these QI and if all these items will be satisfied we can affirm to have a real good quality process of CRC care for the whole population. The foreseeable future in quality evaluation and improvement for health care will likely involve more and more frequently the use of QI by regulatory and accrediting agencies, stakeholders, clinicians, individual hospitals and health care providers, as well as patients. This underlines that the QI should be defined, developed and tested with scientific evidence-based rigor in a careful and transparent manner, taking into account their degree of relevancy, validity, reliability and feasibility.[22, 24] Although QI have been defined in several different ways, all authors agreed that the final aim is the improvement of patients outcome.[23, 25, 40]

The systematic trend analysis of QI allows to assess immediate changes and improvements in the diagnostic-therapeutic process that could be translated in a short-term benefit for patient, without waiting for survival analysis typically needed some years to be produced because of the patients' follow-up. Furthermore, this system of evaluation and auto-evaluation could favour the surveillance and monitoring of the comprehensive level of the oncologic care in the region, the clinical performance homogeneity, the possible weakness of the clinical network, and finally the corrective interventions to be adopted to improve the QoCC.

With this study, we hope to increase the awareness of the value of QI in health care so to encourage more uniform practices and improve provider documentation of medical care in our region; moreover, we hope that standardization of QI among different regions will help to define threshold of minimal standard of care.

## **REFERENCE LIST**

- Malin JL, Schneider EC, Epstein AM, et al. Results of the National Initiative for Cancer Care Quality: how can we improve the quality of cancer care in the United States? J Clin Oncol 2006;24(4):626-34
  - doi: JCO.2005.03.3365 [pii]10.1200/JCO.2005.03.3365 [published Online First: Epub Date]].
- Schneider EC, Malin JL, Kahn KL, et al. Developing a system to assess the quality of cancer care: ASCO's national initiative on cancer care quality. J Clin Oncol 2004;22(15):2985-91 doi: 10.1200/JCO.2004.09.08722/15/2985 [pii][published Online First: Epub Date]].
- 3. Campbell SM, Roland MO, Buetow SA. Defining quality of care. Soc Sci Med 2000;**51**(11):1611-25
  - doi: S0277953600000575 [pii][published Online First: Epub Date]].
- Neuss MN, Desch CE, McNiff KK, et al. A process for measuring the quality of cancer care: the Quality Oncology Practice Initiative. J Clin Oncol 2005;23(25):6233-9 doi:JCO.2005.05.948 [pii]10.1200/JCO.2005.05.948 [published Online First: Epub Date]].
- Duvalko KM, Sherar M, Sawka C. Creating a system for performance improvement in cancer care: Cancer Care Ontario's clinical governance framework. Cancer Control 2009;16(4):293-302
- Mainz J, Hansen AM, Palshof T, et al. National quality measurement using clinical indicators: the Danish National Indicator Project. J Surg Oncol 2009;99(8):500-4 doi:10.1002/jso.21192[published Online First: Epub Date]|.
- 7. Gagliardi AR, Simunovic M, Langer B, et al. Development of quality indicators for colorectal cancer surgery, using a 3-step modified Delphi approach. Can J Surg 2005;48(6):441-52

doi: S0140-6736(03)15383-4 [pii]10.1016/S0140-6736(03)15383-4[published Online First: Epub Date]|.

- 9. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. 2010.
- 10. NICER. Secondary 2012. http://www.nicer.org.
- 11. Bordoni A, Lorez M, Bouchardy C, et al. Trends in colorectal cancer survival in Switzerland. Bulletin Suisse du Cancer 2012;1/2012:51-54
- 12. Bouchardy C, Lutz JM, Kühni C, et al. *I tumori in Svizzera*. *Situazione e sviluppi dal 1983 al 2007*. Neuchâtel: Ufficio Federale di Statistica (UFS), 2011.
- Sant M, Allemani C, Santaquilani M, et al. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 2009;45(6):931-91 doi: S0959-8049(08)00926-X [pii]10.1016/j.ejca.2008.11.018[published Online First: Epub Date]|.
- 14. Donabedian A. Evaluating the quality of medical care. Milbank Q 1966;83:691-729
- 15. Fink A, Kosecoff J, Chassin M, et al. Consensus methods: characteristics and guidelines for use. Am J Public Health 1984;74(9):979-83
- Jones J, Hunter D. Consensus methods for medical and health services research. BMJ 1995;**311**(7001):376-80
- Brook RH. The Rand/UCLA appropriateness method. In: McCormic KA, Moore SR, Siegel RA, eds. Clinical practice guideline development: methodology perspectives. Rockville, Md: Agency for Health Care Policy and Research, 1994:59-70.
- Krzyzanowska MK, Barbera L, Elit L, et al. Identifying population-level indicators to measure the quality of cancer care for women. Int J Qual Health Care 2011;23(5):554-64 doi: mzr043 [pii]10.1093/intqhc/mzr043[published Online First: Epub Date]].

59 60

1 2

## **BMJ Open**

2	
3	19. Leape LL, Park RE, Kahan JP, et al. Group judgments of appropriateness: the effect of panel
4	composition. Qual Assur Health Care 1992;4(2):151-9
5	20. Campbell SM, Hann M, Roland MO, et al. The effect of panel membership and feedback on
6 7	ratings in a two-round Delphi survey: results of a randomized controlled trial. Med Care
8	1999; <b>37</b> (9):964-8
9	21. Coulter I, Adams A, Shekelle P. Impact of varying panel membership on ratings of
10	appropriateness in consensus panels: a comparison of a multi- and single disciplinary panel.
11	Health Serv Res 1995; <b>30</b> (4):577-91
12	22. Wollersheim H, Hermens R, Hulscher M, et al. Clinical indicators: development and
13 14	applications. Neth J Med 2007; <b>65</b> (1):15-22
14	23. Mainz J. Defining and classifying clinical indicators for quality improvement. Int J Qual Health
16	Care 2003;15(6):523-30 24. Mainz J. Developing evidence-based clinical indicators: a state of the art methods primer. Int J
17	Qual Health Care 2003;15 Suppl 1:i5-11
18	25. Rubin HR, Pronovost P, Diette GB. From a process of care to a measure: the development and
19	testing of a quality indicator. Int J Qual Health Care 2001; <b>13</b> (6):489-96
20	26. Labianca R, Nordlinger B, Beretta GD, et al. Primary colon cancer: ESMO Clinical Practice
21	Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol 2010; <b>21</b> (suppl.
22 23	5):v70-v77
23 24	27. NCCN. Colon Cancer. 2.2011 ed: NCCN, 2011.
25	28. Pfister DG, Benson AB, 3rd, Somerfield MR. Clinical practice. Surveillance strategies after
26	curative treatment of colorectal cancer. N Engl J Med 2004; <b>350</b> (23):2375-82
27	doi: 10.1056/NEJMcp010529350/23/2375 [pii][published Online First: Epub Date]].
28	29. Li Destri G, Di Cataldo A, Puleo S. Colorectal cancer follow-up: useful or useless? Surg Oncol
29	2006; <b>15</b> (1):1-12
30 31	doi: S0960-7404(06)00025-9 [pii]10.1016/j.suronc.2006.06.001[published Online First:
32	Epub Date] .
33	30. Campbell SM, Braspenning J, Hutchinson A, et al. Research methods used in developing and
34	applying quality indicators in primary care. Qual Saf Health Care 2002;11(4):358-64
35	31. McGory ML, Shekelle PG, Ko CY. Development of quality indicators for patients undergoing
36	colorectal cancer surgery. J Natl Cancer Inst 2006;98(22):1623-33
37	doi: 98/22/1623 [pii]10.1093/jnci/djj438[published Online First: Epub Date] .
38 39	32. Ayanian JZ, Landrum MB, Normand SL, et al. Rating the appropriateness of coronary
39 40	angiographydo practicing physicians agree with an expert panel and with each other? N
41	Engl J Med 1998; <b>338</b> (26):1896-904
42	doi: 10.1056/NEJM199806253382608[published Online First: Epub Date].
43	33. Sackett DL, Starus SE, Richardson WS, et al. Evidence-Based Medicine: How to Practice and
44	Teach. 2nd ed. London: Churchill Livingstone, 2000.
45	34. Qualità delle cure contro il cancro (QC3) nel territorio della Svizzera Italiana. Risultatai
46 47	preliminari dei tumori colorettali incidenti nel 2011. XXXVII GRELL Annual Meeting;
48	May 16-18, 2012 16-18 May 2012; Porto, Portugal.
49	35. QoCC Study: indicators of quality of cancer care in Southern Switzerland. 33rd IACR Annual
50	Meeting; October 11-13, 2011; Balaclava, Mauritius.
51	36. Bouchardy C, Rapiti E, Blagojevic S, et al. Older female cancer patients: importance, causes,
52	and consequences of undertreatment. J Clin Oncol 2007;25(14):1858-69
53	doi: 25/14/1858 [pii]10.1200/JCO.2006.10.4208[published Online First: Epub Date] .
54 55	37. Bouchardy C, Rapiti E, Fioretta G, et al. Undertreatment strongly decreases prognosis of breast
55 56	cancer in elderly women. J Clin Oncol 2003; <b>21</b> (19):3580-7
57	doi: 10.1200/JCO.2003.02.046 JCO.2003.02.046 [pii][published Online First: Epub Date] .
58	
59	
60	

15

- 38. van Gijn W, van de Velde CJ. 2010 SSO John Wayne clinical research lecture: rectal cancer outcome improvements in Europe: population-based outcome registrations will conquer the world. Ann Surg Oncol 2011;18(3):691-6 doi: 10.1245/s10434-010-1326-3[published Online First: Epub Date]].
- 39. van Gijn W, van de Velde CJ. Improving quality of cancer care through surgical audit. Eur J Surg Oncol 2010;36 Suppl 1:S23-6 doi: S0748-7983(10)00202-7
  - [pii]10.1016/j.ejso.2010.06.026[published Online First: Epub Date]].
- 40. Characteristics of clinical indicators. QRB Qual Rev Bull 1989;15(11):330-9
- 41. Wilkins T, Reynolds PL. Colorectal cancer: a summary of the evidence for screening and prevention. Am Fam Physician 2008;**78**(12):1385-92
- 42. Sikka V, Ornato JP. Cancer diagnosis and outcomes in Michigan EDs vs other settings. Am J Emerg Med 2011

doi: S0735-6757(10)00574-7 [pii]10.1016/j.ajem.2010.11.029[published Online First: Epub Date]|.

- 43. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008;134(5):1570-95 doi: S0016-5085(08)00232-1 [pii]10.1053/j.gastro.2008.02.002[published Online First:
- Epub Date]|. 44. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003;**124**(2):544-

doi: 10.1053/gast.2003.50044S0016508502158951 [pii][published Online First: Epub Date]|.

- 45. Majumdar SR, Fletcher RH, Evans AT. How does colorectal cancer present? Symptoms, duration, and clues to location. Am J Gastroenterol 1999;**94**(10):3039-45 doi: S0002927099005109 [pii]10.1111/j.1572-0241.1999.01454.x[published Online First: Epub Date]].
- 46. QOPI. Summary of the measures. Spring 2011. Secondary Summary of the measures. Spring 2011. 2011. <u>http://qopi.asco.org/Methodology</u>.
- 47. Smith N, Brown G. Preoperative staging of rectal cancer. Acta Oncol 2008;47(1):20-31 doi: 783360368 [pii]10.1080/02841860701697720[published Online First: Epub Date]].
- 48. Schneider PM, Vallbohmer D, Ploenes Y, et al. Evaluation of quality indicators following implementation of total mesorectal excision in primarily resected rectal cancer changed future management. Int J Colorectal Dis 2011;26(7):903-9 doi: 10.1007/s00384-011-1155-2[published Online First: Epub Date].
- 49. ACR. Practice Guidelines and Technical Standards. Secondary Practice Guidelines and Technical Standards 2011. <u>http://www.acr.org/guidelines</u>.
- 50. Taylor FG, Quirke P, Heald RJ, et al. Preoperative High-resolution Magnetic Resonance Imaging Can Identify Good Prognosis Stage I, II, and III Rectal Cancer Best Managed by Surgery Alone: A Prospective, Multicenter, European Study That Recruited Consecutive Patients With Rectal Cancer. Ann Surg 2011
  - doi: 10.1097/SLA.0b013e31820b8d52[published Online First: Epub Date]|.
- 51. Beets-Tan RG, Beets GL. Local staging of rectal cancer: A review of imaging. J Magn Reson Imaging 2011;**33**(5):1012-9
  - doi: 10.1002/jmri.22475[published Online First: Epub Date]|.
- 52. Bellows CF, Jaffe B, Bacigalupo L, et al. Clinical significance of magnetic resonance imaging findings in rectal cancer. World J Radiol 2011;3(4):92-104 doi: 10.4329/wjr.v3.i4.92[published Online First: Epub Date]|.

## **BMJ Open**

53. Ta	aylor FG, Quirke P, Heald RJ, et al. One millimetre is the safe cut-off for magnetic resonance imaging prediction of surgical margin status in rectal cancer. Br J Surg 2011; <b>98</b> (6):872-79
54. Lu	doi: 10.1002/bjs.7458[published Online First: Epub Date] . Igli A, Tornillo L, Cathomas G, et al. Colon et rectum. In: Dirnhofer S, Bubendorf L, Lehr H- A, et al., eds. Recommandations pour la qualité - SSPath. Bâle: Sociéte Suisse de
55. W	Pathologie, 2011. ashington K, Berlin J, Branton P, et al. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Vers. 3.1.0.0. In: Pathologists CoA, ed. Cancer protocols and Checklists, 2011.
56. M	acDonald AJ, McEwan H, McCabe M, et al. Age at death of patients with colorectal cancer and the effect of lead-time bias on survival in elective vs emergency surgery. Colorectal Dis 2011; <b>13</b> (5):519-25
57. As	doi: CDI2183 [pii]10.1111/j.1463-1318.2009.02183.x[published Online First: Epub Date] . scanelli S, Navarra G, Tonini G, et al. Early and late outcome after surgery for colorectal cancer: elective versus emergency surgery. Tumori 2003; <b>89</b> (1):36-41
58. Bi	ondo S, Marti-Rague J, Kreisler E, et al. A prospective study of outcomes of emergency and elective surgeries for complicated colonic cancer. Am J Surg 2005; <b>189</b> (4):377-83 doi: S0002-9610(05)00085-1 [pii]10.1016/j.amjsurg.2005.01.009[published Online First: Epub Date]].
59. Th	nompson GA, Cocks JR, Collopy BT, et al. Clinical indicators in colorectal surgery. J Qual Clin Pract 1996; <b>16</b> (1):31-5; discussion 37
60. M	orris EJ, Taylor EF, Thomas JD, et al. Thirty-day postoperative mortality after colorectal cancer surgery in England. Gut 2011; <b>60</b> (6):806-13
61. M	doi: gut.2010.232181 [pii]10.1136/gut.2010.232181[published Online First: Epub Date] . cArdle CS, McKee RF, Finlay IG, et al. Improvement in survival following surgery for colorectal cancer. Br J Surg 2005; <b>92</b> (8):1008-13 doi: 10.1002/bjs.4874[published Online First: Epub Date] .
62. Rı	<ul> <li>doi: 10.1002/0js.4874[published Online First: Epub Date]].</li> <li>atten HJ, den Dulk M, Lemmens VE, et al. Controversies of total mesorectal excision for rectal cancer in elderly patients. Lancet Oncol 2008;9(5):494-501</li> <li>doi: S1470-2045(08)70129-3 [pii]10.1016/S1470-2045(08)70129-3[published Online First: Epub Date]].</li> </ul>
63. Ro	Deput Dates].
64. Ku	urtz JE, Heitz D, Serra S, et al. Adjuvant chemotherapy in elderly patients with colorectal cancer. A retrospective analysis of the implementation of tumor board recommendations in a single institution. Crit Rev Oncol Hematol 2010;74(3):211-7 doi: S1040-8428(09)00120-6 [pii]10.1016/j.critrevonc.2009.05.003[published Online First: Epub Date]].
65. Ja	rry J, Faucheron JL, Moreno W, et al. Delayed colo-anal anastomosis is an alternative to prophylactic diverting stoma after total mesorectal excision for middle and low rectal carcinomas. Eur J Surg Oncol 2010; <b>37</b> (2):127-33 doi: S0748-7983(10)00607-4 [pii]10.1016/j.ejso.2010.12.008[published Online First: Epub
66. Ju	Date] . nginger T, Gonner U, Trinh TT, et al. Permanent stoma after low anterior resection for rectal cancer. Dis Colon Rectum 2010; <b>53</b> (12):1632-9 doi: 10.1007/DCR.0b013e3181ed0aae00003453-201012000-00007 [pii][published Online First: Epub Date] .
67. No	euman HB, Patil S, Fuzesi S, et al. Impact of a Temporary Stoma on the Quality of Life of Rectal Cancer Patients Undergoing Treatment. Ann Surg Oncol 2010 doi: 10.1245/s10434-010-1446-9[published Online First: Epub Date] .
	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

- 68. Ramirez JM, Aguilella V, Valencia J, et al. Transanal endoscopic microsurgery for rectal cancer. Long-term oncologic results. Int J Colorectal Dis 2011 doi: 10.1007/s00384-011-1132-9[published Online First: Epub Date]|.
- 69. Lezoche G, Guerrieri M, Baldarelli M, et al. Transanal endoscopic microsurgery for 135 patients with small nonadvanced low rectal cancer (iT1-iT2, iN0): short- and long-term results. Surg Endosc 2010
  - doi: 10.1007/s00464-010-1347-9[published Online First: Epub Date]|.
- 70. Doornebosch PG, Tollenaar RA, De Graaf EJ. Is the increasing role of Transanal Endoscopic Microsurgery in curation for T1 rectal cancer justified? A systematic review. Acta Oncol 2009;48(3):343-53
  - doi: 904089695 [pii]10.1080/02841860802342408[published Online First: Epub Date]].
- 71. Elferink MA, Siesling S, Lemmens VE, et al. Variation in Lymph Node Evaluation in Rectal Cancer: A Dutch Nationwide Population-Based Study. Ann Surg Oncol 2010 doi: 10.1245/s10434-010-1269-8[published Online First: Epub Date]].
- 72. Elferink MA, Siesling S, Visser O, et al. Large variation between hospitals and pathology laboratories in lymph node evaluation in colon cancer and its impact on survival, a nationwide population-based study in the Netherlands. Ann Oncol 2011;**22**(1):110-7 doi: mdq312 [pii]10.1093/annonc/mdq312[published Online First: Epub Date]|.
- 73. Kelder W, Inberg B, Schaapveld M, et al. Impact of the number of histologically examined lymph nodes on prognosis in colon cancer: a population-based study in the Netherlands. Dis Colon Rectum 2009;52(2):260-7

- 74. Vather R, Sammour T, Kahokehr A, et al. Lymph node evaluation and long-term survival in Stage II and Stage III colon cancer: a national study. Ann Surg Oncol 2009;16(3):585-93 doi: 10.1245/s10434-008-0265-8[published Online First: Epub Date]|.
- 75. Lindebjerg J, Spindler KL, Ploen J, et al. The prognostic value of lymph node metastases and tumour regression grade in rectal cancer patients treated with long-course preoperative chemoradiotherapy. Colorectal Dis 2009;11(3):264-9 doi: CDI1599 [pii]10.1111/j.1463-1318.2008.01599.x[published Online First: Epub Date]|.
- 76. Choi HK, Law WL, Poon JT. The optimal number of lymph nodes examined in stage II colorectal cancer and its impact of on outcomes. BMC Cancer 2010;10:267 doi: 1471-2407-10-267 [pii]10.1186/1471-2407-10-267 [published Online First: Epub Date]].
- 77. Nelson H, Petrelli N, Carlin A, et al. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 2001;**93**(8):583-96
- 78. Smith AJ, Driman DK, Spithoff K, et al. Guideline for optimization of colorectal cancer surgery and pathology. J Surg Oncol 2010;101(1):5-12 doi: 10.1002/jso.21395[published Online First: Epub Date]|.
- 79. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;**27**(19):3109-16
- doi: JCO.2008.20.6771 [pii]10.1200/JCO.2008.20.6771 [published Online First: Epub Date]|. 80. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon
- cancer. N Engl J Med 2005;**352**(26):2696-704 doi: 352/26/2696 [pii]10.1056/NEJMoa043116[published Online First: Epub Date]|.
- 81. Van Cutsem E, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009;**27**(19):3117-25
- doi: JCO.2008.21.6663 [pii]10.1200/JCO.2008.21.6663 [published Online First: Epub Date]|. 82. Sobrero A. Lower GI. In: ESMO, ed. ESMO HIghlights 2010, 2010.

doi: 10.1007/DCR.0b013e318197916400003453-200902000-00013 [pii][published Online First: Epub Date]].

## **BMJ Open**

1 2	
3	83. Des Guetz G, Nicolas P, Perret GY, et al. Does delaying adjuvant chemotherapy after curative
4	surgery for colorectal cancer impair survival? A meta-analysis. Eur J Cancer
5	2010;46(6):1049-55
6	doi: S0959-8049(10)00039-0 [pii]10.1016/j.ejca.2010.01.020[published Online First: Epub
7	Date] .
8	84. Dienstmann R, Vilar E, Tabernero J. Molecular predictors of response to chemotherapy in
9 10	colorectal cancer. Cancer J 2011;17(2):114-26
10	doi: 10.1097/PPO.0b013e318212f84400130404-201103000-00007 [pii][published Online
12	First: Epub Date].
13	85. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for
14	metastatic colorectal cancer. N Engl J Med 2009;360(14):1408-17
15	doi: 360/14/1408 [pii]10.1056/NEJMoa0805019[published Online First: Epub Date] .
16	86. Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and BRAF
17	mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J
18	Clin Oncol 2011; <b>29</b> (10):1261-70
19	

doi: JCO.2010.30.1366 [pii]10.1200/JCO.2010.30.1366 [published Online First: Epub Date]].

- 87. Van Cutsem E, Nordlinger B, Cervantes A. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol 2010;**21**(suppl. 5):v93-v97
- 88. Glimelius B, Holm T, Blomqvist L. Chemotherapy in addition to preoperative radiotherapy in locally advanced rectal cancer - a systematic overview. Rev Recent Clin Trials 2008;3(3):204-11
- 89. Glimelius B, Pahlman L, Cervantes A. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;**21**(suppl. 5):v82-v86
- 90. Landheer ML, Therasse P, van de Velde CJ. The importance of quality assurance in surgical oncology in the treatment of colorectal cancer. Surg Oncol Clin N Am 2001;10(4):885-914, x
- 91. Wagner G. Tumor-Lokalisationsschlüssel. International Classification of Diseases for Oncology ICD-O, 2. Topographischer Teil. 5th ed. Berlin: Springer-Verlag, 1993.

## **APPENDIX (List of Collaborators)**

Members of the QC<sub>3</sub> CRC Working Group are listed as following:

Barizzi J., Clinical Pathology, Cantonal Institute of Pathology, 6600 Locarno, Switzerland; Bihl F., Gastroenterology Dept., Ospedale Regionale Bellinzona e Valli, 6500 Bellinzona Switzerland; Christoforidis D., General Surgery Dept., Ospedale Regionale di Lugano, 6900 Lugano, Switzerland; Franzetti-Pellanda A., Radiation Oncology Dept., Clinica Luganese, 6900 Lugano, Switzerland; Giovanella L., Nuclear Medicine Dept., Oncology Institute of Southern Switzerland (IOSI), 6500 Bellinzona, Switzerland; Heinkel J., Radiology Dept., Ospedale La Carità, 6600 Locarno, Switzerland; Maffei M., Gastroenterology Dept., Ospedale Regionale di Lugano, 6900 Lugano, Switzerland; Mazzucchelli L., Clinical Pathology, Cantonal Institute of Pathology, 6600 Locarno, Switzerland; Miazza B., Gastroenterology Dept., Ospedale Regionale di Lugano, 6900 Lugano, Switzerland; Pelloni A., General Surgery Dept., Ospedale La Carità, 6600 Locarno, Switzerland; Quattropani C., Gastroenterology Dept., Clinica Luganese, 6900 Lugano, Switzerland; Rosso R., General Surgery Dept., Ospedale Regionale di Lugano, 6900 Lugano, Switzerland; Saletti P., Medical Oncology Dept., Oncology Institute of Southern Switzerland (IOSI), 6500 Bellinzona, Switzerland; Valli M. C., Radiation Oncology Dept., Oncology Institute of Southern Switzerland (IOSI), 6500 Bellinzona, Switzerland; Varini M., Medical Oncology Dept., Clinica Sant'Anna, 6900 Lugano, Switzerland; Wyttenbach R., Radiology Dept., Ospedale Regionale Bellinzona e Valli, 6500 Bellinzona, Switzerland.

## **FUNDING**

This work was supported by Krebsforschung Schweiz, grant number KFS – 02668-08-2010, and by Advisory Board Research Ente Ospedaliero Cantonale Bellinzona, grant number ABREOC 10/2010.

The funding sources have not any involvement in the study design, in the collection, analysis and interpretation of data, in the writing of the report and in the decision to submit the paper for publication.

## **COMPETING INTERESTS**

The Authors have no competing interests.

## **DATA SHARING**

railable. There is no additional data available.

### **AUTHORS' CONTRIBUTION**

I declare that V. Bianchi, A. Bordoni, A. Spitale and L. Mazzucchelli have directly participated in the planning of the manuscript; that V. Bianchi, A. Bordoni, A. Spitale and the QC<sub>3</sub> Colorectal Working Group have directly participated in the conducting of the project; that V. Bianchi, A. Bordoni, A. Spitale and L. Ortelli have directly participated in the reporting, acquisition of data or analysis and interpretation of data; and that V. Bianchi and A. Bordoni are responsible for the overall content as guarantors of the work. Finally, I declare that all the Authors have drafted and revised the paper critically for important intellectual content, and that they have given final approval of the version published. None of the Authors have competing interests.

## ACKNOWLEDGEMENTS

We are particularly grateful to the QC<sub>3</sub> CRC AB Members, who contribute to critically review the QC<sub>3</sub> CRC QI, for their precious collaboration:

Prof. Franco Cavalli, Scientific Director, Oncologic Institute of Italian Switzerland (IOSI), Bellinzona, Switzerland; Prof. Gian Dorta, Director, Digestive Endoscopy Dept., Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland; Prof. Jean Faivre, Director, Registre Bourguignon des Cancers Digestifs, Dijon Cedex , France; Prof. Stefano Fanti, Director, PET Center, Policlinico S. Orsola-Malpighi, Bologna, Italy; Prof. Roberto Labianca, Director, Oncology and Haematology Dept., Ospedali Riuniti, Bergamo, Italy; Prof. Sebastiano Martinoli, Director, General Surgery Dept., Clinica Luganese, Lugano, Switzerland; Prof. Philip Quirke, Director, Leeds Institute of Molecular Medicine (LIMM), Section of Pathology, Wellcome Trust Brenner Building, St James's University Hospital, Leeds, United Kingdom; Prof. Emmanuel Tiret, Chef Pôle Digestif des Hôpitaux Univesitaires Paris Est, Chef Service de Chirurgie Générale et Digestive, Hôpital Saint-Antoine, Paris, France; Prof. Vincenzo Valentini, Director, Unità

#### **BMJ Open**

Operativa Complessa Radioterapia 1, Policlinico Universitario Agostino Gemelli, Rome, Italy; Prof. Dominik Weishaupt, Director, Radiology Dept., Stadtspital Triemli, Zürich, Switzerland.

## 

## COPYRIGHT


The Corresponding Author has the right to grant on behalf of all Authors and does grant on behalf of all Authors, an exclusive licence on a worldwide basis to the BMJ Publishing Group Ltd, and its Licensees to permit this article (if accepted) to be published in BMJ Open and any other BMJPGL products to exploit all subsidiary rights, as set out in your licence and the Corresponding Author accepts and understands that any supply made under these terms is made by BMJPGL to the ng Author. Corresponding Author.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

## **BMJ Open**

FIGURE 1 - Process used to select quality indicators for colorectal cancer care

QI = Quality Indicators; QC<sub>3</sub> CRC-WG = QC3 Colorectal Cancer Working Group; AB = Advisory Board



## Figure 1. Process used to select quality indicators for colorectal cancer care

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

# Table 1. Quality indicators of colorectal cancer care according to diagnostic-

# therapeutic process (diagnosis, pathology, treatment, outcome) and tumour site

TUMOUR SITE	QUALITY INDICATOR	DENOMINATOR	REFERENCES
DIAGNOSIS	(n=6)		
C&R	Proportion of patients with colorectal cancer and diagnosis based on symptoms <i>vs</i> screening <i>vs</i> accidental finding	Patients with colorectal cancer	[41-45]
C&R	Proportion of patients with colorectal cancer, evaluated by preoperative colonoscopy	Patients with colorectal cancer undergoing surgery	[7, 26-27, 46]
R	Proportion of patients with rectal cancer and description of the tumour localization (distance <i>ab ano</i> ) in the endoscopic/pathologic documentation	Patients with rectal cancer undergoing endoscopy	[1, 47-48]
C&R	Proportion of patients with colorectal cancer and requests for an initial CT and/or a MRI examination completed by clinical information according to the ACR guidelines	Patients with colorectal cancer undergoing initial CT and/or MRI examination	[7, 49]
R	Proportion of patients with low rectal # cancer undergoing pelvic MRI of staging	Patients with low rectal cancer	[50-52]
R	Proportion of patients with rectal cancer and a preoperative MRI reporting the description of the radial margin status (mm)	Patients with rectal cancer undergoing preoperative MRI	[53]
PATHOLOG	Y (n=3)	4	
R	Proportion of patients with rectal cancer for which the request for the pathological examination includes the information of neo-adjuvant RT±ChT	Patients with rectal cancer undergoing neo-adjuvant RT±ChT and surgery	Proposed by CRC-WG
C&R	Proportion of patients with colorectal cancer and a sufficient number of tumour samples ( $\geq 3$ )	Patients with colorectal cancer undergoing surgery	Proposed by CRC-WG
C&R	Proportion of patients with colorectal cancer and a definitive pathological report including the following characteristics: surgical intervention, sample length, tumour localization according to WHO, tumour size, histological type according to WHO, histological grade, resection margins, lympho-vascular invasion, perineural invasion, tumour deposits (discontinuous extramural extension), pathological staging (AJCC pTNM), number of retrieved lymph nodes, treatment effect, macroscopic integrity of the mesorectum (for rectum only)	Patients with colorectal cancer undergoing surgery	[54-55]

TREATM	ENT (n=16)		
C&R	Proportion of patients with colorectal cancer operated in emergency <sup>§</sup>	Patients with colorectal cancer undergoing surgery	[56-58]
C&R	Proportion of patients with colorectal cancer and dead within 30 days and 6 months from the surgery (postoperative mortality)	Patients with colorectal cancer undergoing surgery	[59-62]
C&R	Proportion of patients with colorectal cancer and postoperative multidisciplinary discussion	Patients with colorectal cancer undergoing surgery	[63-64]
R	Proportion of patients with malignant rectal polyp (pT1) and complete endoscopic polypectomy	Patients with malignant rectal polyp (pT1)	Proposed by the CRC-WG
R	Proportion of patients with low rectal <sup>#</sup> cancer and surgical intervention with sphincter preservation	Patients with low rectal cancer undergoing surgery	[7, 65-67]
R	Proportion of patients with rectal cancer undergoing TEM with R0 resection	Patients with rectal cancer undergoing TEM	[68-70]
C&R	Proportion of patients with colorectal cancer and a number of resected lymph nodes $\geq 12$	Patients with colorectal cancer undergoing surgery, but no neo- adjuvant therapy	[7, 26-27, 46, 71- 76]
C&R	Proportion of patients with colorectal cancer operated on with free margins	Patients with colorectal cancer undergoing surgery	[7, 77-78]
C&R	Proportion of patients with colorectal cancer and AJCC TNM clinical stage I (from T2N0M0) to III (any T, N1M0) undergoing a surgical resection with anastomosis	Patients with colorectal cancer and AJCC TNM stage I (from T2N0M0) to III	[26-27, 77-78]
С	Proportion of patients with colon cancer and AJCC TNM stage II (T3N0M0, T4N0M0) high-risk (presence of at least one of the following factors: LN<12, G3, lymph-vascular or perineural invasion, tumour obstruction, tumour perforation, pT4) or III undergoing adjuvant ChT	Patients with colon cancer and AJCC TNM stage II high-risk or III	[26-27, 46, 79-82]
С	Proportion of patients with colon cancer AJCC TNM stage II high-risk or stage III undergoing adjuvant ChT within 8 weeks from surgical resection	Patients with colon cancer and AJCC TNM stage II high-risk or III undergoing adjuvant ChT	[83]
C&R	Proportion of patients with colorectal cancer and histology of the primary tumour or metastases obtained before the beginning of ChT	Patients with colorectal cancer undergoing primary ChT	[26-27]
C&R	Proportion of patients with colorectal cancer and unresectable metastases undergoing first-line ChT or bio-ChT	Patients with colorectal cancer and unresectable metastases	[84-87]
C&R	Proportion of patients with colorectal cancer and hepatic metastases primarily unresectable turned into resectable metastases after neo-adjuvant ChT	Patients with colorectal cancer and unresectable hepatic metastases undergoing neo- adjuvant ChT	[87]

2
2 3
4
4 5
5
6
7
8
9
10
10
11
12
13
14
15
16
17
17
18
3 4 5 6 7 8 9 10 11 2 3 4 15 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 3 3 4 3 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 3 4 5 6 7 8 9 10 11 2 3 3 4 5 6 7 8 9 10 11 2 3 3 4 5 6 7 8 9 10 11 2 3 3 3 4 3 5 6 7 8 9 10 11 2 3 3 3 4 3 5 6 7 8 9 10 11 2 3 3 4 3 5 6 7 8 9 10 11 2 3 3 4 3 5 6 7 8 9 10 11 11 11 11 11 11 11 11 11 11 11 11
20
21
22
22
23
24
25
26
27
28
20
29
30
31
32
33
34
25
30
36
37
38
39
40
41
41
42
43
44
45
46
47
48
49
50
51
52
53
53 54
55
56
57
58
59
09

60

R	Proportion of patients with locally advanced rectal cancer (T3-4 and/or any T, N+ and M0) undergoing neo-adjuvant RT±ChT	Patients with locally advanced rectal cancer	[88-89]
R	Proportion of patients with rectal cancer and undergoing neo-adjuvant RT±ChT operated within 6-8 weeks after the end of neo-adjuvant RT±ChT	Patients with rectal cancer undergoing neo-adjuvant RT±ChT followed by surgery	[89]
OUTCOM	(E (n=2)		
C&R	Analysis of overall survival at 1, 3, 5 and 10 years from diagnosis	Patients with colorectal cancer	[7, 90]

Patients with colorectal cancer

curatively treated

[7, 90]

## Abbreviation:

C&R

Analysis of disease-free survival

C&R= colon-rectum; C= colon; R= rectum; ACR= American College of Radiology; CT= computed tomography; MRI= magnetic resonance imaging; AJCC= American Joint Committee on Cancer; RT= radiotherapy; ChT= chemotherapy; WHO= World Health Organization; TEM= transanal endoscopic microsurgery.

<sup>§</sup>emergency: within 24 hours from the onset of symptoms; <sup>#</sup>low rectum: 4 to 7.5 cm from the dentate line [91]



# Quality indicators of Clinical Cancer Care (QC<sub>3</sub>) in colorectal cancer

Journal:	BMJ Open
Manuscript ID:	bmjopen-2013-002818.R1
Article Type:	Research
Date Submitted by the Author:	02-May-2013
Complete List of Authors:	Bianchi, Valentina; Cantonal Institute of Pathology, Ticino Cancer Registry Spitale, Alessandra; Cantonal Institute of Pathology, Ticino Cancer Registry Ortelli, Laura; Cantonal Institute of Pathology, Ticino Cancer Registry Mazzucchelli, Luca; Cantonal Institute of Pathology, Clinical Pathology Bordoni, Andrea; Cantonal Institute of Pathology, Ticino Cancer Registry
<b>Primary Subject Heading</b> :	Qualitative research
Secondary Subject Heading:	Oncology
Keywords:	QUALITATIVE RESEARCH, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Gastrointestinal tumours < ONCOLOGY, Gastrointestinal tumours < GASTROENTEROLOGY



## **Original Article**

## Quality indicators of Clinical Cancer Care (QC<sub>3</sub>) in colorectal cancer

Valentina Bianchi<sup>1</sup>, Alessandra Spitale<sup>1</sup>, Laura Ortelli<sup>1</sup>, Luca Mazzucchelli<sup>2</sup>, Andrea Bordoni<sup>1</sup> and the QC<sub>3</sub> CRC Working Group<sup>3</sup>

<sup>1</sup>Cantonal Institute of Pathology, Ticino Cancer Registry, 6600 Locarno, Switzerland <sup>2</sup>Cantonal Institute of Pathology, Clinical Pathology, 6600 Locarno, Switzerland <sup>3</sup>Members of the QC<sub>3</sub> Colorectal Working Group are listed in the Appendix

## Running title: Quality indicators of clinical care in colorectal cancer

### **Corresponding author:**

Valentina Bianchi, M.D., Cantonal Institute of Pathology, Ticino Cancer Registry, , Via in Selva 24, 6600 Locarno, Switzerland - e-mail: <u>valentina.bianchi-galdi@ti.ch</u>; phone: +41 91 8160826; fax: +41 91 8160829

*Key words:* quality of cancer care, colorectal cancer, quality indicators, cancer registry, population-based study

## Word count: 3702 (excluding the Abstract)

## ABSTRACT

**Objectives:** Assessing the quality of cancer care (QoCC) has become increasingly important to providers, regulators and purchasers of care worldwide. Aim of this study was to develop evidence-based quality indicators (QI) for colorectal cancer (CRC) to be applied in a population-based setting.

**Design:** A comprehensive evidence-based literature search was performed to identify the initial list of QI, which were then selected and developed using a two-step modified Delphi process involving two multidisciplinary expert panels with expertise in colorectal cancer care, quality of care and epidemiology.

**Setting:** The QC<sub>3</sub> population-based project, which involve all the public and private hospitals and clinics present on the territory of Canton Ticino (South Switzerland).

**Participants:** Ticino Cancer Registry, The Colorectal Cancer Working Group (CRC-WG) and the external academic Advisory Board (AB).

**Main outcome measures:** Set of quality indicators (QI) which encompass the whole diagnostictreatment process of colorectal cancer.

**Results:** Of the 149 QI emerged from 181 sources of literature, 104 were selected during the inperson meeting of the CRC-WG. During the Delphi process, the CRC-WG shortened the list to 89 QI. The AB finally validated 27 QI according to the phase of care: diagnosis (N=6), pathology (N=3), treatment (N=16), and outcome (N=2).

**Conclusions:** Using the validated Delphi methodology, including literature review of the evidence and integration of expert opinions from local clinicians and international experts we were able to develop a list of QI to assess QoCC for CRC. This will hopefully guarantee feasibility of data retrieval, acceptance and translation of QI into the daily clinical practice to improve QoCC. Moreover, evidence-based selected QI allow to assess immediate changes and improvements in the diagnostic-therapeutic process that could be translated in a short-term benefit for patients with a possible gaining both in overall and disease-free survival.

## **BMJ Open**

## **ARTICLE SUMMARY**

## **Article focus**

- Quality of Cancer care (QoCC) studies on specific quality indicators (QI) developed worldwide since the late '90s showed both a continuous improvement of oncologic care provided by the clinical structures involved and an increased availability of specialized care in the considered areas.
- This study aims to define evidence-based QI for colorectal cancer (CRC) care, in order to favour a feasible evaluation of the oncologic diagnostic-therapeutic process from a population-based cancer registration and data collection point of view.

## Key messages

- QI should be defined, developed and tested with scientific evidence-based rigor in a careful and transparent manner, taking into account their degree of relevancy, validity, reliability and feasibility.
- The selected CRC QI can be applied in a population-based setting, implying the inclusion of the elderly, considering age an extremely important determinant of treatment.

## Strengths and limitations of this study

- To develop the CRC QI we used a formal iterative process, the RAND/UCLA
   Appropriateness Methodology widely diffused and validated within other QoCC research.
   The selected QI are representative of the main steps of the diagnostic-therapeutic process.
- Due to the evidence that research studies demonstrated that single-discipline panels select different indicators than do multidisciplinary panels and to maximize the applicability of CRC QI, we constituted two panels of experts, a local Working Group and an external national/international academic Advisory Board, which could offer a multidisciplinary perspective on practice and who can guarantee that the selected QI and their results will be comparable with national and international data.
- Possible limitations of the current work are the following:

- the level of evidence found in the literature. This situation is common to many aspects of health care, and it was the reason that the expert panel methodology was developed specifically, to identify the processes that are most likely to be valid measures of quality when the highest level of evidence is not available.
- the literature selection could have missed some relevant articles. However, members of the Working Group were likely to be very familiar with the literature, and had the opportunity to suggest other indicators based on their experience and literature search; in this way, we believe to have integrated the best research evidence with clinical expertise.
- the feasibility of measuring indicators in terms of data collection and calculation. However, both the Working Group and the Advisory Board were concerned about the feasibility, validity and reliability of clinical data collection, necessary for the calculation of each single indicator at the population-based level. In fact, in order to warrant an accurate measurement, those indicators reaching more than 70% of the agreement, confirming their scientific and clinical value, but evaluated at least by one of the experts not feasible and difficult to be collected at the population-based level, were definitely excluded. In this way, we have overcome the feasibility limit.



#### **BMJ Open**

## INTRODUCTION

Research on QoCC performed during the last decade has demonstrated that the increase in knowledge on treatments with proven efficacy do not directly translate into optimal delivery of such treatments to patients. Moreover, accumulating evidence suggests that underuse and overuse of care may occur for patients with cancer.[1-2] In addition to survival analysis, to evaluate and compare quality of care at the population-based level, the assessment of QoCC has become increasingly important to providers, regulators and purchasers of care to growing demand for services, rising costs, constrained resources and evidence of variation in clinical practice.[3]

QoCC studies and structured programmes on specific quality indicators (QI) have been developed worldwide since the late '90s, showing both a continuous improvement of oncologic care provided by the clinical structures involved and an increased availability of specialized care in the considered areas. Most of these studies have been implemented at the regional level on a territory with uniform legislative, health and geographical characteristics, increasing the likelihood of recruitment of involved clinicians.[1 4-7]

So far, in Switzerland no population-based study on QoCC with a prospective design has been implemented. In addition to the yearly renewed international guidelines for each type of cancer, there is still the need to evaluate the real conditions of care in the community. Population-based Cancer Registry data are therefore essential to describe and reflect real world and routine care as well as to provide regular feedback to healthcare workers and decision makers about the management of a disease in the daily practice and those treatments that are routinely prescribed and/or effective in all patient groups.[8] Moreover, Cancer Registries represent an independent observatory, thus assuring a fair evaluation service, avoiding any conflicts of interest. We, therefore, implemented the QC<sub>3</sub> project, focusing on QoCC about the diagnosis-treatment process in colon-rectum, prostate, uterus, ovary and lung cancers in the territory of Canton Ticino (South Switzerland).

Colorectal cancer (CRC) is an important health issue worldwide. It is the most common malignancy in Europe (excluding non-melanoma skin cancers) and the second most common in terms of cancerrelated mortality.[9] In Switzerland, CRC is the second and third most frequent tumour in women and men, respectively. About 4000 CRC cases are diagnosed annually, corresponding to a European age-standardized incidence rate equal to 49.4 and 30.6 cases per 100'000 inhabitants in men and women, respectively, and representing the 11% of all tumours.[10-12] CRC is the third leading cancer cause of death in Switzerland, with approximately 1600 deaths/year, corresponding to a European age-standardized mortality rate equal to 18.5 and 10.6 cases per 100'000 inhabitants in men and women, respectively. With a 5-year survival probability equal to 60%, Switzerland is the country with the most favourable prognosis in Europe.[13] A recent Swiss report with follow up to 2009 show an additional 5 year survival increase to 62%.[11]

The aims of the  $QC_3$  project are the following: 1) to define and confirm evidence-based QoCC indicators for the tumour localizations above cited, in order to favour a feasible evaluation of the oncologic diagnostic-therapeutic process from a population-based cancer registration and data collection point of view; 2) to define and implement at the regional level standards of care for each QoCC measure, in terms of minimum and target requirements. In the present report we will describe the initial part of the QC<sub>3</sub> project, meaning the process followed to identify the panel of specific QoCC indicators for the CRC, as well as the list of QoCC indicators identified and approved both by a dedicated Working Group of local health care providers and by an external independent Advisory Board, in a perspective of data collection feasibility by a population-based cancer registry.

#### **BMJ Open**

# MATERIAL AND METHODS

The QC<sub>3</sub> project is a prospective, descriptive study on the QoCC to be implemented in a populationbased setting; it is performed by the Ticino Cancer Registry on a 3-year time period (2011-2013) on the territory of Canton Ticino (South Switzerland). In this paper we focus on the initial part of the project: the identification of the CRC quality indicators which will be used to evaluate the QoCC about CRC in our region.

Quality indicators (QI) for CRC were developed involving a local expert panel, named QC<sub>3</sub> Colorectal Working Group (CRC-WG). Elected members, selected on the basis of their expertise and on their daily clinical involvement in CRC care, were contacted to have their interest confirmed in being involved. The final QC<sub>3</sub> CRC-WG encompassed two pathologists, four gastroenterologists, two oncologists, three surgeons, two radiologists, two radiation oncologists and one nuclear medicine specialist, for a total of 15 panellists all working in the public or in the private hospitals and clinics of Canton Ticino (see Appendix 1).

Published studies and references were identified through a comprehensive search on PubMed/MEDLINE, using initially specific strings/expressions, such as the following: "quality of care OR quality indicators AND colorectal cancer", "diagnosis OR diagnostic AND quality indicators AND colorectal cancer", "pathology OR pathological AND quality indicators AND colorectal cancer", "surgery OR surgical AND quality indicators AND colorectal cancer", "radiation oncology OR radiotherapy AND quality indicators AND colorectal cancer", "chemotherapy AND quality indicators AND colorectal cancer", "chemotherapy AND quality indicators AND colorectal cancer", "surveillance OR follow-up OR outcome AND quality indicators AND colorectal cancer", "preoperative care OR perioperative care OR intraoperative care OR postoperative care AND colorectal cancer", "population-based AND quality indicators AND colorectal cancer". For each of the identified candidate indicators, we performed a systematic literature review to identify the highest level of evidence supporting the validity of that quality indicator for articles published from 1990 onwards. The reference list of the included articles were also examined to identify any additional article that had not been identified in

the MEDLINE search. We included all the peer-reviewed articles, but case reports, letters, abstracts or editorials. If evidence at the highest level were limited or absent, then lower levels of evidence were evaluated. For example, if data were not available from randomized controlled trials, cohort or case-control studies, case series and expert opinion or clinical guidelines were reviewed. A selection of already approved QI provided by the American Society of Clinical Oncology (ASCO), the National Comprehensive Cancer Network (NCCN), the National Initiative on Cancer Care Quality (NICCQ), the Quality Oncology Practice Initiative (QOPI) and the Florida Initiative for Quality Cancer Care (FIQCC), were included in the evaluation list, with the aim to transfer them from the clinical to the population-based setting.[1-2 4 7 14-20]

The initial QI list emerged from 181 sources of literature, and it was proposed to the CRC-WG in the context of an in-person meeting held at the very beginning of the process. The list was then left to the QC<sub>3</sub> CRC-WG's evaluation for a period of two weeks. The participants were asked to provide a whole opinion with written comments about those QI considered pertinent for the assessment of CRC care quality, to suggest additional QI not already included in the list and to delete those QI considered not suitable. In order to make the selection and evaluation easier, the QI were subdivided in chapters recalling the Donabedian's and the National Initiative for Cancer Care Quality schemes: diagnosis and staging, pathology, treatment, follow-up, outcome.[2 21]

## **Delphi Round 1**

 The QI selection was done by using a 2-step modified Delphi process.[22] The initial list of QI, reanalyzed by the QC<sub>3</sub> CRC-WG, was formatted as a questionnaire, where for each indicator was specified the numerator, the denominator and the sources of evidence from which it was extracted. The questionnaire was distributed by regular mail to the QC<sub>3</sub> CRC-WG, so to maintain it anonymous, along with a stamped, addressed return envelope and an attached letter with the deadline date of two weeks from the receipt and the instruction for voting. Respondents were asked to rate each QI adopting the RAND Appropriateness Methodology (scale 1 to 9, 1 = extremely

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

 inappropriate; 9 = extremely appropriate), according to selection criteria of relevance, scientific soundness (validity, reliability, comparability) and feasibility (precise definition and specification, data feasibility, reliability of data collection).[23-25] Each QI was judged as validated if it reached a strong consensus for acceptance ( $\geq$ 70% of the QC<sub>3</sub> CRC-WG rated the QI with a vote  $\geq$ 7), discarded if it reached a strong consensus for exclusion ( $\geq$ 70% of the QC<sub>3</sub> CRC-WG rated the QI with a votes  $\leq$  3) and in stand-by if there was an unclear consensus (4  $\leq$  votes  $\leq$  6), which implies an eventual in-person meeting.

# **Delphi Round 2**

The Delphi Round 2 questionnaire was performed with the same modalities of the first round and enclosed the frequency distribution of round 1 votes, allowing the panellists to eventually alter their responses, in the light of colleagues' assessments.[23]

## **Advisory Board Review**

The list of selected QI derived from the two Delphi rounds was then submitted to an independent external national/international academic multidisciplinary Advisory Board (AB), in order to get an additional evaluation on the suitability of QI as "quality" indexes according to the criteria shown in the previous paragraph. The intent was to achieve at least one health professional for each specialty. The AB included one pathologist, one gastroenterologist, two oncologists, two surgeons, one radiologist, one radiation oncologist, one nuclear medicine specialist and one epidemiologist, for a total of 10 experts in CRC care (see Acknowledgements); all the panellists are daily involved in the CRC care and they had been contacted with the same modalities of the QC<sub>3</sub> CRC WG. The selected QI as well as the corresponding literature sources were distributed to the AB as an electronic form where their opinion about QI were expressed both as megatrends (i.e. response yes/no to the suitability of each QI) and as eventual additional comments.[26] We considered every single QI as finally approved by the AB if it achieved  $\geq 70\%$  of the agreement (i.e.  $\geq 70\%$  of respondents should

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

have answered "yes"). Besides the vote ("yes" *versus* "no"), the panellists had the chance to comment the single QI from a population-based cancer registration and data collection point of view. Therefore, those QI reaching more than 70% of the agreement, confirming their scientific and clinical value, but evaluated at least by one of the experts "not completely feasible and difficult to be collected at the population-based level", were definitely excluded.

#### **BMJ Open**

## RESULTS

The QI selection process began in January 2011 and ended in December 2011.

Participation of CRC-WG members throughout the process was high: 15 (100%) participated to the in-person meeting, 12 (80%) completed both the Delphi round 1 and 2. The Delphi Round 1 questionnaire respondent time were in the range of 18 to 60 days, while for the Round 2, the delay time was in the range of 8 to 55 days; these delays and the time for recruitment of the AB influence the long time spent for this part of the project.

The Figure 1 summarizes the entire process used to select QI for CRC care. The literature search produces 181 citations dealing with CRC QoCC, including also already validated QI provided by the ASCO, NCCN, NICCQ, QOPI and FIQCC.[1-2 4 7 14-20] From this search, we initially selected a total of 149 QI, which were proposed to the CRC-WG in the context of the initial inperson meeting. The following discussion and revision reduced the list to 104 OI before the modified Delphi process started; these QI were divided into the following areas: diagnosis and staging, pathology, treatment, follow-up and outcome. After the whole Delphi process the list was shortened to 89 QI, distributed as following: diagnosis and staging (N=16), pathology (N=20), treatment (N=38), follow-up (N=10), and outcome (N=5). The QI finally underwent to the AB's evaluation; this last step, according to the procedure described in the methods, shortened the final list to 27 OI diagnosis (N=6), pathology (N=3); treatment (N=16), follow-up (N=0), and outcome (N=2). Table 1 reports detailed information for each QI: a) QI description; b) criteria for patients inclusion in the numerator and denominator; c) list of the necessary medical documentation that should be collected by the Cancer Registry to extract the needed and relevant information to built the specific QI, such as the report of the endoscopy, the pathology report of the biopsy and/or surgical resection, the preoperative radiological reports (e.g. TAC and MRI), the surgery report, the tumour board documentation, the oncological report, the radiotherapy report and database/documentation of the regional Office of Population Registry Rosters for the assessment of patients vital status (for outcome QI); d) QI rationale; e) related references.

#### DISCUSSION

In the preliminary phase of the QC<sub>3</sub> project shown in this paper we developed a panel of evidencebased CRC QI which are suitable to be implemented in a population-based setting. To develop the QC<sub>3</sub> QI we used a formal iterative process, the RAND/UCLA Appropriateness Methodology widely diffused and validated within other QoCC research.[23-24] Due to the evidence that research studies demonstrated that single-discipline panels select different indicators than do multidisciplinary panels and to maximize the applicability of QC<sub>3</sub> CRC QI, we constituted a working group which could offer a multidisciplinary perspective on practice, including specialists, professionals, clinicians and researchers coming from both public and private hospitals.[27-33] Moreover, we have used a further validation step enrolling an independent national/international academic AB. This choice was due to the aim of measuring QoCC within a Swiss region, with a point of view on the population-based data collection and evaluation, and of obtaining results which will be comparable with national and international data. We believe that the expertise and multidisciplinary representativeness of the QC3 CRC-WG and of the AB will surely increase quality, acceptance and translation of QI into the daily clinical practice.

The selected QI are representative of the main steps of the diagnostic-therapeutic process. The diagnosis QI reflect the importance of a pre-operative evaluation and staging, reliable evaluation of the tumour localization and local invasion, and particularly for the rectal cancers, of a feasible and effective surgery. The first indicator of the "diagnosis" group is important to understand what happens in a territory where there is not an organized screening programme for colorectal cancers, but only an opportunistic screening strategy. If the tumour is detected because the physician submit the patients older than 50 years old to a fecal occult blood test (FOBT) or colonoscopy control or if a patient, being aware of the possible risk, asks his family doctor to undergo screening examinations, is an interesting data to be evaluated, also in the hypothesis of a colorectal cancer screening programme implementation. We, therefore, believe that a higher proportion of patients diagnosed through screening (FOBT or colonoscopy in asymptomatic patients) would represent a

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

#### **BMJ Open**

higher diagnostic quality, since the therapeutic approach and, consequently, the patients outcome (in terms of recurrence and survival) would be more favourable, as reported in the literature.[20 34-39] The pathology QI reflect the importance of a good communication between clinicians and pathologists in terms of patient's clinical history and consequent evaluation of the effectiveness of a neo-adjuvant therapy; moreover, there is a need of standardization of the pathologic report following the international guidelines (e.g. take at least three samples of tumour during the macroscopy), not leaving any items unexplained or implicit. In particular, the third QI reported in Table 1 (pathology section) refers to the surgical pathology report, which derives from the surgical curative intervention and should be as complete as possible to be useful for the future decision about patient's treatment. Our intent is to calculate it for all listed items considered together, but also for each item individually analyzed: e.g. proportion of patients with colorectal cancer and a definitive pathological report including the surgical intervention description; proportion of patients with colorectal cancer and a definitive pathological report including the tumour size; proportion of patients with colorectal cancer and a definitive pathological report including the resection margins; proportion of patients with colorectal cancer and a definitive pathological report including the pathological staging (AJCC pTNM); etc... The treatment QI cover the general issues of surgery, such as emergency, postoperative mortality and a multidisciplinary discussion of the clinical case; furthermore, they focus on the debate of the retrieved lymph nodes, on the timing between radiotherapy and surgery, on the adjuvant chemotherapy and on the attitude towards the metastatic patients. The two main items of the outcome chapter refers to the overall and disease-free survival. Although it is necessary to wait for a certain follow-up period (i.e. 1, 3, 5 to 10 years from the date diagnosis for the calculation of overall survival, and from the date of curative treatment for the calculation of disease-free survival), they will represent the overall resume of the diagnostic and treatment quality of CRC patients. Our intent will be to analyse overall and disease-free survival according to some of the proposed QI (such as QI concerning the pathological characteristics of the tumours, QI of the adjuvant chemotherapy in patients with colon cancer and AJCC TNM stage II

 high-risk or III, QI of colorectal patients operated on with free margins, QI of locally advanced rectal cancer patients undergoing neo-adjuvant radio±chemotherapy, etc...). We will finally compare our results with other regional and national reality, favouring the interpretation of each single QI. Concerning the QI about follow-up, AB did not finally include any of them. Indeed, although the follow-up procedures are suggested by several international guidelines, they are based on level II-III evidence and controversies remain regarding selection of optimal strategies for following up patients after potentially curative CRC surgery.[40-43]

The first limitation of the current work is the level of evidence found in the literature. For some indicators, strong evidence of their validity was not available from RCTs. However this situation is common to many aspects of health care, and it was the very reason that the expert panel methodology was developed – specifically, to identify the processes that are most likely to be valid measures of quality when the highest level of evidence is not available. [19 23 44] Secondly, we may have missed some studies during the literature search and, consequently, some QI has not been proposed to the QC<sub>3</sub>CRC-WG since the beginning of the QI revision process. However, this limitation should have been overcome by the fact that the members of the QC<sub>3</sub> CRC-WG were likely to be very familiar with the literature, and had the opportunity to suggest other QI based on their experience and literature search [7 27-28 45] Thus we integrated the best research evidence with clinical expertise, as reported by Sackett et al. [46] A further limit could be the feasibility of measuring QI in terms of data collection and calculation, which is immediately the next step. Actually, the QI selected by both the  $QC_3$  CRC-WG and the AB represent an ideal set of criteria to measure the quality of CRC care; at the same time they both were concerned about the feasibility, validity and reliability of clinical data collection, necessary for the calculation of each single QI at the population-based level. This is the reason why most of the identified  $QC_3$  QI are common to many QoCC studies. [1-2 4 7 14-20] Besides the traditional Delphi process, the panellists had the chance to comment the single QI from a population-based cancer registration and data collection point of view. Therefore, in order to warrant an accurate measurement, those QI reaching more than

#### **BMJ Open**

70% of the agreement, confirming their scientific and clinical value, but evaluated at least by one of the experts not feasible and difficult to be collected at the population-based level, were definitely excluded. In addition, we performed a retrospective preliminary pilot collection on the detailed and necessary incidence data of CRC occurred in 2011, realising that the measurement of most QI is feasible, whereas for some selected QI the retrieving of variables would need additional efforts; some preliminary results were presented in national and international conferences and congresses, receiving positive feedback by both the clinical and epidemiological setting.[47-50] Only the definitive results will give us the proportion of missing information, whose magnitude will be assessed.

The selected  $QC_3$  CRC QI will be applied in a population-based setting, where age is an extremely important determinant of treatment. The elderly are rarely included in the randomized clinical trials with the consequence of a possible "underuse of treatment". [25 51-52] At a broad European level, national audit registries in surgical oncology have led to improvements with a great impact and they offered the possibility, as for our project, to perform research on patients that are usually excluded from clinical trials such as elderly and co-morbid patients. [53-54] Evidence suggests that the relative benefits of treatment for the elderly are similar to those seen for cancer patients in general, though decision making for treatment becomes more complex as life expectancy, co-existing illnesses, and functional status all need to be considered. [25 51-52] Applying these QI and if all these items will be satisfied we can affirm to have a real good quality process of CRC care for the whole population. The foreseeable future in quality evaluation and improvement for health care will likely involve more and more frequently the use of QI by regulatory and accrediting agencies, stakeholders, clinicians, individual hospitals and health care providers, as well as patients. This underlines that the QI should be defined, developed and tested with scientific evidence-based rigor in a careful and transparent manner, taking into account their degree of relevancy, validity, reliability and feasibility.[30 32] Although QI have been defined in several different ways, all authors agreed that the final aim is the improvement of patients outcome.[31 33 55]

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

The systematic trend analysis of QI allows to assess immediate changes and improvements in the diagnostic-therapeutic process that could be translated in a short-term benefit for patient, without waiting for survival analysis typically needed some years to be produced because of the patients' follow-up. Furthermore, this system of evaluation and auto-evaluation could favour the surveillance and monitoring of the comprehensive level of the oncologic care in the region, the clinical performance homogeneity, the possible weakness of the clinical network, and finally the corrective interventions to be adopted to improve the QoCC.

With this study, we hope to increase the awareness of the value of QI in health care so to encourage more uniform practices and improve provider documentation of medical care in our region; moreover, we hope that standardization of QI among different regions will help to define threshold of minimal standard of care.

#### **BMJ Open**

## **APPENDIX (List of Collaborators)**

Members of the QC<sub>3</sub> CRC Working Group are listed as following:

Barizzi J., Clinical Pathology, Cantonal Institute of Pathology, 6600 Locarno, Switzerland; Bihl F., Gastroenterology Dept., Ospedale Regionale Bellinzona e Valli, 6500 Bellinzona Switzerland; Christoforidis D., General Surgery Dept., Ospedale Regionale di Lugano, 6900 Lugano, Switzerland; Franzetti-Pellanda A., Radiation Oncology Dept., Clinica Luganese, 6900 Lugano, Switzerland; Giovanella L., Nuclear Medicine Dept., Oncology Institute of Southern Switzerland (IOSI), 6500 Bellinzona, Switzerland; Heinkel J., Radiology Dept., Ospedale La Carità, 6600 Locarno, Switzerland; Maffei M., Gastroenterology Dept., Ospedale Regionale di Lugano, 6900 Lugano, Switzerland; Mazzucchelli L., Clinical Pathology, Cantonal Institute of Pathology, 6600 Locarno, Switzerland; Miazza B., Gastroenterology Dept., Ospedale Regionale di Lugano, 6900 Lugano, Switzerland; Pelloni A., General Surgery Dept., Ospedale La Carità, 6600 Locarno, Switzerland; Quattropani C., Gastroenterology Dept., Clinica Luganese, 6900 Lugano, Switzerland; Rosso R., General Surgery Dept., Ospedale Regionale di Lugano, 6900 Lugano, Switzerland; Saletti P., Medical Oncology Dept., Oncology Institute of Southern Switzerland (IOSI), 6500 Bellinzona, Switzerland; Valli M. C., Radiation Oncology Dept., Oncology Institute of Southern Switzerland (IOSI), 6500 Bellinzona, Switzerland; Varini M., Medical Oncology Dept., Clinica Sant'Anna, 6900 Lugano, Switzerland; Wyttenbach R., Radiology Dept., Ospedale Regionale Bellinzona e Valli, 6500 Bellinzona, Switzerland.

# FUNDING

This work was supported by Krebsforschung Schweiz, grant number KFS – 02668-08-2010, and by Advisory Board Research Ente Ospedaliero Cantonale Bellinzona, grant number ABREOC 10/2010.

The funding sources have not any involvement in the study design, in the collection, analysis and interpretation of data, in the writing of the report and in the decision to submit the paper for publication.

# COMPETING INTERESTS

The Authors have no competing interests.

# DATA SHARING

no additional data available.

# **AUTHORS' CONTRIBUTION**

I declare that V. Bianchi, A. Bordoni, A. Spitale and L. Mazzucchelli have directly participated in the planning of the manuscript; that V. Bianchi, A. Bordoni, A. Spitale and the QC<sub>3</sub> Colorectal Working Group have directly participated in the conducting of the project; that V. Bianchi, A. Bordoni, A. Spitale and L. Ortelli have directly participated in the reporting, acquisition of data or analysis and interpretation of data; and that V. Bianchi and A. Bordoni are responsible for the overall content as guarantors of the work. Finally, I declare that all the Authors have drafted and revised the paper critically for important intellectual content, and that they have given final approval of the version published. None of the Authors have competing interests.

#### **BMJ Open**

# ACKNOWLEDGEMENTS

We are particularly grateful to the  $QC_3$  CRC AB Members, who contribute to critically review the  $QC_3$  CRC QI, for their precious collaboration:

Prof. Franco Cavalli, Scientific Director, Oncologic Institute of Italian Switzerland (IOSI), Bellinzona, Switzerland; Prof. Gian Dorta, Director, Digestive Endoscopy Dept., Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland; Prof. Jean Faivre, Director, Registre Bourguignon des Cancers Digestifs, Dijon Cedex , France; Prof. Stefano Fanti, Director, PET Center, Policlinico S. Orsola-Malpighi, Bologna, Italy; Prof. Roberto Labianca, Director, Oncology and Haematology Dept., Ospedali Riuniti, Bergamo, Italy; Prof. Sebastiano Martinoli, Director, General Surgery Dept., Clinica Luganese, Lugano, Switzerland; Prof. Philip Quirke, Director, Leeds Institute of Molecular Medicine (LIMM), Section of Pathology, Wellcome Trust Brenner Building, St James's University Hospital, Leeds, United Kingdom; Prof. Emmanuel Tiret, Chef Pôle Digestif des Hôpitaux Univesitaires Paris Est, Chef Service de Chirurgie Générale et Digestive, Hôpital Saint-Antoine, Paris, France; Prof. Vincenzo Valentini, Director, Unità Operativa Complessa Radioterapia 1, Policlinico Universitario Agostino Gemelli, Rome, Italy; Prof. Dominik Weishaupt, Director, Radiology Dept., Stadtspital Triemli, Zürich, Switzerland.



# COPYRIGHT

The Corresponding Author has the right to grant on behalf of all Authors and does grant on behalf of all Authors, an exclusive licence on a worldwide basis to the BMJ Publishing Group Ltd, and its Licensees to permit this article (if accepted) to be published in BMJ Open and any other BMJPGL products to exploit all subsidiary rights, as set out in your licence and the Corresponding Author accepts and understands that any supply made under these terms is made by BMJPGL to the Corresponding Author.

ling Author.

#### **BMJ Open**

# **LEGENDS TO FIGURES**

FIGURE 1 - Process used to select quality indicators for colorectal cancer care

QI = Quality Indicators; QC<sub>3</sub> CRC-WG = QC3 Colorectal Cancer Working Group; AB = Advisory Board

# Table 1. Quality indicators of colorectal cancer care according to diagnostic-therapeutic process (diagnosis, pathology, treatment - surgery, chemotherapy and radiotherapy - and outcome) and tumour site.

CLINICAL DOMAIN	SITE	QUALITY INDICATOR	NUMERATOR	DENOMINATOR	MEDICAL DOCUMENTATION	RATIONALE	REF
	colorectal cancer and diag	Proportion of patients with colorectal cancer and diagnosis based on symptoms vs screening vs accidental finding	Number of patients with colorectal cancer whose diagnosis is based on symptoms, defined as appearance or persistence of clinical events and signs, such as rectal bleeding, occult blood in stool, weight loss with no apparent cause, general abdominal discomfort, bowel obstruction, change in bowel habits, constant tiredness, anaemia	Number of patients with colorectal cancer	Request form of endoscopic examination Endoscopy and surgical pathology reports Reports/discharge letters coming from all hospital units/department (i.e. surgery, medicine, radiation oncology,	Assessment of the patient's take charge	[18 34- 38]
			Number of patients with colorectal cancer whose diagnosis is based on screening, defined as regular examination, such as faecal occult blood test (FOBT) or colonoscopy in asymptomatic patients		medical oncology )		
SIS			Number of patients with colorectal cancer whose diagnosis is an accidental finding following examinations or therapies for other diseases (e.g. hospital admission for other causes)	eL:			
DIAGNOSIS (n=6)	C&R	Proportion of patients with colorectal cancer, evaluated by preoperative colonoscopy	Number of patients with colorectal cancer who have been evaluated by a preoperative colonoscopy	Number of patients with colorectal cancer undergoing surgery	Endoscopy report Request form of pathology examination Pathology report of endoscopy	Planning of further diagnostic procedures and treatments Comprehensiveness of diagnostic and staging evaluation	[7 16 18 40-41]
	R	Proportion of patients with rectal cancer and description of the tumour localization (distance <i>ab ano</i> ) in the endoscopic/pathologic documentation	Number of patients with rectal cancer who have the description of the tumour localization, in terms of distance <i>ab ano</i> , in the endoscopic/pathologic documentation	Number of patients with rectal cancer undergoing endoscopy	Endoscopy report Request form of pathology examination Pathology report of endoscopy	Planning of further diagnostic procedures and treatments Comprehensiveness of diagnostic and staging evaluation	[1 19 56- 57]
	C&R	Proportion of patients with colorectal cancer and requests for an initial CT and/or a MRI examination completed by clinical information according to the ACR guidelines	Number of patients with colorectal cancer for which the request of an initial CT and/or a MRI examination is completed by clinical information according to the ACR guidelines	Number of patients with colorectal cancer undergoing initial CT and/or MRI examination	Radiology (CT and/or MRI examination) report	Providing the necessary information for a comprehensive radiological examination	[7 58]
						Assessment of the quality of the flux of clinical information	

	R	Proportion of patients with low rectal <sup>a</sup> cancer undergoing pelvic MRI of staging	Number of patients with low rectal <sup>a</sup> cancer who have undergone a pelvic MRI of staging	Number of patients with low rectal cancer	Radiology (MRI examination) report Discharge letters coming from all hospital units/department (i.e. surgery, medicine, medical oncology, radiation oncology )	Planning of further diagnostic procedures and treatments Comprehensiveness of diagnostic and staging evaluation	[19 59-61]
	R	Proportion of patients with rectal cancer and a preoperative MRI reporting the description of the radial margin status (mm)	Number of patients with rectal cancer who have undergone a preoperative MRI reporting the description of the radial margin status (mm)	Number of patients with rectal cancer undergoing preoperative MRI	Radiology (MRI examination) report	Planning of further diagnostic procedures and treatments Comprehensiveness of diagnostic and staging evaluation	[62]
	R	Proportion of patients with rectal cancer for which the request for the pathological examination includes the information of neo-adjuvant RT±ChT	Number of patients with rectal cancer for which the request for the pathological examination includes the information of neo-adjuvant RT±ChT	Number of patients with rectal cancer undergoing neo-adjuvant RT±ChT and surgery <sup>a</sup>	Request form of pathology examination Surgical pathology report	Providing the necessary information for a comprehensive pathological examination Assessment of the quality of the flux of clinical information	Proposed by CRC-WG
	C&R	Proportion of patients with colorectal cancer and a sufficient number of tumour samples $(\geq 3)$	Number of patients with colorectal cancer for which 3 or more tumour sample were processed for the pathological analysis	Number of patients with colorectal cancer undergoing surgery <sup>a</sup>	Surgical pathology report	Comprehensiveness of pathology examination	Proposed by CRC-WG
PATHOLOGY (n=3)	C&R	Proportion of patients with colorectal cancer and a surgical pathology report including the following characteristics: - surgical intervention description - sample length - tumour localization according to WHO - tumour size - histological type according to WHO - histological grade - resection margins - lymph-vascular invasion - perineural invasion - tumour deposits (discontinuous extramural extension)	Number of patients with colorectal cancer whose pathological report includes the following characteristics: - surgical intervention description - sample length - tumour localization according to WHO - tumour size - histological type according to WHO - histological grade - resection margins - lymph-vascular invasion - perineural invasion - tumour deposits (discontinuous extramural extension) - pathological staging (AJCC pTNM) - number of retrieved lymph nodes - treatment effect -macroscopic integrity of the mesorectum	Number of patients with colorectal cancer undergoing surgery <sup>a</sup>	Surgical pathology report	Comprehensiveness and standardisation of surgical pathology report Comprehensiveness of staging evaluation Planning of further treatments	[18-19 63-64]

Page	24	of	79
------	----	----	----

2	
-	
3	
1	
4	
5	
~	
6	
7	
'	
8	
0	
9	
1	0
1	1
1	2
	~
1:	3
4	1
14	4
1	5
	~
10	b
- 2 3 4 5 6 7 8 9 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2	7
I	(
1	8
	0
1	9
2	n
~	
2	1
2	$\mathbf{r}$
2	Z
2	3
2	
24	4
2	5
2	5
2	6
	-
2	1
2	Q
2	0
- 29	9
2	0
3	U
3	1
0	
3	2
2	2
5	
3	4
0	-
3	0
3	6
~	_
3	1
2	ρ
3	U
3	9
4	0
	-
4	1
4	2
4	
4	4
4	
4	
4	υ
4	7
4	Ŋ
4	a
	-

TREATMENT

		- pathological staging (AJCC	(for rectum only)				
		pTNM) - number of retrieved lymph nodes					
		- treatment effect					
		-macroscopic integrity of the mesorectum (for rectum only)					
		(this quality indicator should be provided for each characteristic)					
	C&R	Proportion of patients with colorectal cancer operated in emergency <sup>b</sup>	Number of patients with colorectal cancer who have been operated in emergency <sup>b</sup>	Number of patients with colorectal cancer undergoing surgery <sup>a</sup>	Radiology and surgery report/discharge letter	Assessment of the patient's take charge	[65-67]
	C&R				Surgical pathology report		F (0 = 1)
	can	Proportion of patients with colorectal cancer and dead	Number of patients with colorectal cancer and dead within 30 days from the surgery	Number of patients with colorectal cancer undergoing surgery <sup>a</sup>	Surgery report/discharge letter	Assessment of the quality of surgical procedure	[68-71]
		within 30 days and 6 months from the surgery (postoperative mortality)	Number of patients with colorectal cancer and dead within 6 months from the surgery		Surgical pathology report Access to regional Office of Population Registry Rosters for the assessment of patients vital status		
	C&R	Proportion of patients with colorectal cancer and postoperative multidisciplinary discussion	Number of patients with colorectal cancer for which there have been a multidisciplinary discussion after surgery	Number of patients with colorectal cancer undergoing surgery <sup>a</sup>	Surgery, Oncology, Radiation Oncology reports/discharge letters Multidisciplinary discussion documentation	Planning of further diagnostic procedures and treatments	[72-73]
(n=16)	R	Proportion of patients with malignant rectal polyp (pT1) and complete endoscopic polypectomy	Number of patients with malignant rectal polyp (pT1) who have undergone a complete endoscopic polypectomy	Number of patients with malignant rectal polyp (pT1)	Endoscopy report, Endoscopic pathology reports	Assessment of the quality of surgical procedure	Proposed by the CRC-WG
	R	Proportion of patients with low rectal <sup>c</sup> cancer and surgical intervention with sphincter preservation	Number of patients with low rectal <sup>c</sup> cancer who have undergone a surgical intervention with sphincter preservation	Number of patients with low rectal cancer undergoing surgery <sup>a</sup>	Surgical pathology report Surgery report/discharge letter	Assessment of the quality of surgical procedure	[7 74-76]
	R	Proportion of patients with rectal cancer undergoing TEM with R0 resection	Number of patients with rectal cancer who had undergone TEM with R0 resection	Number of patients with rectal cancer undergoing TEM	Surgical pathology report Surgery report/discharge letter	Assessment of the quality of surgical procedure	[77-79]
	C&R	Proportion of patients with colorectal cancer and a number of resected lymph nodes $\geq 12$	Number of patients with colorectal cancer with a number of resected lymph nodes $\geq$ 12	Number of patients with colorectal cancer undergoing surgery <sup>a</sup> , but no neo-adjuvant therapy	Surgical pathology report Surgery report/discharge letter	Assessment of the quality of surgical procedure and pathology examination	[7 14 16 40-41 80- 85]
	C&R	Proportion of patients with colorectal cancer operated on with free margins	Number of patients with colon cancer who have undergone surgery and have free margins	Number of patients with colorectal cancer undergoing surgery <sup>a</sup>	Surgical pathology report Surgery report/discharge	Assessment of the quality of surgical procedure	[7 86-87]

				letter		
C&R	Proportion of patients with colorectal cancer and AJCC TNM clinical stage I (from T2N0M0) to III (any T, N1M0) undergoing a surgical resection with anastomosis	Number of patients with colon cancer and AJCC TNM clinical stage I (from T2N0M0) to III (any T, N1M0) who have undergone a surgical resection with anastomosis	Number of patients with colorectal cancer and AJCC TNM stage I (from T2N0M0) to III	Radiology report Surgical pathology report Surgery report/discharge letter	Assessment of the quality of surgical procedure	[40- 86-8
C	Proportion of patients with colon cancer and AJCC TNM stage II (T3N0M0, T4N0M0) high-risk (presence of at least one of the following factors: LN<12, G3, lymph-vascular or perineural invasion, tumour obstruction, tumour perforation, pT4) or III undergoing adjuvant ChT	Number of patients with colon cancer and AJCC TNM stage II (T3N0M0, T4N0M0) high-risk (presence of at least one of the following factors: LN<12, G3, lymph- vascular or perineural invasion, tumour obstruction, tumour perforation, pT4) or III, who have undergone adjuvant ChT	Number of patients with colon cancer and AJCC TNM stage II high-risk or III, undergoing surgery <sup>a</sup>	Radiology report Surgical pathology report Surgery, oncology reports/discharge letters	Assessment of the quality of oncologic treatment	[16 40-41 91
С	Proportion of patients with colon cancer AJCC TNM stage II high-risk or stage III undergoing adjuvant ChT within 8 weeks from surgical resection	Number of patients with colon cancer and AJCC TNM stage II high-risk or III, who have undergone adjuvant ChT within 8 weeks from surgical resection	Number of patients with colon cancer and AJCC TNM stage II high-risk or III undergoing surgery <sup>a</sup> and adjuvant ChT	Radiology report Surgical pathology report Surgery, oncology reports/discharge letters	Assessment of the quality of oncologic treatment	[189
C&R	Proportion of patients with colorectal cancer and histology of the primary tumour or metastases obtained before the beginning of ChT	Number of patients with colorectal cancer and histology of the primary tumour or metastases obtained before the beginning of ChT	Number of patients with colorectal cancer undergoing primary ChT	Radiology and pathology reports Oncology report/discharge letter	Assessment of the quality of oncologic treatment	[40-4
C&R	Proportion of patients with colorectal cancer and unresectable metastases undergoing first-line ChT or bio-ChT	Number of patients with colorectal cancer and unresectable metastases who have undergone a first-line ChT or bio-ChT	Number of patients with colorectal cancer and unresectable metastases	Radiology and pathology reports Oncology report/discharge letter	Assessment of the quality of oncologic treatment	[93-9
C&R	Proportion of patients with colorectal cancer and hepatic metastases primarily unresectable turned into resectable metastases after neo- adjuvant ChT	Number of patients with colorectal cancer and hepatic metastases primarily unresectable turned into resectable metastases after neo-adjuvant ChT	Number of patients with colorectal cancer and unresectable hepatic metastases undergoing neo- adjuvant ChT	Radiology report Oncology report/discharge letter	Assessment of the quality of oncologic treatment	[96
R	Proportion of patients with locally advanced rectal cancer (T3-4 and/or any T, N+ and M0) undergoing neo-adjuvant RT±ChT	Proportion of patients with locally advanced rectal cancer (T3-4 and/or any T, N+ and M0) who have undergone neo- adjuvant RT±ChT	Number of patients with locally advanced rectal cancer undergoing surgery <sup>a</sup>	Endoscopic pathology report Radiology report Radiation Oncology and oncology reports/discharge letters	Assessment of the quality of oncologic and radio- oncologic treatment	[97-9
R	Proportion of patients with	Number of patients with rectal cancer who	Number of patients with rectal	Endoscopic pathology	Assessment of the quality	[18 9

		rectal cancer and undergoing neo-adjuvant RT±ChT operated within 6-8 weeks after the end of neo-adjuvant RT±ChT	have undergone neo-adjuvant RT±ChT and were operated within 6-8 weeks after the end of neo-adjuvant RT±ChT	cancer undergoing neo-adjuvant RT±ChT followed by surgery <sup>a</sup>	report Radiology report Radiation Oncology and oncology reports/discharge letters Surgical pathology report	of oncologic and radio- oncologic treatment	
OME 2)	C&R	Analysis of overall survival at 1, 3, 5 and 10 years from diagnosis	Number of patients with colorectal cancer who survive at 1, 3, 5 and 10 years from diagnosis	Number of patients with colorectal cancer	Access to regional Office of Population Registry Rosters for the assessment of patients vital status	Assessment of overall survival	[7 99]
OUTC( (n=2	C&R	Analysis of disease-free survival at 1, 3, 5 and 10 years from the curative treatment	Number of patients with colorectal cancer who are disease-free at 1, 3, 5 and 10 years from the curative treatment	Number of patients with colorectal cancer curatively treated	Reports/discharge letters coming from all hospital units/department (i.e. surgery, medicine, oncology, radio-oncology)	Assessment of disease-free survival	[7 99]

# Abbreviation:

C&R= colon-rectum; C= colon; R= rectum; FOBT= Faecal Occult Blood Test; ACR= American College of Radiology; CT= computed tomography; MRI= magnetic resonance imaging; AJCC= American Joint Committee on Cancer; RT= radiotherapy; ChT= chemotherapy; WHO= World Health Organization; TEM= transanal endoscopic microsurgery.

<sup>a</sup> surgery excludes endoscopic resection and colostomy

<sup>b</sup> emergency: within 24 hours from the onset of symptoms;

<sup>c</sup> low rectum: 4 to 7.5 cm from the dentate line [100]

7

8

9

10

11

12

13

14 15

16

17

18

19

20

21

22

23 24

25

26

27

28

29

30

31

32

33

34 35

36

37

38

39

40

41

42

43

44 45

46

47

48

49

50

51

52

53

54 55

56

57

58

59 60

# BMJ Open

# **REFERENCE LIST**

- 1. Malin JL, Schneider EC, Epstein AM, et al. Results of the National Initiative for Cancer Care Quality: how can we improve the quality of cancer care in the United States? J Clin Oncol 2006;**24**(4):626-34 doi: JCO.2005.03.3365 [pii]
- 10.1200/JCO.2005.03.3365[published Online First: Epub Date]|.
- Schneider EC, Malin JL, Kahn KL, et al. Developing a system to assess the quality of cancer care: ASCO's national initiative on cancer care quality. J Clin Oncol 2004;22(15):2985-91 doi: 10.1200/JCO.2004.09.087
- 22/15/2985 [pii][published Online First: Epub Date]|.
- 3. Campbell SM, Roland MO, Buetow SA. Defining quality of care. Soc Sci Med 2000;**51**(11):1611-25 doi: S0277953600000575 [pii][published Online First: Epub Date]|.
- Neuss MN, Desch CE, McNiff KK, et al. A process for measuring the quality of cancer care: the Quality Oncology Practice Initiative. J Clin Oncol 2005;23(25):6233-9 doi: JCO.2005.05.948 [pii]
- 10.1200/JCO.2005.05.948[published Online First: Epub Date]|.
- Duvalko KM, Sherar M, Sawka C. Creating a system for performance improvement in cancer care: Cancer Care Ontario's clinical governance framework. Cancer Control 2009;16(4):293-302
- Mainz J, Hansen AM, Palshof T, et al. National quality measurement using clinical indicators: the Danish National Indicator Project. J Surg Oncol 2009;99(8):500-4 doi: 10.1002/jso.21192[published Online First: Epub Date]].
- 7. Gagliardi AR, Simunovic M, Langer B, et al. Development of quality indicators for colorectal cancer surgery, using a 3-step modified Delphi approach. Can J Surg 2005;48(6):441-52
- Peppercorn JM, Weeks JC, Cook EF, et al. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 2004;363(9405):263-70 doi: S0140-6736(03)15383-4 [pii]
- 10.1016/S0140-6736(03)15383-4[published Online First: Epub Date]].
- 9. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;**46**(4):765-81 doi: S0959-8049(09)00926-5 [pii]
- 10.1016/j.ejca.2009.12.014[published Online First: Epub Date]].
- 10. NICER. Secondary 2012. http://www.nicer.org.
- 11. Bordoni A, Lorez M, Bouchardy C, et al. Trends in colorectal cancer survival in Switzerland. Bulletin Suisse du Cancer 2012;**1/2012**:51-54
- 12. Bouchardy C, Lutz JM, Kühni C, et al. *I tumori in Svizzera*. *Situazione e sviluppi dal 1983 al 2007*. Neuchâtel: Ufficio Federale di Statistica (UFS), 2011.
- Sant M, Allemani C, Santaquilani M, et al. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 2009;45(6):931-91 doi: S0959-8049(08)00926-X [pii]
- 10.1016/j.ejca.2008.11.018[published Online First: Epub Date]|.
- Desch CE, Benson AB, 3rd, Somerfield MR, et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2005;23(33):8512-9 doi: JCO.2005.04.0063 [pii]
- 10.1200/JCO.2005.04.0063[published Online First: Epub Date]|.
- Desch CE, McNiff KK, Schneider EC, et al. American Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures. J Clin Oncol 2008;26(21):3631-7 doi: 26/21/3631 [pii]
- 10.1200/JCO.2008.16.5068[published Online First: Epub Date]].
- QOPI. Summary of the measures. Spring 2011. Secondary Summary of the measures. Spring 2011. 2011. <u>http://qopi.asco.org/Methodology</u>.

- Jacobsen PB, Shibata D, Siegel EM, et al. Measuring quality of care in the treatment of colorectal cancer: the moffitt quality practice initiative. J Oncol Pract 2007;3(2):60-5 doi: 10.1200/JOP.0722002[published Online First: Epub Date]|.
- 18. Malafa MP, Corman MM, Shibata D, et al. The Florida Initiative for Quality Cancer Care: a regional project to measure and improve cancer care. Cancer Control 2009;**16**(4):318-27
- McGory ML, Shekelle PG, Ko CY. Development of quality indicators for patients undergoing colorectal cancer surgery. J Natl Cancer Inst 2006;98(22):1623-33 doi: 98/22/1623 [pii]
- 10.1093/jnci/djj438[published Online First: Epub Date]].
- 20. Siegel EM, Jacobsen PB, Malafa M, et al. Evaluating the quality of colorectal cancer care in the state of Florida: results from the Florida Initiative for Quality Cancer Care. J Oncol Pract 2012;8(4):239-45 doi: 10.1200/JOP.2011.000477
- 3774677 [pii][published Online First: Epub Date]].

- 21. Donabedian A. Evaluating the quality of medical care. Milbank Q 1966;83:691-729
- 22. Fink A, Kosecoff J, Chassin M, et al. Consensus methods: characteristics and guidelines for use. Am J Public Health 1984;74(9):979-83
- 23. Jones J, Hunter D. Consensus methods for medical and health services research. BMJ 1995;**311**(7001):376-80
- Brook RH. The Rand/UCLA appropriateness method. In: McCormic KA, Moore SR, Siegel RA, eds. Clinical practice guideline development: methodology perspectives. Rockville, Md: Agency for Health Care Policy and Research, 1994:59-70.
- 25. Krzyzanowska MK, Barbera L, Elit L, et al. Identifying population-level indicators to measure the quality of cancer care for women. Int J Qual Health Care 2011;**23**(5):554-64 doi: mzr043 [pii]
- 10.1093/intqhc/mzr043[published Online First: Epub Date]|.
- Blind K, Cuhls K, Grupp H. Personal attitudes in the assessment of the future of science and technology: a facton analysis approach. Technological forecastning and social change, 2001:131-49.
- 27. Leape LL, Park RE, Kahan JP, et al. Group judgments of appropriateness: the effect of panel composition. Qual Assur Health Care 1992;4(2):151-9
- 28. Campbell SM, Hann M, Roland MO, et al. The effect of panel membership and feedback on ratings in a two-round Delphi survey: results of a randomized controlled trial. Med Care 1999;37(9):964-8
- 29. Coulter I, Adams A, Shekelle P. Impact of varying panel membership on ratings of appropriateness in consensus panels: a comparison of a multi- and single disciplinary panel. Health Serv Res 1995;**30**(4):577-91
- Wollersheim H, Hermens R, Hulscher M, et al. Clinical indicators: development and applications. Neth J Med 2007;65(1):15-22
- Mainz J. Defining and classifying clinical indicators for quality improvement. Int J Qual Health Care 2003;15(6):523-30
- 32. Mainz J. Developing evidence-based clinical indicators: a state of the art methods primer. Int J Qual Health Care 2003;15 Suppl 1:i5-11
- 33. Rubin HR, Pronovost P, Diette GB. From a process of care to a measure: the development and testing of a quality indicator. Int J Qual Health Care 2001;**13**(6):489-96
- 34. Wilkins T, Reynolds PL. Colorectal cancer: a summary of the evidence for screening and prevention. Am Fam Physician 2008;**78**(12):1385-92
- 35. Sikka V, Ornato JP. Cancer diagnosis and outcomes in Michigan EDs vs other settings. Am J Emerg Med 2011 doi: S0735-6757(10)00574-7 [pii]
- 10.1016/j.ajem.2010.11.029[published Online First: Epub Date]].
- 36. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American

# **BMJ Open**

3	College of Radiology. Gastroenterology 2008;134(5):1570-95 doi: S0016-5085(08)00232-1
4	[pii]
5	10.1053/j.gastro.2008.02.002[published Online First: Epub Date]].
6	37. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical
7	guidelines and rationale-Update based on new evidence. Gastroenterology 2003;124(2):544-
8	60 doi: 10.1053/gast.2003.50044
9	S0016508502158951 [pii][published Online First: Epub Date] .
10	38. Majumdar SR, Fletcher RH, Evans AT. How does colorectal cancer present? Symptoms,
11	duration, and clues to location. Am J Gastroenterol 1999; <b>94</b> (10):3039-45 doi:
12	
13	S0002927099005109 [pii]
14	10.1111/j.1572-0241.1999.01454.x[published Online First: Epub Date]].
15	39. Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with
16 17	screening flexible sigmoidoscopy. N Engl J Med 2012;366(25):2345-57 doi:
18	10.1056/NEJMoa1114635[published Online First: Epub Date] .
19	40. Labianca R, Nordlinger B, Beretta GD, et al. Primary colon cancer: ESMO Clinical Practice
20	Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol 2010;21(suppl.
21	5):v70-v77
22	41. NCCN. Colon Cancer. 2.2011 ed: NCCN, 2011.
23	42. Pfister DG, Benson AB, 3rd, Somerfield MR. Clinical practice. Surveillance strategies after
24	curative treatment of colorectal cancer. N Engl J Med 2004;350(23):2375-82 doi:
25	10.1056/NEJMcp010529
26	350/23/2375 [pii][published Online First: Epub Date]].
27	43. Li Destri G, Di Cataldo A, Puleo S. Colorectal cancer follow-up: useful or useless? Surg Oncol
28	2006; <b>15</b> (1):1-12 doi: S0960-7404(06)00025-9 [pii]
29	10.1016/j.suronc.2006.06.001[published Online First: Epub Date] .
30	
31	44. Campbell SM, Braspenning J, Hutchinson A, et al. Research methods used in developing and
32	applying quality indicators in primary care. Qual Saf Health Care 2002;11(4):358-64
33	45. Ayanian JZ, Landrum MB, Normand SL, et al. Rating the appropriateness of coronary
34	angiographydo practicing physicians agree with an expert panel and with each other? N Engl
35 36	J Med 1998; <b>338</b> (26):1896-904 doi: 10.1056/NEJM199806253382608[published Online First:
37	Epub Date] .
38	46. Sackett DL, Starus SE, Richardson WS, et al. Evidence-Based Medicine: How to Practice and
39	Teach. 2nd ed. London: Churchill Livingstone, 2000.
40	47. Qualità delle cure contro il cancro (QC3) nel territorio della Svizzera Italiana. Risultatai
41	preliminari dei tumori colorettali incidenti nel 2011. XXXVII GRELL Annual Meeting; May
42	16-18, 2012 16-18 May 2012; Porto, Portugal.
43	48. QoCC Study: indicators of quality of cancer care in Southern Switzerland. 33rd IACR Annual
44	Meeting; October 11-13, 2011; Balaclava, Mauritius.
45	49. Bordoni A, Spitale A, Mazzucchelli L, et al. QC3: quality of comprehensive cancer care in
46	Southern Switzerland. 34th IACR Annual Meeting. Cork, Ireland: IACR, 2012, 17-19
47	September.
48	50. Bordoni A, Spitale A, Mazzucchelli L, et al. <i>Defining evidence-based clinical oncologic cares</i>
49	<i>quality indicators. ENCR Scientific Meeting.</i> Cork, Ireland: ENCR, 2012, 19-20 September.
50	51. Bouchardy C, Rapiti E, Blagojevic S, et al. Older female cancer patients: importance, causes,
51	and consequences of undertreatment. J Clin Oncol 2007; <b>25</b> (14):1858-69 doi: 25/14/1858 [pii]
52 53	10.1200/JCO.2006.10.4208[published Online First: Epub Date]].
53 54	52. Bouchardy C, Rapiti E, Fioretta G, et al. Undertreatment strongly decreases prognosis of breast
55	cancer in elderly women. J Clin Oncol 2003; <b>21</b> (19):3580-7 doi: 10.1200/JCO.2003.02.046
56	•
57	JCO.2003.02.046 [pii][published Online First: Epub Date]].
58	53. van Gijn W, van de Velde CJ. 2010 SSO John Wayne clinical research lecture: rectal cancer
59	outcome improvements in Europe: population-based outcome registrations will conquer the
60	
	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

world. Ann Surg Oncol 2011;18(3):691-6 doi: 10.1245/s10434-010-1326-3[published Online First: Epub Date]|. 54. van Gijn W, van de Velde CJ. Improving quality of cancer care through surgical audit. Eur J Surg Oncol 2010;36 Suppl 1:S23-6 doi: S0748-7983(10)00202-7 [pii] 10.1016/j.ejso.2010.06.026[published Online First: Epub Date]|. 55. Characteristics of clinical indicators. QRB Qual Rev Bull 1989;15(11):330-9 56. Smith N, Brown G. Preoperative staging of rectal cancer. Acta Oncol 2008;47(1):20-31 doi: 783360368 [pii] 10.1080/02841860701697720[published Online First: Epub Date]|. 57. Schneider PM, Vallbohmer D, Ploenes Y, et al. Evaluation of guality indicators following implementation of total mesorectal excision in primarily resected rectal cancer changed future management. Int J Colorectal Dis 2011;26(7):903-9 doi: 10.1007/s00384-011-1155-2[published Online First: Epub Date]]. 58. ACR. Practice Guidelines and Technical Standards. Secondary Practice Guidelines and Technical Standards 2011. http://www.acr.org/guidelines. 59. Taylor FG, Quirke P, Heald RJ, et al. Preoperative High-resolution Magnetic Resonance Imaging Can Identify Good Prognosis Stage I, II, and III Rectal Cancer Best Managed by Surgery Alone: A Prospective, Multicenter, European Study That Recruited Consecutive Patients With Rectal Cancer. Ann Surg 2011 doi: 10.1097/SLA.0b013e31820b8d52[published Online First: Epub Date]|. 60. Beets-Tan RG, Beets GL. Local staging of rectal cancer: A review of imaging. J Magn Reson Imaging 2011;33(5):1012-9 doi: 10.1002/jmri.22475[published Online First: Epub Date]. 61. Bellows CF, Jaffe B, Bacigalupo L, et al. Clinical significance of magnetic resonance imaging findings in rectal cancer. World J Radiol 2011;3(4):92-104 doi: 10.4329/wjr.v3.i4.92[published Online First: Epub Date]]. 62. Taylor FG, Quirke P, Heald RJ, et al. One millimetre is the safe cut-off for magnetic resonance imaging prediction of surgical margin status in rectal cancer. Br J Surg 2011;98(6):872-79 doi: 10.1002/bjs.7458[published Online First: Epub Date]]. 63. Lugli A, Tornillo L, Cathomas G, et al. Colon et rectum. In: Dirnhofer S, Bubendorf L, Lehr H-A, et al., eds. Recommandations pour la qualité - SSPath. Bâle: Sociéte Suisse de Pathologie, 2011. 64. Washington K, Berlin J, Branton P, et al. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Vers. 3.1.0.0. In: Pathologists CoA, ed. Cancer protocols and Checklists, 2011. 65. MacDonald AJ, McEwan H, McCabe M, et al. Age at death of patients with colorectal cancer and the effect of lead-time bias on survival in elective vs emergency surgery. Colorectal Dis 2011;13(5):519-25 doi: CDI2183 [pii] 10.1111/j.1463-1318.2009.02183.x[published Online First: Epub Date]|. 66. Ascanelli S, Navarra G, Tonini G, et al. Early and late outcome after surgery for colorectal cancer: elective versus emergency surgery. Tumori 2003;89(1):36-41 67. Biondo S, Marti-Rague J, Kreisler E, et al. A prospective study of outcomes of emergency and elective surgeries for complicated colonic cancer. Am J Surg 2005;189(4):377-83 doi: S0002-9610(05)00085-1 [pii] 10.1016/j.amjsurg.2005.01.009[published Online First: Epub Date]]. 68. Thompson GA, Cocks JR, Collopy BT, et al. Clinical indicators in colorectal surgery. J Qual Clin Pract 1996;16(1):31-5; discussion 37 69. Morris EJ, Taylor EF, Thomas JD, et al. Thirty-day postoperative mortality after colorectal cancer surgery in England. Gut 2011;60(6):806-13 doi: gut.2010.232181 [pii] 10.1136/gut.2010.232181[published Online First: Epub Date]].

1 2

# BMJ Open

С	Ardle CS, McKee RF, Finlay IG, et al. Improvement in survival following surgery for olorectal cancer. Br J Surg 2005; <b>92</b> (8):1008-13 doi: 10.1002/bjs.4874[published Online
	irst: Epub Date] .
re	tten HJ, den Dulk M, Lemmens VE, et al. Controversies of total mesorectal excision for ectal cancer in elderly patients. Lancet Oncol 2008; <b>9</b> (5):494-501 doi: S1470-2045(08)70129-
	[pii]
	6/S1470-2045(08)70129-3[published Online First: Epub Date]].
c	gers SO, Jr., Ayanian JZ, Ko CY, et al. Surgeons' volume of colorectal cancer procedures and ollaborative decision-making about adjuvant therapies. Ann Surg 2009; <b>250</b> (6):895-900 doi: 0.1097/SLA.0b013e3181afe0c6[published Online First: Epub Date]].
ca si	rtz JE, Heitz D, Serra S, et al. Adjuvant chemotherapy in elderly patients with colorectal ancer. A retrospective analysis of the implementation of tumor board recommendations in a ingle institution. Crit Rev Oncol Hematol 2010;74(3):211-7 doi: S1040-8428(09)00120-6
	pii] 6/i aritravana 2000 05 002[muhlishad Onlina First: Enuh Data]
	6/j.critrevonc.2009.05.003[published Online First: Epub Date] .
pi ca	ry J, Faucheron JL, Moreno W, et al. Delayed colo-anal anastomosis is an alternative to rophylactic diverting stoma after total mesorectal excision for middle and low rectal arcinomas. Eur J Surg Oncol 2010; <b>37</b> (2):127-33 doi: S0748-7983(10)00607-4 [pii]
	6/j.ejso.2010.12.008[published Online First: Epub Date] .
	ginger T, Gonner U, Trinh TT, et al. Permanent stoma after low anterior resection for rectal ancer. Dis Colon Rectum 2010; <b>53</b> (12):1632-9 doi: 10.1007/DCR.0b013e3181ed0aae
000034	53-201012000-00007 [pii][published Online First: Epub Date] .
	uman HB, Patil S, Fuzesi S, et al. Impact of a Temporary Stoma on the Quality of Life of
	ectal Cancer Patients Undergoing Treatment. Ann Surg Oncol 2010 doi: 10.1245/s10434- 10-1446-9[published Online First: Epub Date].
77. Rar	nirez JM, Aguilella V, Valencia J, et al. Transanal endoscopic microsurgery for rectal
ca	ancer. Long-term oncologic results. Int J Colorectal Dis 2011 doi: 10.1007/s00384-011- 132-9[published Online First: Epub Date]].
	zoche G, Guerrieri M, Baldarelli M, et al. Transanal endoscopic microsurgery for 135
pa re	atients with small nonadvanced low rectal cancer (iT1-iT2, iN0): short- and long-term esults. Surg Endosc 2010 doi: 10.1007/s00464-010-1347-9[published Online First: Epub
	Date]].
Ν	ornebosch PG, Tollenaar RA, De Graaf EJ. Is the increasing role of Transanal Endoscopic ficrosurgery in curation for T1 rectal cancer justified? A systematic review. Acta Oncol
	009; <b>48</b> (3):343-53 doi: 904089695 [pii]
	0/02841860802342408[published Online First: Epub Date]].
С	erink MA, Siesling S, Lemmens VE, et al. Variation in Lymph Node Evaluation in Rectal Cancer: A Dutch Nationwide Population-Based Study. Ann Surg Oncol 2010 doi:
	0.1245/s10434-010-1269-8[published Online First: Epub Date]].
la	erink MA, Siesling S, Visser O, et al. Large variation between hospitals and pathology aboratories in lymph node evaluation in colon cancer and its impact on survival, a nationwide opulation-based study in the Netherlands. Ann Oncol 2011; <b>22</b> (1):110-7 doi: mdq312 [pii]
	3/annonc/mdq312[published Online First: Epub Date]].
	lder W, Inberg B, Schaapveld M, et al. Impact of the number of histologically examined
ly	mph nodes on prognosis in colon cancer: a population-based study in the Netherlands. Dis colon Rectum 2009; <b>52</b> (2):260-7 doi: 10.1007/DCR.0b013e3181979164
	[53-200902000-00013 [pii][published Online First: Epub Date]].
	ther R, Sammour T, Kahokehr A, et al. Lymph node evaluation and long-term survival in
S	tage II and Stage III colon cancer: a national study. Ann Surg Oncol 2009; <b>16</b> (3):585-93 doi: 0.1245/s10434-008-0265-8[published Online First: Epub Date]].

- 84. Lindebjerg J, Spindler KL, Ploen J, et al. The prognostic value of lymph node metastases and tumour regression grade in rectal cancer patients treated with long-course preoperative chemoradiotherapy. Colorectal Dis 2009;11(3):264-9 doi: CDI1599 [pii]
- 10.1111/j.1463-1318.2008.01599.x[published Online First: Epub Date]|.
- Choi HK, Law WL, Poon JT. The optimal number of lymph nodes examined in stage II colorectal cancer and its impact of on outcomes. BMC Cancer 2010;10:267 doi: 1471-2407-10-267 [pii]
- 10.1186/1471-2407-10-267[published Online First: Epub Date]|.

- 86. Nelson H, Petrelli N, Carlin A, et al. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 2001;93(8):583-96
- 87. Smith AJ, Driman DK, Spithoff K, et al. Guideline for optimization of colorectal cancer surgery and pathology. J Surg Oncol 2010;**101**(1):5-12 doi: 10.1002/jso.21395[published Online First: Epub Date]].
- Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27(19):3109-16 doi: JCO.2008.20.6771 [pii]
- 10.1200/JCO.2008.20.6771[published Online First: Epub Date]].
- Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352(26):2696-704 doi: 352/26/2696 [pii]
- 10.1056/NEJMoa043116[published Online First: Epub Date]].
- 90. Van Cutsem E, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009;**27**(19):3117-25 doi: JCO.2008.21.6663 [pii]
- 10.1200/JCO.2008.21.6663[published Online First: Epub Date]|.
- 91. Sobrero A. Lower GI. In: ESMO, ed. ESMO HIghlights 2010, 2010.
- 92. Des Guetz G, Nicolas P, Perret GY, et al. Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis. Eur J Cancer 2010;46(6):1049-55 doi: S0959-8049(10)00039-0 [pii]
- 10.1016/j.ejca.2010.01.020[published Online First: Epub Date]|.
- 93. Dienstmann R, Vilar E, Tabernero J. Molecular predictors of response to chemotherapy in colorectal cancer. Cancer J 2011;17(2):114-26 doi: 10.1097/PPO.0b013e318212f844
- 00130404-201103000-00007 [pii][published Online First: Epub Date]|.
- 94. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;**360**(14):1408-17 doi: 360/14/1408 [pii]
- 10.1056/NEJMoa0805019[published Online First: Epub Date]|.
- 95. Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011;**29**(10):1261-70 doi: JCO.2010.30.1366 [pii]
- 10.1200/JCO.2010.30.1366[published Online First: Epub Date]|.
- 96. Van Cutsem E, Nordlinger B, Cervantes A. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol 2010;21(suppl. 5):v93-v97
- 97. Glimelius B, Holm T, Blomqvist L. Chemotherapy in addition to preoperative radiotherapy in locally advanced rectal cancer - a systematic overview. Rev Recent Clin Trials 2008;3(3):204-
- Glimelius B, Pahlman L, Cervantes A. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(suppl. 5):v82-v86
- 99. Landheer ML, Therasse P, van de Velde CJ. The importance of quality assurance in surgical oncology in the treatment of colorectal cancer. Surg Oncol Clin N Am 2001;**10**(4):885-914, x
- 100. Wagner G. Tumor-Lokalisationsschlüssel. International Classification of Diseases for Oncology ICD-O, 2. Topographischer Teil. 5th ed. Berlin: Springer-Verlag, 1993.

# Quality indicators of Clinical Cancer Care (QC<sub>3</sub>) in colorectal cancer

Valentina Bianchi<sup>1</sup>, Alessandra Spitale<sup>1</sup>, <u>Laura Ortelli<sup>1</sup></u>, Luca Mazzucchelli<sup>2</sup>, Andrea Bordoni<sup>1</sup> and the QC<sub>3</sub> CRC Working Group<sup>3</sup>

<sup>1</sup>Cantonal Institute of Pathology, Ticino Cancer Registry, 6600 Locarno, Switzerland <sup>2</sup>Cantonal Institute of Pathology, Clinical Pathology, 6600 Locarno, Switzerland <sup>3</sup>Members of the QC<sub>3</sub> Colorectal Working Group are listed in the Appendix

Running title: Quality indicators of clinical care in colorectal cancer

#### **Corresponding author:**

Valentina Bianchi, M.D., Cantonal Institute of Pathology, Ticino Cancer Registry, , Via in Selva 24, 6600 Locarno, Switzerland - e-mail: <u>valentina.bianchi-galdi@ti.ch</u>; phone: +41 91 8160826; fax: +41 91 8160829

*Key words:* quality of cancer care, colorectal cancer, quality indicators, cancer registry, population-based study

Word count: 28113702 (excluding the Abstract)

2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
• • • •
22 23 24
24
24 25
25
26
27
28
26 27 28 29 30
30
31
22
32
33
33 34 35 36
35 36 37 38
36
37
38
39
39
40
41
42
43
44
45
46
40 47
48
49
50
51
52
53
54
55
55 56
56
57
58
59
60

## ABSTRACT

**Objectives:** Assessing the quality of cancer care (QoCC) has become increasingly important to providers, regulators and purchasers of care worldwide. Aim of this study was to develop evidence-based quality indicators (QI) for colorectal cancer (CRC) to be applied in a population-based setting.

**Design:** A comprehensive evidence-based literature search was performed to identify the initial list of QI, which were then selected and developed using a two-step modified Delphi process involving two multidisciplinary expert panels with expertise in colorectal cancer care, quality of care and epidemiology.

**Setting:** The QC<sub>3</sub> population-based project, which involve all the public and private hospitals and clinics present on the territory of Canton Ticino (South Switzerland).

**Participants:** Ticino Cancer Registry, The Colorectal Cancer Working Group (CRC-WG) and the external academic Advisory Board (AB).

**Main outcome measures:** Set of quality indicators (QI) which encompass the whole diagnostictreatment process of colorectal cancer.

**Results:** Of the 149 QI emerged from 181 sources of literature, 104 were selected during the inperson meeting of the CRC-WG. During the Delphi process, the CRC-WG shortened the list to 89 QI. The AB finally validated 27 QI according to the phase of care: diagnosis (N=6), pathology (N=3), treatment (N=16), and outcome (N=2).

**Conclusions:** Using the validated Delphi methodology, including literature review of the evidence and integration of expert opinions from local clinicians and international experts we were able to develop a list of QI to assess QoCC for CRC. This will hopefully guarantee feasibility of data retrieval, acceptance and translation of QI into the daily clinical practice to improve QoCC. Moreover, evidence-based selected QI allow to assess immediate changes and improvements in the diagnostic-therapeutic process that could be translated in a short-term benefit for patients with a possible gaining both in overall and disease-free survival.

#### ARTICLE SUMMARY

#### Article focus

- Quality of Cancer care (QoCC) studies on specific quality indicators (QI) developed worldwide since the late '90s showed both a continuous improvement of oncologic care provided by the clinical structures involved and an increased availability of specialized care in the considered areas.
- This study aims to define evidence-based QI for colorectal cancer (<u>CRC</u>) care (<u>CRC</u>), in order to favour the <u>a feasible</u> evaluation of the oncologic diagnostic-therapeutic process\_; which can be followed by the definition of standards of care for each QI, in terms of minimum and target requirements.from a population-based cancer registration and data collection point of view.

#### Key messages

- QI should be defined, developed and tested with scientific evidence-based rigor in a careful and transparent manner, taking into account their degree of relevancy, validity, reliability and feasibility.
- The selected CRC QI can be applied in a population-based setting, implying the inclusion of the elderly, considering age an extremely important determinant of treatment.

#### Strengths and limitations of this study

- To develop the CRC QI we used a formal iterative process, the RAND/UCLA
   Appropriateness Methodology widely diffused and validated within other QoCC research.
   The selected QI are representative of the main steps of the diagnostic-therapeutic process.
- Due to the evidence that research studies demonstrated that single-discipline panels select different indicators than do multidisciplinary panels and to maximize the applicability of CRC QI, we constituted two panels of experts, a local Working Group and an external national/international academic Advisory Board, which could offer a multidisciplinary

### **BMJ Open**

perspective on practice and who can guarantee that the selected QI and their results will be comparable with national and international data .--• The pPossible limitations of the current work are the following:  $\succ$  is the level of evidence found in the literature. However this situation is common to  $\leftarrow$ Formatted: Bullets and Numbering many aspects of health care, and it was the reason that the expert panel methodology was developed – specifically, to identify -the processes that are most likely to be valid measures of quality when the highest level of evidence is not available. > the literature selection could have missed some relevant articles. However, members of the Working Group were likely to be very familiar with the literature, and had the opportunity to suggest other indicators based on their experience and literature search; in this way, we believe to have integrated the best research evidence with clinical expertise. > the feasibility of measuring indicators in terms of data collection and calculation. However, both the Working Group and the Advisory Board were concerned about the feasibility, validity and reliability of clinical data collection, necessary for the

calculation of each single indicator at the population-based level. In fact, in order to

warrant an accurate measurement, those indicators reaching more than 70% of the

agreement, confirming their scientific and clinical value, but evaluated at least by

one of the experts not feasible and difficult to be collected at the population-based

level, were definitely excluded. In this way, we have overcome the feasibility limit.

## INTRODUCTION

Research on QoCC performed during the last decade has demonstrated that the increase in knowledge on treatments with proven efficacy do not directly translate into optimal delivery of such treatments to patients. Moreover, accumulating evidence suggests that underuse and overuse of care may occur for patients with cancer.[1-2][1-2] In addition to survival analysis, to evaluate and compare quality of care at the population-based level, the assessment of QoCC has become increasingly important to providers, regulators and purchasers of care to growing demand for services, rising costs, constrained resources and evidence of variation in clinical practice.[3][3] QoCC studies and structured programmes on specific quality indicators (QI) have been developed worldwide since the late '90s, showing both a continuous improvement of oncologic care provided by the clinical structures involved and an increased availability of specialized care in the considered areas. Most of these studies have been implemented at the regional level on a territory with uniform legislative, health and geographical characteristics, increasing the likelihood of recruitment of

involved clinicians. [1 4-7][1, 4 7]

So far, in Switzerland no population-based study on QoCC with a prospective design has been implemented. In addition to the yearly renewed international guidelines for each type of cancer, there is still the need to evaluate the real conditions of care in the community. Population-based Cancer Registry data are therefore essential to describe and reflect real world and routine care as well as to provide regular feedback to healthcare workers and decision makers about the management of a disease in the daily practice and those treatments that are routinely prescribed and/or effective in all patient groups.[8][8] Moreover, Cancer Registries represent an independent observatory, thus assuring a fair evaluation service, avoiding any conflicts of interest. We, therefore, implemented the QC<sub>3</sub> project, focusing on QoCC about the diagnosis-treatment process in colon-rectum, prostate, uterus, ovary and lung cancers in the territory of Canton Ticino (South Switzerland). Field Code Changed

#### **BMJ Open**

Colorectal cancer (CRC) is an important health issue worldwide. It is the most common malignancy in Europe (excluding non-melanoma skin cancers) and the second most common in terms of cancerrelated mortality.[9][9] In Switzerland, CRC is the second and third most frequent tumour in women and men, respectively. About 4000 CRC cases are diagnosed annually, corresponding to a European age-standardized incidence rate equal to 49.4 and 30.6 cases per 100'000 inhabitants in men and women, respectively, and representing the 11% of all tumours.[10-12][10-12] CRC is the third leading cancer cause of death in Switzerland, with approximately 1600 deaths/year, corresponding to a European age-standardized mortality rate equal to 18.5 and 10.6 cases per 100'000 inhabitants in men and women, respectively. With a 5-year survival probability equal to 60%, Switzerland is the country with the most favourable prognosis in Europe. [13] [13] A recent Swiss report with follow up to 2009 show an additional 5 year survival increase to 62%.[11][11] The aims of the QC<sub>3</sub> study-project are the following: 1) to define and <u>confirm</u> evidence-based QoCC indicators for the tumour localizations above cited, in order to favour a feasible evaluation of the oncologic diagnostic-therapeutic process from a population-based cancer registration and data collection point of viewan improvement of the short term oncologic diagnostic therapeutic process; 2) to define and implement at the regional level standards of care for each QoCC measure, in terms of minimum and target requirements. In the present report we will describe the initial part of the  $QC_3$  project, meaning the process followed to identify the panel of specific QoCC indicators for the CRC, as well as the list of QoCC indicators identified and approved both by a dedicated Working Group of local health care providers and by an external independent Advisory Board, in a perspective of data collection feasibility by a population-based cancer registry.

## MATERIAL AND METHODS

The  $QC_3$  project is a prospective, descriptive study on the QoCC to be implemented in a populationbased setting; it is performed by the Ticino Cancer Registry on a 3-year time period (2011-2013) on the territory of Canton Ticino (South Switzerland). In this paper we focus on the initial part of the project: the identification of the CRC quality indicators which will be used to evaluate the QoCC about CRC in our region.

Quality indicators (QI) for CRC were developed involving a local expert panel, named QC<sub>3</sub> Colorectal Working Group (CRC-WG). Elected members, selected on the basis of their expertise and on their daily clinical involvement in CRC care, were contacted to have their interest confirmed in being involved. The final QC<sub>3</sub> CRC-WG encompassed two pathologists, four gastroenterologists, two oncologists, three surgeons, two radiologists, two radiation oncologists and one nuclear medicine specialist, for a total of 15 panellists all working in the public or in the private hospitals and clinics of Canton Ticino (see Appendix 1).

Published studies and references were identified through a comprehensive search on PubMed/MEDLINE, using initially specific strings/expressions, such as the following: "quality of care OR quality indicators AND colorectal cancer", "diagnosis OR diagnostic AND quality indicators AND colorectal cancer", "pathology OR pathological AND quality indicators AND colorectal cancer", "surgery OR surgical AND quality indicators AND colorectal cancer", "radiation oncology OR radiotherapy AND quality indicators AND colorectal cancer", "rehemotherapy AND quality indicators AND colorectal cancer", "chemotherapy AND quality indicators AND colorectal cancer", "chemotherapy AND quality indicators AND colorectal cancer", "surveillance OR follow-up OR outcome AND quality indicators AND colorectal cancer", "preoperative care OR perioperative care OR intraoperative care OR postoperative care AND colorectal cancer", "population-based AND quality indicators AND colorectal cancer". For each of the identified candidate indicators, we performed a systematic literature review to identify the highest level of evidence supporting the validity of that quality indicator for articles published from 1990 onwards. The reference list of the included articles were also examined to identify any additional article that had not been identified in

#### **BMJ Open**

the MEDLINE search. We included all the peer-reviewed articles, but case reports, letters, abstracts or editorials. If evidence at the highest level were limited or absent, then lower levels of evidence were evaluated. For example, if data were not available from randomized controlled trials, cohort or case-control studies, case series and expert opinion or clinical guidelines were reviewed. A selection of already approved QI provided by the American Society of Clinical Oncology (ASCO), the National Comprehensive Cancer Network (NCCN), the National Initiative on Cancer Care Quality (NICCQ), the Quality Oncology Practice Initiative (QOPI) and the Florida Initiative for Quality Cancer Care (FIQCC), were included in the evaluation list, with the aim to transfer them from the clinical to the population-based setting [1-2 4 7 14-20] The initial QI list emerged from 181 sources of literature, and it was proposed to the CRC-WG in the context of an in-person meeting held at the very beginning of the process. The list was then left to the  $QC_3$  CRC-WG's evaluation for a period of two weeks. The participants were asked to provide a whole opinion with written comments about those QI considered pertinent for the assessment of CRC care quality, to suggest additional QI not already included in the list and to delete those QI considered not suitable. In order to make the selection and evaluation easier, the QI were subdivided in chapters recalling the Donabedian's and the National Initiative for Cancer Care Quality schemes: diagnosis and staging, pathology, treatment, follow-up, outcome. [2 21] [2, 14]

#### **Delphi Round 1**

The QI selection was done by using a 2-step modified Delphi process.[22][15] The initial list of QI, re-analyzed by the QC<sub>3</sub> CRC-WG, was formatted as a questionnaire, where for each indicator was specified the numerator, the denominator and the sources of evidence from which it was extracted. The questionnaire was distributed by regular mail to the QC<sub>3</sub> CRC-WG, so to maintain it anonymous, along with a stamped, addressed return envelope and an attached letter with the deadline date of two weeks from the receipt and the instruction for voting. Respondents were asked to rate each QI adopting the RAND Appropriateness Methodology (scale 1 to 9, 1 = extremely

Formatted: English (U.K.), Do not check spelling or grammar

inappropriate; 9 = extremely appropriate), according to selection criteria of relevance, scientific soundness (validity, reliability, comparability) and feasibility (precise definition and specification, data feasibility, reliability of data collection).[23-25][16-18] Each QI was judged as validated if it reached a strong consensus for acceptance ( $\geq$ 70% of the QC<sub>3</sub> CRC-WG rated the QI with a vote  $\geq$ 7), discarded if it reached a strong consensus for exclusion ( $\geq$ 70% of the QC<sub>3</sub> CRC-WG rated the QI with a votes  $\leq$  3) and in stand-by if there was an unclear consensus ( $4 \leq$  votes  $\leq$  6), which implies an eventual in-person meeting.

#### Delphi Round 2

The Delphi Round 2 questionnaire was performed with the same modalities of the first round and enclosed the frequency distribution of round 1 votes, allowing the panellists to eventually alter their responses, in the light of colleagues' assessments.[23][16]

#### **Advisory Board Review**

The list of selected QI derived from the two Delphi rounds was then submitted to an independent external national/international academic multidisciplinary Advisory Board (AB), in order to get an additional evaluation on the suitability of QI as "quality" indexes according to the criteria shown in the previous paragraph. The intent was to achieve at least one health professional for each specialty. The AB included one pathologist, one gastroenterologist, two oncologists, two surgeons, one radiologist, one radiation oncologist, one nuclear medicine specialist and one epidemiologist, for a total of 10 experts in CRC care (see Acknowledgements); all the panellists are daily involved in the CRC care and they had been contacted with the same modalities of the QC<sub>3</sub> CRC WG. The selected QI as well as the corresponding literature sources were distributed to the AB as an electronic form where their opinion about QI were expressed both as megatrends (i.e. response yes/no to the suitability of each QI) and as eventual additional comments.[26] We considered every single QI as finally approved by the AB if it achieved  $\geq 70\%$  of the agreement (i.e.  $\geq 70\%$  of respondents should

## **BMJ Open**

4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
1/	
8 9 10 11 12 13 14 15	
-	
16	
17 18 19	
18	
19	
20	
21	
22	
23	
20	
24 25 26 27	
25	
26	
27	
28 29 30	
29	
30	
31	
22	
32 33 34 35 36 37	
33	
34	
35	
36	
37	
38	
20	
40	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49 50	
50	
51	
52	
53	
54	
55	
56	
56 57	
58	
59	
60	

have answered "yes"). Besides the vote ("yes" versus "no"), the panellists had the chance to comment the single QI from a population-based cancer registration and data collection point of view. Therefore, those QI reaching more than 70% of the agreement, confirming their scientific and clinical value, but evaluated at least by one of the experts "not completely feasible and difficult to be collected at the population-based level", were definitely excluded.

# RESULTS

The QI selection process began in January 2011 and ended in December 2011.

Participation of CRC-WG members throughout the process was high: 15 (100%) participated to the in-person meeting, 12 (80%) completed both the Delphi round 1 and 2. The Delphi Round 1 questionnaire respondent time were in the range of 18 to 60 days, while for the Round 2, the delay time was in the range of 8 to 55 days; these delays and the time for recruitment of the AB influence the long time spent for this part of the project.

The Figure 1 summarizes the entire process used to select QI for CRC care. The literature search produces 181 citations dealing with CRC QoCC, including also already validated QI provided by the ASCO, NCCN, NICCQ, QOPI and FIQCC. [1-2 4 7 14-20] From this search, we initially selected a total of 149 QI, which were proposed to the CRC-WG in the context of the initial inperson meeting. The following discussion and revision reduced the list to 104 QI before the modified Delphi process started; these QI were divided into the following areas: diagnosis and staging, pathology, treatment, follow-up and outcome. After the whole Delphi process the list was shortened to 89 QI, distributed as following: diagnosis and staging (N=16), pathology (N=20), treatment (N=38), follow-up (N=10), and outcome (N=5). The QI finally underwent to the AB's evaluation; this last step, according to the procedure described in the methods, shortened the final list to 27 QI (Tab.1): diagnosis (N=6), pathology (N=3); treatment (N=16), follow-up (N=0), and outcome (N=2). Table 1 reports detailed information for each QI: a) QI description; b) criteria for patients inclusion in the numerator and denominator; c) list of the necessary medical documentation that should be collected by the Cancer Registry to extract the needed and relevant information to built the specific QI, such as the report of the endoscopy, the pathology report of the biopsy and/or surgical resection, the preoperative radiological reports (e.g. TAC and MRI), the surgery report, the tumour board documentation, the oncological report, the radiotherapy report and database/documentation of the regional Office of Population Registry Rosters for the assessment of patients vital status (for outcome QI); d) QI rationale; e) related references.

## DISCUSSION

In the preliminary phase of the QC<sub>3</sub> project shown in this paper we developed a panel of evidencebased CRC QI which are suitable to be implemented in a population-based setting. To develop the QC<sub>3</sub> QI we used a formal iterative process, the RAND/UCLA Appropriateness Methodology widely diffused and validated within other QoCC research.[23-24][16-17] Due to the evidence that research studies demonstrated that single-discipline panels select different indicators than do multidisciplinary panels and to maximize the applicability of QC<sub>3</sub> CRC QI, we constituted a working group which could offer a multidisciplinary perspective on practice, including specialists, professionals, clinicians and researchers coming from both public and private hospitals.[27-33][19-25] Moreover, we have used a further validation step enrolling an independent national/international academic AB. This choice was due to the aim of measuring QoCC within a Swiss region, with a point of view on the population-based data collection and evaluation, and of obtaining results which will be comparable with national and international data. We believe that the expertise and multidisciplinary representativeness of the QC3 CRC-WG and of the AB will surely increase quality, acceptance and translation of QI into the daily clinical practice-. The selected QI are representative of the main steps of the diagnostic-therapeutic process. The diagnosis QI reflect the importance of a pre-operative evaluation and staging, reliable evaluation of the tumour localization and local invasion, and particularly for the rectal cancers, of a feasible and effective surgery. The first indicator of the "diagnosis" group is important to understand what happens in a territory where there is not an organized screening programme for colorectal cancers, but only an opportunistic screening strategy. If the tumour is detected because the physician submit the patients older than 50 years old to a fecal occult blood test (FOBT) or colonoscopy control or if a patient, being aware of the possible risk, asks his family doctor to undergo screening examinations, is an interesting data to be evaluated, also in the hypothesis of a colorectal cancer screening programme implementation. We, therefore, believe that a higher proportion of patients diagnosed through screening (FOBT or colonoscopy in asymptomatic patients) would represent a

### **BMJ Open**

> higher diagnostic quality, since the therapeutic approach and, consequently, the patients outcome (in terms of recurrence and survival) would be more favourable, as reported in the literature.[20 34-<u>39</u> The pathology QI reflect the importance of a good communication between clinicians and pathologists in terms of patient's clinical history and consequent evaluation of the effectiveness of a neo-adjuvant therapy; moreover, there is a need of standardization of the pathologic report following the international guidelines (e.g. take at least three samples of tumour during the macroscopy), not leaving any items unexplained or implicit. In particular, the third QI reported in Table 1 (pathology section) refers to the surgical pathology report, which derives from the surgical curative intervention and should be as complete as possible to be useful for the future decision about patient's treatment. Our intent is to calculate it for all listed items considered together, but also for each item individually analyzed: e.g. proportion of patients with colorectal cancer and a definitive pathological report including the surgical intervention description; proportion of patients with colorectal cancer and a definitive pathological report including the tumour size; proportion of patients with colorectal cancer and a definitive pathological report including the resection margins; proportion of patients with colorectal cancer and a definitive pathological report including the pathological staging (AJCC pTNM); etc... The treatment QI cover the general issues of surgery, such as emergency, postoperative mortality and a multidisciplinary discussion of the clinical case; furthermore, they focus on the debate of the retrieved lymph nodes, on the timing between radiotherapy and surgery, on the adjuvant chemotherapy and on the attitude towards the metastatic patients. The two main items of the outcome chapter refers to the overall and disease-free survival. Although -it is necessary to wait for a certain follow-up period (i.e. 1, 3, 5 to 10 years from the date diagnosis for the calculation of overall survival, and from the date of curative treatment for the calculation of disease-free survival), they will represent the overall resume of the diagnostic and treatment quality of CRC patients. Our intent will be to analyse overall and disease-free survival according to some of the proposed QI (such as QI concerning the pathological characteristics of the tumours, QI of the adjuvant chemotherapy in patients with colon cancer and AJCC TNM stage II

### **BMJ Open**

high-risk or III, QI of colorectal patients operated on with free margins, QI of locally advanced rectal cancer patients undergoing neo-adjuvant radio±chemotherapy, etc...). We will finally compare our results with other regional and national reality, favouring the interpretation of each single QL Concerning the QI about follow-up, AB did not finally include any of them. Indeed, although the follow-up procedures are suggested by several international guidelines, they are based on level II-III evidence and controversies remain regarding selection of optimal strategies for following up patients after potentially curative CRCeolorectal cancer surgery.-[40-43][26-29] The first limitation of the current work is the level of evidence found in the literature. For some indicators, strong evidence of their validity was not available from RCTs. However this situation is common to many aspects of health care, and it was the very reason that the expert panel methodology was developed - specifically, to identify the processes that are most likely to be valid measures of quality when the highest level of evidence is not available.[19 23 44][16, 30 31] Secondly, we may have missed some studies during the literature search and, consequently, some QI has not been proposed to the  $QC_3$  CRC-WG since the beginning of the QI revision process. However, this limitation should have been overcome by the fact that the members of the QC<sub>3</sub> CRC-WG were likely to be very familiar with the literature, and had the opportunity to suggest other QI based on their experience and literature search. [7 27-28 45] [7, 19-20, 32] Thus we integrated the best research evidence with clinical expertise, as reported by Sackett et al. [46][33] A further limit could be the feasibility of measuring QI in terms of data collection and calculation, which is immediately the next step. Actually, the QI selected by both the QC<sub>3</sub> CRC-WG and the AB represent an ideal set of criteria to measure the quality of CRC care; at the same time they both were concerned about the feasibility, validity and reliability of clinical data collection, necessary for the calculation of each single QI at the population-based level. This is the reason why most of the identified QC<sub>3</sub> QI are common to many QoCC studies.[1-2 4 7 14-20] Besides the traditional Delphi process, the panellists had the chance to comment the single OI from a population-based cancer registration and data collection point of view. Therefore, in order to warrant an accurate

measurement, those QI reaching more than 70% of the agreement, confirming their scientific and clinical value, but evaluated at least by one of the experts not feasible and difficult to be collected at the population-based level, were definitely excluded. In addition, we performed a retrospective preliminary pilot collection on the detailed and necessary incidence data of CRC occurred in 2011, realising that the measurement of most QI is feasible, whereas for some selected QI the retrieving of variables should would need be additional effortsly tested; some preliminary results were presented in national and international conferences and congresses, receiving positive feedback by both the clinical and epidemiological setting. [47-50] [34-35] Only the definitive results will give us the proportion of missing information, whose magnitude will be assessed. The selected QC<sub>3</sub> CRC QI will be applied in a population-based setting, where age is an extremely important determinant of treatment. The elderly are rarely included in the randomized clinical trials with the consequence of a possible "underuse of treatment". [25 51-52][18, 36 37] At a broad European level, national audit registries in surgical oncology have led to improvements with a great impact and they offered the possibility, as for our project, to perform research on patients that are usually excluded from clinical trials such as elderly and co-morbid patients. [53-54][38-39] Evidence suggests that the relative benefits of treatment for the elderly are similar to those seen for cancer patients in general, though decision making for treatment becomes more complex as life expectancy, co-existing illnesses, and functional status all need to be considered. [25 51-52][18, 36-371 Applying these QI and if all these items will be satisfied we can affirm to have a real good quality process of CRC care for the whole population. The foreseeable future in quality evaluation and improvement for health care will likely involve more and more frequently the use of QI by regulatory and accrediting agencies, stakeholders, clinicians, individual hospitals and health care providers, as well as patients. This underlines that the QI should be defined, developed and tested with scientific evidence-based rigor in a careful and transparent manner, taking into account their degree of relevancy, validity, reliability and feasibility.[30 32][22, 24] Although QI have been

### **BMJ Open**

defined in several different ways, all authors agreed that the final aim is the improvement of patients outcome.[31 33 55][23, 25, 40]

The systematic trend analysis of QI allows to assess immediate changes and improvements in the diagnostic-therapeutic process that could be translated in a short-term benefit for patient, without waiting for survival analysis typically needed some years to be produced because of the patients' follow-up. Furthermore, this system of evaluation and auto-evaluation could favour the surveillance and monitoring of the comprehensive level of the oncologic care in the region, the clinical performance homogeneity, the possible weakness of the clinical network, and finally the corrective interventions to be adopted to improve the QoCC.

With this study, we hope to increase the awareness of the value of QI in health care so to encourage more uniform practices and improve provider documentation of medical care in our region;

moreover, we hope that standardization of QI among different regions will help to define threshold of minimal standard of care.

### **APPENDIX (List of Collaborators)**

Members of the QC<sub>3</sub> CRC Working Group are listed as following:

Barizzi J., Clinical Pathology, Cantonal Institute of Pathology, 6600 Locarno, Switzerland; Bihl F., Gastroenterology Dept., Ospedale Regionale Bellinzona e Valli, 6500 Bellinzona Switzerland; Christoforidis D., General Surgery Dept., Ospedale Regionale di Lugano, 6900 Lugano, Switzerland; Franzetti-Pellanda A., Radiation Oncology Dept., Clinica Luganese, 6900 Lugano, Switzerland; Giovanella L., Nuclear Medicine Dept., Oncology Institute of Southern Switzerland (IOSI), 6500 Bellinzona, Switzerland; Heinkel J., Radiology Dept., Ospedale La Carità, 6600 Locarno, Switzerland; Maffei M., Gastroenterology Dept., Ospedale Regionale di Lugano, 6900 Lugano, Switzerland; Mazzucchelli L., Clinical Pathology, Cantonal Institute of Pathology, 6600 Locarno, Switzerland; Miazza B., Gastroenterology Dept., Ospedale Regionale di Lugano, 6900 Lugano, Switzerland; Pelloni A., General Surgery Dept., Ospedale La Carità, 6600 Locarno, Switzerland; Quattropani C., Gastroenterology Dept., Clinica Luganese, 6900 Lugano, Switzerland; Rosso R., General Surgery Dept., Ospedale Regionale di Lugano, 6900 Lugano, Switzerland; Saletti P., Medical Oncology Dept., Oncology Institute of Southern Switzerland (IOSI), 6500 Bellinzona, Switzerland; Valli M. C., Radiation Oncology Dept., Oncology Institute of Southern Switzerland (IOSI), 6500 Bellinzona, Switzerland; Varini M., Medical Oncology Dept., L Clinica Sant'Anna, 6900 Lugano, Switzerland; Wyttenbach R., Radiology Dept., Ospedale Regionale Bellinzona e Valli, 6500 Bellinzona, Switzerland.

### FUNDING

This work was supported by Krebsforschung Schweiz, grant number KFS - 02668-08-2010, and by

Advisory Board Research Ente Ospedaliero Cantonale Bellinzona, grant number ABREOC

### 10/2010.

The funding sources have not any involvement in the study design, in the collection, analysis and interpretation of data, in the writing of the report and in the decision to submit the paper for

# publication.

## **COMPETING INTERESTS**

The Authors have no competing interests.

### DATA SHARING

There is no additional data available.

### **AUTHORS' CONTRIBUTION**

have direc I declare that V. Bianchi, A. Bordoni, A. Spitale and L. Mazzucchelli have directly participated in the planning of the manuscript; that V. Bianchi, A. Bordoni, A. Spitale and the QC<sub>3</sub> Colorectal Working Group have directly participated in the conducting of the project; that V. Bianchi, A. Bordoni, A. Spitale and L. Ortelli have directly participated in the reporting, acquisition of data or analysis and interpretation of data; and that V. Bianchi and A. Bordoni are responsible for the overall content as guarantors of the work. Finally, I declare that all the Authors have drafted and revised the paper critically for important intellectual content, and that they have given final approval of the version published. None of the Authors have competing interests.

### ACKNOWLEDGEMENTS

We are particularly grateful to the QC<sub>3</sub> CRC AB Members, who contribute to critically review the QC<sub>3</sub> CRC QI, for their precious collaboration:

Prof. Franco Cavalli, Scientific Director, Oncologic Institute of Italian Switzerland (IOSI),
Bellinzona, Switzerland; Prof. Gian Dorta, Director, Digestive Endoscopy Dept., Centre
Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland; Prof. Jean Faivre, Director,
Registre Bourguignon des Cancers Digestifs, Dijon Cedex , France; Prof. Stefano Fanti, Director,
PET Center, Policlinico S. Orsola-Malpighi, Bologna, Italy; Prof. Roberto Labianca, Director,
Oncology and Haematology Dept., Ospedali Riuniti, Bergamo, Italy; Prof. Sebastiano Martinoli,
Director, General Surgery Dept., Clinica Luganese, Lugano, Switzerland; Prof. Philip Quirke,
Director, Leeds Institute of Molecular Medicine (LIMM), Section of Pathology, Wellcome Trust
Brenner Building, St James's University Hospital, Leeds, United Kingdom; Prof. Emmanuel Tiret,
Chef Pôle Digestif des Hôpitaux Univesitaires Paris Est, Chef Service de Chirurgie Générale et
Digestive, Hôpital Saint-Antoine, Paris, France; Prof. Vincenzo Valentini, Director, Unità
Operativa Complessa Radioterapia 1, Policlinico Universitario Agostino Gemelli, Rome, Italy;
Prof. Dominik Weishaupt, Director, Radiology Dept., Stadtspital Triemli, Zürich, Switzerland.

## COPYRIGHT

<text><text><text> The Corresponding Author has the right to grant on behalf of all Authors and does grant on behalf of all Authors, an exclusive licence on a worldwide basis to the BMJ Publishing Group Ltd, and its Licensees to permit this article (if accepted) to be published in BMJ Open and any other BMJPGL products to exploit all subsidiary rights, as set out in your licence and the Corresponding Author accepts and understands that any supply made under these terms is made by BMJPGL to the Corresponding Author.

## **LEGENDS TO FIGURES**

FIGURE 1 - Process used to select quality indicators for colorectal cancer care

 . quality indicators for colorectal c.

 . CRC-WG = QC3 Colorectal Cancer Work.

 QI = Quality Indicators; QC<sub>3</sub> CRC-WG = QC3 Colorectal Cancer Working Group; AB = Advisory Board

# Table 1. Quality indicators of colorectal cancer care according to diagnostic-therapeutic process (diagnosis, pathology,

treatment - surgery, chemotherapy and radiotherapy - and outcome) and tumour site.

<b>CLINICAL</b>	<u>SITE</u>	<b>QUALITY INDICATOR</b>	NUMERATOR	<b>DENOMINATOR</b>	MEDICAL	RATIONALE	REF
<b>DOMAIN</b>					<b>DOCUMENTATION</b>		
SIS	<u>C&amp;R</u>	Proportion of patients with colorectal cancer and diagnosis based on symptoms vs screening vs accidental finding	Number of patients with colorectal cancer whose diagnosis is based on symptoms, defined as appearance or persistence of clinical events and signs, such as rectal bleeding, occult blood in stool, weight loss with no apparent cause, general abdominal discomfort, bowel obstruction, change in bowel habits, constant tiredness, anaemia Number of patients with colorectal cancer whose diagnosis is based on screening, defined as regular examination, such as faecal occult blood test (FOBT) or colonoscopy in asymptomatic patients Number of patients with colorectal cancer whose diagnosis is an accidental finding following examinations or therapies for other diseases (e.g. hospital admission for other causes)	Number of patients with colorectal cancer	Request form of endoscopic examination Endoscopy and surgical pathology reports Reports/discharge letters coming from all hospital units/department (i.e. surgery, medicine, radiation oncology, medical oncology )	Assessment of the patient's take charge	[ <u>18 34-</u> <u>38]</u>
<u>DIAGNOSIS</u> (n=6)	<u>C&amp;R</u>	Proportion of patients with colorectal cancer, evaluated by preoperative colonoscopy	Number of patients with colorectal cancer who have been evaluated by a preoperative colonoscopy	Number of patients with colorectal cancer undergoing surgery.	Endoscopy report Request form of pathology examination Pathology report of endoscopy	Planning of further diagnostic procedures and treatments Comprehensiveness of diagnostic and staging evaluation	[ <u>7 16 18</u> <u>40-41]</u>
	R	Proportion of patients with rectal cancer and description of the tumour localization (distance <i>ab ano</i> ) in the endoscopic/pathologic documentation	Number of patients with rectal cancer who have the description of the tumour localization, in terms of distance <i>ab ano</i> , in the endoscopic/pathologic documentation	Number of patients with rectal cancer undergoing endoscopy	Endoscopy report Request form of pathology examination Pathology report of endoscopy	Planning of further diagnostic procedures and treatments Comprehensiveness of diagnostic and staging evaluation	[ <u>1 19 56-</u> <u>57]</u>
	<u>C&amp;R</u>	Proportion of patients with colorectal cancer and requests for an initial CT and/or a MRI examination completed by clinical information according to the ACR guidelines	Number of patients with colorectal cancer for which the request of an initial CT and/or a MRI examination is completed by clinical information according to the ACR guidelines	Number of patients with colorectal cancer undergoing initial CT and/or MRI examination	Radiology (CT and/or MRI examination) report	Providing the necessary information for a comprehensive radiological examination Assessment of the quality of the flux of clinical information	[ <u>7 58]</u>

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

	R	Proportion of patients with low rectal <sup>a</sup> cancer undergoing pelvic <u>MRI of staging</u>	Number of patients with low rectal* cancer who have undergone a pelvic MRI of staging	Number of patients with low rectal cancer	Radiology (MRI examination) report Discharge letters coming from all hospital units/department (i.e. surgery, medicine, medical oncology, radiation oncology, 1	Planning of further diagnostic procedures and treatments Comprehensiveness of diagnostic and staging evaluation	[ <u>19 59-</u> <u>61]</u>
	<u>R</u>	Proportion of patients with rectal cancer and a preoperative MRI reporting the description of the radial margin status (mm)	Number of patients with rectal cancer who have undergone a preoperative MRI reporting the description of the radial margin status (mm)	Number of patients with rectal cancer undergoing preoperative <u>MRI</u>	Radiology (MRI examination) report	Planning of further diagnostic procedures and treatments Comprehensiveness of diagnostic and staging evaluation	<u>[62]</u>
	<u>R</u>	Proportion of patients with rectal cancer for which the request for the pathological examination includes the information of neo-adjuvant <u>RT±ChT</u>	Number of patients with rectal cancer for which the request for the pathological examination includes the information of neo-adjuvant RT±ChT	Number of patients with rectal cancer undergoing neo-adjuvant RT±ChT and surgery. <sup>a</sup>	Request form of pathology examination Surgical pathology report	Providing the necessary information for a comprehensive pathological examination Assessment of the quality of the flux of clinical information	Proposed by CRC-WG
	<u>C&amp;R</u>	Proportion of patients with colorectal cancer and a sufficient number of tumour samples (23)	Number of patients with colorectal cancer for which 3 or more tumour sample were processed for the pathological analysis	Number of patients with colorectal cancer undergoing surgery.*	Surgical pathology report	Comprehensiveness of pathology examination	Proposed by CRC-WG
PATHOLOGY (n=3)	C&R	Proportion of patients with colorectal cancer and a surgical pathology report including the following characteristics: - surgical intervention description - sample length - tumour localization according to WHQ - tumour size - histological type according to WHQ - histological grade - resection margins - lymph-vascular invasion - perineural invasion - tumour deposits (discontinuous extramural extension)	Number of patients with colorectal cancer whose pathological report includes the following characteristics:           - surgical intervention description           - sample length           - tumour localization according to WHO           - tumour size           - histological grade           - resection margins           - lymph-vascular invasion           - pathological staging (AJCC pTNM)           - number of retrieved lymph nodes           - treatment effect	Number of patients with colorectal cancer undergoing surgery <sup>a</sup>	Surgical pathology report	Comprehensiveness and standardisation of surgical pathology report Comprehensiveness of staging evaluation Planning of further treatments	[ <u>18-19</u> <u>63-64</u> ]

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

		- pathological staging (AJCC pTNM)     - number of retrieved lymph nodes     - treatment effect     -macroscopic integrity of the mesorectum (for rectum only)     (this quality indicator should be provided for each characteristic)	(for rectum only)				
	<u>C&amp;R</u>	Proportion of patients with colorectal cancer operated in emergency <sup>b</sup>	Number of patients with colorectal cancer who have been operated in emergency <sup>b</sup>	Number of patients with colorectal cancer undergoing surgery <sup>a</sup>	Radiology and surgery report/discharge letter Surgical pathology report	Assessment of the patient's take charge	[65-67]
	<u>C&amp;R</u>	Proportion of patients with colorectal cancer and dead within 30 days and 6 months from the surgery (postoperative mortality)	Number of patients with colorectal cancer and dead within 30 days from the surgery Number of patients with colorectal cancer and dead within 6 months from the surgery	Number of patients with colorectal cancer undergoing surgery <sup>a</sup>	Surgery report/discharge letter Surgical pathology report Access to regional Office of Population Registry Rosters for the assessment of patients vital status	Assessment of the quality of surgical procedure	[68-71]
INT	<u>C&amp;R</u>	Proportion of patients with colorectal cancer and postoperative multidisciplinary discussion	Number of patients with colorectal cancer for which there have been a multidisciplinary discussion after surgery	Number of patients with colorectal cancer undergoing surgery <sup>a</sup>	Surgery, Oncology, Radiation Oncology reports/discharge letters Multidisciplinary discussion documentation	Planning of further diagnostic procedures and treatments	<u>[72-73]</u>
TREATMENT (n=16)	<u>R</u>	Proportion of patients with malignant rectal polyp (pT1) and complete endoscopic polypectomy	Number of patients with malignant rectal polyp (pT1) who have undergone a complete endoscopic polypectomy	<u>Number of patients with</u> <u>malignant rectal polyp (pT1)</u>	Endoscopy report, Endoscopic pathology reports	Assessment of the quality of surgical procedure	Proposed by the CRC-WG
-	<u>R</u>	Proportion of patients with low rectal <sup>c</sup> cancer and surgical intervention with sphincter preservation	Number of patients with low rectal <sup>c</sup> cancer who have undergone a surgical intervention with sphincter preservation	Number of patients with low rectal cancer undergoing surgery *	Surgical pathology report Surgery report/discharge letter	Assessment of the quality of surgical procedure	<u>[7 74-76]</u>
	<u>R</u>	Proportion of patients with rectal cancer undergoing TEM with R0 resection	Number of patients with rectal cancer who had undergone TEM with R0 resection	Number of patients with rectal cancer undergoing TEM	Surgical pathology report Surgery report/discharge letter	Assessment of the quality of surgical procedure	<u>[77-79]</u>
	<u>C&amp;R</u>	$\frac{Proportion of patients with}{colorectal cancer and a number} of resected lymph nodes \geq 12$	Number of patients with colorectal cancer with a number of resected lymph nodes $\geq \frac{12}{2}$	Number of patients with colorectal cancer undergoing surgery <sup>a</sup> , but no neo-adjuvant therapy	Surgical pathology report Surgery report/discharge letter	Assessment of the quality of surgical procedure and pathology examination	[7 14 16 40-41 80- <u>85]</u>
	<u>C&amp;R</u>	Proportion of patients with colorectal cancer operated on with free margins	Number of patients with colon cancer who have undergone surgery and have free margins	Number of patients with colorectal cancer undergoing surgery <sup>a</sup>	Surgical pathology report Surgery report/discharge	Assessment of the quality of surgical procedure	[ <u>7 86-87]</u>

$1 \\ 2 \\ 3 \\ 4 \\ 5 \\ 6 \\ 7 \\ 8 \\ 9 \\ 10 \\ 11 \\ 2 \\ 13 \\ 4 \\ 15 \\ 16 \\ 17 \\ 18 \\ 19 \\ 20 \\ 12 \\ 23 \\ 24 \\ 25 \\ 26 \\ 27 \\ 28 \\ 9 \\ 30 \\ 1 \\ 32 \\ 33 \\ 34 \\ 35 \\ 36 \\ 37 \\ 8 \\ 30 \\ 36 \\ 37 \\ 8 \\ 30 \\ 36 \\ 37 \\ 8 \\ 30 \\ 36 \\ 37 \\ 8 \\ 30 \\ 36 \\ 37 \\ 8 \\ 30 \\ 36 \\ 37 \\ 8 \\ 30 \\ 36 \\ 37 \\ 8 \\ 30 \\ 36 \\ 37 \\ 8 \\ 30 \\ 36 \\ 37 \\ 8 \\ 30 \\ 30 \\ 30 \\ 30 \\ 30 \\ 30 \\ 30 $	
3	
4 5	
6	
7	
8	
9 10	
11	
12	
13	
14	
16	
17	
18	
20	
21	
22	
23	
25	
26	
27	
28 29	
30	
31	
32	
33 34	
35	
36	
37	
<b>5M</b>	
40	
41 42	
42 43	
43	
45	
46	
47 48	
40 ⊿Q	

				letter		
<u>C&amp;R</u>	Proportion of patients with colorectal cancer and AJCC TNM clinical stage I (from T2N0M0) to III (any T, NIM0) undergoing a surgical resection with anastomosis	Number of patients with colon cancer and AJCC TNM clinical stage 1 (from T2N0M0) to III (any T, N1M0) who have undergone a surgical resection with anastomosis	Number of patients with colorectal cancer and AJCC TNM stage I (from T2N0M0) to III	Radiology report Surgical pathology report Surgery report/discharge letter	Assessment of the quality of surgical procedure	[40- <u>86-</u> 8
<u>C</u>	Proportion of patients with colon cancer and AJCC TNM stage II (T3N0M0, T4N0M0) high-risk (presence of at least one of the following factors: LN<12, G3, lymph-vascular or perineural invasion, tumour obstruction, tumour perforation, pT4) or III undergoing adjuvant ChT	Number of patients with colon cancer and AJCC TNM stage II (T3N0M0, T4N0M0) high-risk (presence of at least one of the following factors: LN<12, G3, lymph- vascular or perineural invasion, tumour obstruction, tumour perforation, pT4) or III, who have undergone adjuvant ChT	Number of patients with colon cancer and AJCC TNM stage II high-risk or III, undergoing surgery. <sup>a</sup>	Radiology report Surgical pathology report Surgery, oncology reports/discharge letters	Assessment of the quality of oncologic treatment	[ <u>16</u> <u>40-41</u> <u>91</u>
<u>C</u>	Proportion of patients with colon cancer AJCC TNM stage II high-risk or stage III undergoing adjuvant ChT within 8 weeks from surgical resection	Number of patients with colon cancer and AJCC TNM stage II high-risk or III, who have undergone adjuvant ChT within 8 weeks from surgical resection	Number of patients with colon cancer and AJCC TNM stage II high-risk or III undergoing surgery <sup>a</sup> and adjuvant ChT	Radiology report Surgical pathology report Surgery, oncology reports/discharge letters	Assessment of the quality of oncologic treatment	[18.9
<u>C&amp;R</u>	Proportion of patients with colorectal cancer and histology of the primary tumour or metastases obtained before the beginning of ChT	Number of patients with colorectal cancer and histology of the primary tumour or metastases obtained before the beginning of ChT	Number of patients with colorectal cancer undergoing primary ChT	Radiology and pathology reports Oncology report/discharge letter	Assessment of the quality of oncologic treatment	[40-4
<u>C&amp;R</u>	Proportion of patients with colorectal cancer and unresectable metastases undergoing first-line ChT or bio-ChT	Number of patients with colorectal cancer and unresectable metastases who have undergone a first-line ChT or bio-ChT	Number of patients with colorectal cancer and unresectable metastases	Radiology and pathology reports Oncology report/discharge letter	Assessment of the quality of oncologic treatment	[93-
<u>C&amp;R</u>	Proportion of patients with colorectal cancer and hepatic metastases primarily unresectable turned into resectable metastases after neo- adjuvant ChT	Number of patients with colorectal cancer and hepatic metastases primarily unresectable turned into resectable metastases after neo-adjuvant ChT	Number of patients with colorectal cancer and unresectable hepatic metastases undergoing neo- adjuvant ChT	Radiology report Oncology report/discharge letter	Assessment of the quality of oncologic treatment	[96
<u>R</u>	Proportion of patients with locally advanced rectal cancer (T3-4 and/or any T, N+ and M0) undergoing neo-adjuvant <u>RT±ChT</u>	Proportion of patients with locally advanced rectal cancer (T3-4 and/or any T, N+ and M0) who have undergone neo- adjuvant RT±ChT	Number of patients with locally advanced rectal cancer undergoing surgery *	Endoscopic pathology report Radiology report Radiation Oncology and oncology reports/discharge letters	Assessment of the quality of oncologic and radio- oncologic treatment	[97-9
<u>R</u>	Proportion of patients with	Number of patients with rectal cancer who	Number of patients with rectal	Endoscopic pathology	Assessment of the quality	[18.9

		rectal cancer and undergoing neo-adjuvant RT±ChT operated within 6-8 weeks after the end of neo-adjuvant RT±ChT	have undergone neo-adjuvant RT±ChT and were operated within 6-8 weeks after the end of neo-adjuvant RT±ChT	cancer undergoing neo-adjuvant RT±ChT followed by surgery <sup>a</sup>	report Radiology report Radiation Oncology and oncology reports/discharge letters Surgical pathology report	of oncologic and radio- oncologic treatment		
DME	<u>C&amp;R</u>	Analysis of overall survival at 1, 3, 5 and 10 years from diagnosis	Number of patients with colorectal cancer who survive at 1, 3, 5 and 10 years from diagnosis	Number of patients with colorectal cancer	Access to regional Office of Population Registry Rosters for the assessment of patients vital status	Assessment of overall survival	[7 99]	_
<u>OUTCOME</u> (n=2)	<u>C&amp;R</u>	Analysis of disease-free survival at 1, 3, 5 and 10 years from the curative treatment	Number of patients with colorectal cancer who are disease-free at 1, 3, 5 and 10 years from the curative treatment	Number of patients with colorectal cancer curatively treated	Reports/discharge letters coming from all hospital units/department (i.e. surgery, medicine, oncology, radio-oncology)	Assessment of disease-free survival	[ <u>7 99]</u>	
Abbrev								
			<u>Im; FOBT= Faecal Occult Blood</u> nerican Joint Committee on Cano					
		l endoscopic microsurgery		ter, <b>KI</b> – Tauloulerapy, C <b>H</b>	<u>– chemomerapy, who</u>	<u>– wong ricaun Organ</u>	<u>izauoii,</u>	
<sup>a</sup> surger	y exclud	es endoscopic resection an	d colostomy					
		thin 24 hours from the onse						
<sup>c</sup> low re	<u>ctum: 4 1</u>	to 7.5 cm from the dentate	line [100]					
<b>.</b>								<b>Formatted:</b> English (I
							5	
			For peer review only	/ - http://bmjopen.bmj	.com/site/about/g	uidelines.xhtml		

REFERENCE LIST		<b>1:</b> Top: 0.98", Header distance from ", Footer distance from edge: 0.49"
1. Malin JL, Schneider EC, Epstein AM, et al. Results of the National Initiative for Cancer Care		<b>l:</b> Font: 12 pt, German d), Do not check spelling or
Quality: how can we improve the quality of cancer care in the United States? J Clin Oncol 2006;24(4):626-34 doi: JCO.2005.03.3365 [pii]		I: Font: 12 pt, Do not check spelling
10.1200/JCO.2005.03.3365[published Online First: Epub Date]].		e Changed
2. Schneider EC, Malin JL, Kahn KL, et al. Developing a system to assess the quality of cancer		I: Font: 12 pt, Bold, Do not check
care: ASCO's national initiative on cancer care quality. J Clin Oncol 2004;22(15):2985-91	spelling or	
doi: 10.1200/JCO.2004.09.087	Formattee	i[1]
22/15/2985 [pii][published Online First: Epub Date]].	Formattee	I [2]
3. Campbell SM, Roland MO, Buetow SA. Defining quality of care. Soc Sci Med	Formattee	<b>I</b> ( [3]
2000;51(11):1611-25 doi: S0277953600000575 [pii][published Online First: Epub Date]].	Formattee	<b>i</b> ( [4]
<u>4. Neuss MN, Desch CE, McNiff KK, et al. A process for measuring the quality of cancer care: the</u>	Formattee	
Quality Oncology Practice Initiative. J Clin Oncol 2005;23(25):6233-9 doi: JCO.2005.05.948	Formattee	
[pii] 10 1200/ICO 2005 05 049[hlinhed Online First Freeh Detail	Formattee	
<u>10.1200/JCO.2005.05.948[published Online First: Epub Date]].</u> 5. Duvalko KM, Sherar M, Sawka C. Creating a system for performance improvement in cancer	Formattee	
care: Cancer Care Ontario's clinical governance framework. Cancer Control 2009;16(4):293-	Formattee	
302	Formattee	
6. Mainz J, Hansen AM, Palshof T, et al. National quality measurement using clinical indicators:	Formattee	
the Danish National Indicator Project. J Surg Oncol 2009;99(8):500-4 doi:	Formattee	([11]
10.1002/jso.21192[published Online First: Epub Date]].	Formattee	[12]
7. Gagliardi AR, Simunovic M, Langer B, et al. Development of quality indicators for colorectal	Formattee	
cancer surgery, using a 3-step modified Delphi approach. Can J Surg 2005;48(6):441-52	Formattee	· · · · · · · · · · · · · · · · · · ·
8. Peppercorn JM, Weeks JC, Cook EF, et al. Comparison of outcomes in cancer patients treated	Formattee	([15]
within and outside clinical trials: conceptual framework and structured review. Lancet	Formatted	
2004; <b>363</b> (9405):263-70 doi: S0140-6736(03)15383-4 [pii]		
10.1016/S0140-6736(03)15383-4[published Online First: Epub Date]].	Formatter	([10]
9. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in	Formattee	( [19]
Europe in 2008. Eur J Cancer 2010; <b>46</b> (4):765-81 doi: S0959-8049(09)00926-5 [pii]	Formattee	( [20]
10.1016/j.ejca.2009.12.014[published Online First: Epub Date]]. 10. NICER. Secondary 2012. http://www.nicer.org.	Formattee	
11. Bordoni A, Lorez M, Bouchardy C, et al. Trends in colorectal cancer survival in Switzerland.	Formattee	[22]
Bulletin Suisse du Cancer 2012; <b>1/2012</b> :51-54	Formattee	[ [23]
12. Bouchardy C, Lutz JM, Kühni C, et al. <i>I tumori in Svizzera. Situazione e sviluppi dal 1983 al</i>	Formattee	[ [27]
2007, Neuchâtel: Ufficio Federale di Statistica (UFS), 2011.	Formattee	[ [23]
13. Sant M, Allemani C, Santaquilani M, et al. EUROCARE-4. Survival of cancer patients	Formattee	( [20]
diagnosed in 1995-1999. Results and commentary. Eur J Cancer 2009;45(6):931-91 doi:	Formattee	i [27]
<u>S0959-8049(08)00926-X [pii]</u>	Formattee	I [28]
10.1016/j.ejca.2008.11.018[published Online First: Epub Date]].	Formattee	<b>i</b> [29]
14. Desch CE, Benson AB, 3rd, Somerfield MR, et al. Colorectal cancer surveillance: 2005 update	Formattee	<b>i</b> ( [30]
of an American Society of Clinical Oncology practice guideline. J Clin Oncol	Formattee	<b>I</b> ( [31]
<u>2005;<b>23</b>(33):8512-9 doi: JCO.2005.04.0063 [pii]</u>	Formattee	<b>i</b> [32]
10.1200/JCO.2005.04.0063[published Online First: Epub Date]].	Formattee	<b>i</b> [33]
15. Desch CE, McNiff KK, Schneider EC, et al. American Society of Clinical Oncology/National	Formattee	i ( [34]
Comprehensive Cancer Network Quality Measures. J Clin Oncol 2008; <b>26</b> (21):3631-7 doi: 26/21/3631 [pii]	Formattee	
<u>10.1200/JCO.2008.16.5068[published Online First: Epub Date]].</u>	Formattee	
16. QOPI. Summary of the measures. Spring 2011. Secondary Summary of the measures. Spring	Formattee	
2011. 2011. http://qopi.asco.org/Methodology.	Formattee	
	Formattee	
1		([03]

## **BMJ Open**

17. Jacobsen PB, Shibata D, Siegel EM, et al. Measuring quality of care in the treatment of		
colorectal cancer: the moffitt quality practice initiative. J Oncol Pract 2007; <b>3</b> (2):60-5 doi:	Formatted	[4
10.1200/JOP.0722002[published Online First: Epub Date]].		
18. Malafa MP, Corman MM, Shibata D, et al. The Florida Initiative for Quality Cancer Care: a	Formatted	[4
regional project to measure and improve cancer care. Cancer Control 2009; <b>16</b> (4):318-27		
19. McGory ML, Shekelle PG, Ko CY. Development of quality indicators for patients undergoing	( <b>-</b>	
colorectal cancer surgery. J Natl Cancer Inst 2006; <b>98</b> (22):1623-33 doi: 98/22/1623 [pii]	Formatted	[42
10.1093/jnci/djj438[published Online First: Epub Date]].		
20. Siegel EM, Jacobsen PB, Malafa M, et al. Evaluating the quality of colorectal cancer care in the	Formatted	[43
state of Florida: results from the Florida Initiative for Quality Cancer Care. J Oncol Pract		
<u>2012;8(4):239-45 doi: 10.1200/JOP.2011.000477</u> 3774677 [pii][published Online First: Epub Date]].		
21. Donabedian A. Evaluating the quality of medical care. Milbank Q 1966; <b>83</b> :691-729		
	Formatted	[44
22. Fink A, Kosecoff J, Chassin M, et al. Consensus methods: characteristics and guidelines for use. Am J Public Health 1984;74(9):979-83	Formatted	[45
23. Jones J, Hunter D. Consensus methods for medical and health services research. BMJ		
<u>1995;<b>311</b>(7001):376-80</u> 24. Brook RH. The Rand/UCLA appropriateness method. In: McCormic KA, Moore SR, Siegel RA, eds.	Formatted	
<u>Clinical practice guideline development: methodology perspectives. Rockville, Md: Agency for Health</u>	Formatted	[47
Care Policy and Research, 1994:59-70.		
25. Krzyzanowska MK, Barbera L, Elit L, et al. Identifying population-level indicators to measure		
the quality of cancer care for women. Int J Qual Health Care 2011;23(5):554-64 doi: mzr043	Formatted	
[pii]	Formatted	[48
10.1093/intqhc/mzr043[published Online First: Epub Date]].		
26. Blind K, Cuhls K, Grupp H. Personal attitudes in the assessment of the future of science and		
technology: a facton analysis approach. Technological forecastning and social change,		
2001:131-49.		
27. Leape LL, Park RE, Kahan JP, et al. Group judgments of appropriateness: the effect of panel		
composition. Qual Assur Health Care 1992;4(2):151-9	Formatted	<b></b>
28. Campbell SM, Hann M, Roland MO, et al. The effect of panel membership and feedback on	Tormatteu	( [49
ratings in a two-round Delphi survey: results of a randomized controlled trial. Med Care		
1999: <b>37</b> (9):964-8	Formatted	[50
29. Coulter I, Adams A, Shekelle P. Impact of varying panel membership on ratings of	Tormatteu	( [50
appropriateness in consensus panels: a comparison of a multi- and single disciplinary panel.		
Health Serv Res 1995; <b>30</b> (4):577-91	Formatted	[51
30. Wollersheim H, Hermens R, Hulscher M, et al. Clinical indicators: development and		([5]
applications. Neth J Med 2007; <b>65</b> (1):15-22	Formatted	
31. Mainz J. Defining and classifying clinical indicators for quality improvement. Int J Qual Health		[52
Care 2003;15(6):523-30	Formatted	[53
32. Mainz J. Developing evidence-based clinical indicators: a state of the art methods primer. Int J	Tornaccu	( [5.
Qual Health Care 2003;15 Suppl 1:i5-11	Formatted	
33. Rubin HR, Pronovost P, Diette GB. From a process of care to a measure: the development and		[54
testing of a quality indicator. Int J Qual Health Care 2001; <b>13</b> (6):489-96	Formatted	
34. Wilkins T, Reynolds PL. Colorectal cancer: a summary of the evidence for screening and	Tornaccu	[5
prevention. Am Fam Physician 2008;78(12):1385-92	Formatted	[5
35. Sikka V, Ornato JP. Cancer diagnosis and outcomes in Michigan EDs vs other settings. Am J		( [5
Emerg Med 2011 doi: S0735-6757(10)00574-7 [pii]		
10.1016/j.ajem.2010.11.029[published Online First: Epub Date] .		
36. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection	Formatted	
of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American	I viniaticu	[5]
Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American		
curren boolety, the 05 whith boolety rask role on colorettal callett, and the American		
2		
2		

<u>College of Radiology. Gastroenterology 2008;<b>134</b>(5):1570-95 doi: S0016-5085(08)00232-1 [pii]</u>		Formatted: Font: 12 pt, Bol spelling or grammar	d, Do not che
10.1053/j.gastro.2008.02.002[published Online First: Epub Date]].	-	Formatted: Font: 12 pt, Do or grammar	not check sp
37. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003; <b>124</b> (2):544-		Formatted: Font: 12 pt, Bol	d, Do not ch
<u>60 doi: 10.1053/gast.2003.50044</u> S0016508502158951 [pii][published Online First: Epub Date]].	<u> </u>	Formatted: Font: 12 pt, Do or grammar	not check sp
38. Majumdar SR, Fletcher RH, Evans AT. How does colorectal cancer present? Symptoms, duration, and clues to location. Am J Gastroenterol 1999; <b>94</b> (10):3039-45 doi:	1	Formatted: Font: 12 pt, Bol spelling or grammar	d, Do not che
S0002927099005109 [pii]		Formatted: Font: 12 pt, Do or grammar	not check sp
<u>10.1111/j.1572-0241.1999.01454.x[published Online First: Epub Date]].</u> <u>39. Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with</u>	1	Formatted: Font: 12 pt, Bol	d, Do not che
screening flexible sigmoidoscopy. N Engl J Med 2012; <b>366</b> (25):2345-57 doi: 10.1056/NEJMoa1114635[published Online First: Epub Date]].	<i>.</i>	spelling or grammar Formatted: Font: 12 pt, Do	not check sp
40. Labianca R, Nordlinger B, Beretta GD, et al. Primary colon cancer: ESMO Clinical Practice	1	or grammar Formatted: Font: 12 pt, Ital	ian (Italy), D
<u>Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol 2010;21(suppl.</u> 5):v70-v77	<	check spelling or grammar Formatted: Font: 12 pt, Bol	d, Italian (Ita
<u>41. NCCN. Colon Cancer. 2.2011 ed: NCCN, 2011.</u> 42. Pfister DG, Benson AB, 3rd, Somerfield MR. Clinical practice. Surveillance strategies after		Do not check spelling or gran <b>Formatted:</b> Font: 12 pt, Ital	nmar
curative treatment of colorectal cancer. N Engl J Med 2004;350(23):2375-82 doi:	·	check spelling or grammar	
10.1056/NEJMcp010529 350/23/2375 [pii][published Online First: Epub Date]].		Formatted: Font: 12 pt, Do or grammar	not check sp
43. Li Destri G, Di Cataldo A, Puleo S. Colorectal cancer follow-up: useful or useless? Surg Oncol 2006;15(1):1-12 doi: S0960-7404(06)00025-9 [pii]		Formatted: Font: 12 pt, Bol spelling or grammar	d, Do not che
10.1016/j.suronc.2006.06.001[published Online First: Epub Date]].		Formatted: Font: 12 pt, Do or grammar	not check sp
<u>44. Campbell SM, Braspenning J, Hutchinson A, et al. Research methods used in developing and applying quality indicators in primary care. Qual Saf Health Care 2002;11(4):358-64</u>		Formatted: Font: 12 pt, Bol spelling or grammar	d, Do not che
45. Ayanian JZ, Landrum MB, Normand SL, et al. Rating the appropriateness of coronary angiographydo practicing physicians agree with an expert panel and with each other? N Engl		Formatted: Font: 12 pt, Do or grammar	not check sp
J Med 1998; <b>338</b> (26):1896-904 doi: 10.1056/NEJM199806253382608[published Online First:		Formatted: Font: 12 pt, Bol spelling or grammar	d, Do not che
Epub Date]]. 46. Sackett DL, Starus SE, Richardson WS, et al. <i>Evidence-Based Medicine: How to Practice and</i>		Formatted: Font: 12 pt, Do	not check sp
<u><i>Teach</i></u> , 2nd ed. London: Churchill Livingstone, 2000. 47. Qualità delle cure contro il cancro (QC3) nel territorio della Svizzera Italiana. Risultatai		or grammar Formatted: Font: 12 pt, Bol	d, Do not che
preliminari dei tumori colorettali incidenti nel 2011. XXXVII GRELL Annual Meeting; May		spelling or grammar	(.
<u>16-18, 2012 16-18 May 2012; Porto, Portugal.</u> 48. QoCC Study: indicators of quality of cancer care in Southern Switzerland. 33rd IACR Annual	111	Formatted	
Meeting; October 11-13, 2011; Balaclava, Mauritius.		Formatted	(.
49. Bordoni A, Spitale A, Mazzucchelli L, et al. <i>QC3: quality of comprehensive cancer care in</i>		Formatted	(.
Southern Switzerland. 34th IACR Annual Meeting. Cork, Ireland: IACR, 2012, 17-19		Formatted	(.
September.		Formatted	(.
50. Bordoni A, Spitale A, Mazzucchelli L, et al. Defining evidence-based clinical oncologic cares		Formatted	
guality indicators. ENCR Scientific Meeting, Cork, Ireland: ENCR, 2012, 19-20 September.		Formatted	
51. Bouchardy C, Rapiti E, Blagojevic S, et al. Older female cancer patients: importance, causes,		Formatted	
and consequences of undertreatment. J Clin Oncol 2007;25(14):1858-69 doi: 25/14/1858 [pii]	Ξ'n,	Formatted	(,
10.1200/JCO.2006.10.4208[published Online First: Epub Date]].	×2	Formatted	
52. Bouchardy C, Rapiti E, Fioretta G, et al. Undertreatment strongly decreases prognosis of breast	- N.		(.
cancer in elderly women. J Clin Oncol 2003;21(19):3580-7 doi: 10.1200/JCO.2003.02.046	S	Formatted	
JCO.2003.02.046 [pii][published Online First: Epub Date]].	1	Formatted	
53. van Gijn W, van de Velde CJ. 2010 SSO John Wayne clinical research lecture: rectal cancer	12	Formatted	
outcome improvements in Europe: population-based outcome registrations will conquer the		Formatted	(.
		Formatted	(.

world. Ann Surg Oncol 2011;18(3):691-6 doi: 10.1245/s10434-010-1326-3[published On	<b>Formatted:</b> Font: 12 pt, Bold, Do not spelling or grammar
First: Epub Date]].	
54. van Gijn W, van de Velde CJ. Improving quality of cancer care through surgical audit. Eur	J or grammar
Surg Oncol 2010; <b>36 Suppl 1</b> ;S23-6 doi: S0748-7983(10)00202-7 [pii]	Formatted: Font: 12 pt, Dutch (Neth
<u>10.1016/j.ejso.2010.06.026[published Online First: Epub Date] .</u>	Do not check spelling or grammar
55. Characteristics of clinical indicators. QRB Qual Rev Bull 1989;15(11):330-9	Formatted: Font: 12 pt, Do not check
56. Smith N, Brown G. Preoperative staging of rectal cancer. Acta Oncol 2008;47(1):20-31 doi 783360368 [pii]	
<u>10.1080/02841860701697720[published Online First: Epub Date] .</u>	<b>Formatted:</b> Font: 12 pt, Bold, Do not spelling or grammar
57. Schneider PM, Vallbohmer D, Ploenes Y, et al. Evaluation of quality indicators following	
<u>implementation of total mesorectal excision in primarily resected rectal cancer changed fu</u>	<b>Formatted:</b> Font: 12 pt, Do not check
management. Int J Colorectal Dis 2011;26(7):903-9 doi: 10.1007/s00384-011-1155-	Will Formatted
2[published Online First: Epub Date]].	Formatted
58. ACR. Practice Guidelines and Technical Standards. Secondary Practice Guidelines and	
Technical Standards 2011, http://www.acr.org/guidelines.	Formatted
59. Taylor FG, Quirke P, Heald RJ, et al. Preoperative High-resolution Magnetic Resonance	Formatted
Imaging Can Identify Good Prognosis Stage I, II, and III Rectal Cancer Best Managed by	Formatted
Surgery Alone: A Prospective, Multicenter, European Study That Recruited Consecutive	Formatted
Patients With Rectal Cancer. Ann Surg 2011 doi: 10.1097/SLA.0b013e31820b8d52[publi	ished
Online First: Epub Date].	Formatted
60. Beets-Tan RG, Beets GL. Local staging of rectal cancer: A review of imaging. J Magn Reso	on Formatted
Imaging 2011; <b>33</b> (5):1012-9 doi: 10.1002/jmri.22475[published Online First: Epub Date]].	
61. Bellows CF, Jaffe B, Bacigalupo L, et al. Clinical significance of magnetic resonance imagi	
findings in rectal cancer. World J Radiol 2011; <b>3</b> (4):92-104 doi:	Formatted
10.4329/wjr.v3.i4.92[published Online First: Epub Date]].	Formatted
62. Taylor FG, Quirke P, Heald RJ, et al. One millimetre is the safe cut-off for magnetic resona	
imaging prediction of surgical margin status in rectal cancer. Br J Surg 2011;98(6):872-79	
doi: 10.1002/bjs.7458[published Online First: Epub Date]].	
63. Lugli A, Tornillo L, Cathomas G, et al. Colon et rectum. In: Dirnhofer S, Bubendorf L, Leh	Pr H-
A, et al., eds. Recommandations pour la qualité - SSPath. Bâle: Sociéte Suisse de Patholog	
2011.	Formatted
64. Washington K, Berlin J, Branton P, et al. Protocol for the examination of specimens from	Formatted
patients with primary carcinoma of the colon and rectum. Vers. 3.1.0.0. In: Pathologists C	Formatted
ed. Cancer protocols and Checklists, 2011.	Formatted
65. MacDonald AJ, McEwan H, McCabe M, et al. Age at death of patients with colorectal canc	cer (
and the effect of lead-time bias on survival in elective vs emergency surgery. Colorectal I	Dis
2011; <b>13</b> (5):519-25 doi: CDI2183 [pii]	Formatted
10.1111/j.1463-1318.2009.02183.x[published Online First: Epub Date]].	Formatted
66. Ascanelli S, Navarra G, Tonini G, et al. Early and late outcome after surgery for colorectal	Formatted
cancer: elective versus emergency surgery. Tumori 2003;89(1):36-41	Formatted
67. Biondo S, Marti-Rague J, Kreisler E, et al. A prospective study of outcomes of emergency a	and
elective surgeries for complicated colonic cancer. Am J Surg 2005;189(4):377-83 doi: S00	
9610(05)00085-1 [pii]	Formatted
10.1016/j.amjsurg.2005.01.009[published Online First: Epub Date]].	Formatted
68. Thompson GA, Cocks JR, Collopy BT, et al. Clinical indicators in colorectal surgery. J Qua	
Clin Pract 1996;16(1):31-5; discussion 37	Formatteu
69. Morris EJ, Taylor EF, Thomas JD, et al. Thirty-day postoperative mortality after colorectal	Formatted
cancer surgery in England. Gut 2011; <b>60</b> (6):806-13 doi: gut.2010.232181 [pii]	Formatted
10.1136/gut.2010.232181[published Online First: Epub Date]].	Formatted
· · · · · · · · · · · · · · · · · · ·	Formatted
	Formatted
	Formatted

# BMJ Open

70. McArdle CS, McKee RF, Finlay IG, et al. Improvement in survival following surgery for colorectal cancer. Br J Surg 2005; <b>92</b> (8):1008-13 doi: 10.1002/bjs.4874[published Online	Formatted: F spelling or gra	Font: 12 pt, Bold, Do not chec Immar
First: Epub Date]].		Font: 12 pt, Do not check spel
71. Rutten HJ, den Dulk M, Lemmens VE, et al. Controversies of total mesorectal excision for	or grammar	
rectal cancer in elderly patients. Lancet Oncol 2008;9(5):494-501 doi: S1470-2045(08)70129-	Formatted: F spelling or gra	Font: 12 pt, Danish, Do not ch Immar
<u>3 [pii]</u> 10.1016/S1470-2045(08)70129-3[published Online First: Epub Date]].	Formatted: F	Font: 12 pt, Do not check spel
72. Rogers SO, Jr., Ayanian JZ, Ko CY, et al. Surgeons' volume of colorectal cancer procedures and collaborative decision-making about adjuvant therapies. Ann Surg 2009; <b>250</b> (6):895-900 doi:		Font: 12 pt, Bold, Do not chec
10.1097/SLA.0b013e3181afe0c6[published Online First: Epub Date]].		Font: 12 pt, Do not check spel
73. Kurtz JE, Heitz D, Serra S, et al. Adjuvant chemotherapy in elderly patients with colorectal	or grammar	
cancer. A retrospective analysis of the implementation of tumor board recommendations in a single institution. Crit Rev Oncol Hematol 2010;74(3):211-7 doi: S1040-8428(09)00120-6		Font: 12 pt, French (France), I lling or grammar
	Formatted: F or grammar	Font: 12 pt, Do not check spel
10.1016/j.critrevonc.2009.05.003[published Online First: Epub Date]]. 74. Jarry J, Faucheron JL, Moreno W, et al. Delayed colo-anal anastomosis is an alternative to		Font: 12 pt, Bold, Do not chec
prophylactic diverting stoma after total mesorectal excision for middle and low rectal	spelling or gra	
carcinomas. Eur J Surg Oncol 2010;37(2):127-33 doi: S0748-7983(10)00607-4 [pii]	or grammar	Font: 12 pt, Do not check spel
10.1016/j.ejso.2010.12.008[published Online First: Epub Date]]. 75. Junginger T, Gonner U, Trinh TT, et al. Permanent stoma after low anterior resection for rectal		Font: 12 pt, Dutch (Netherland spelling or grammar
cancer. Dis Colon Rectum 2010; <b>53</b> (12):1632-9 doi: 10.1007/DCR.0b013e3181ed0aae	Formatted	· · · ·
00003453-201012000-00007 [pii][published Online First: Epub Date]].	Formatted	([
76. Neuman HB, Patil S, Fuzesi S, et al. Impact of a Temporary Stoma on the Quality of Life of	Formatted	
Rectal Cancer Patients Undergoing Treatment. Ann Surg Oncol 2010 doi: 10.1245/s10434-	Formatted	
010-1446-9[published Online First: Epub Date]].	Formatted	
77. Ramirez JM, Aguilella V, Valencia J, et al. Transanal endoscopic microsurgery for rectal	Formatted	()
cancer. Long-term oncologic results. Int J Colorectal Dis 2011 doi: 10.1007/s00384-011-		
1132-9[published Online First: Epub Date]].	Formatted	()
78. Lezoche G, Guerrieri M, Baldarelli M, et al. Transanal endoscopic microsurgery for 135	Formatted	
patients with small nonadvanced low rectal cancer (iT1-iT2, iN0): short- and long-term	<b>Formatted</b>	
results. Surg Endosc 2010 doi: 10.1007/s00464-010-1347-9[published Online First: Epub	Formatted	
Date]].	Formatted	
79. Doornebosch PG, Tollenaar RA, De Graaf EJ. Is the increasing role of Transanal Endoscopic	Formatted	
Microsurgery in curation for T1 rectal cancer justified? A systematic review. Acta Oncol	Formatted	
<u>2009;<b>48</b>(3):343-53 doi: 904089695 [pii]</u>	Formatted	(
10.1080/02841860802342408[published Online First: Epub Date]].	Formatted	
80. Elferink MA, Siesling S, Lemmens VE, et al. Variation in Lymph Node Evaluation in Rectal Cancer: A Dutch Nationwide Population-Based Study. Ann Surg Oncol 2010 doi:	Formatted	
10.1245/s10434-010-1269-8[published Online First: Epub Date]].	Formatted	(
81. Elferink MA, Siesling S, Visser O, et al. Large variation between hospitals and pathology	Formatted	
laboratories in lymph node evaluation in colon cancer and its impact on survival, a nationwide	Formatted	(
population-based study in the Netherlands. Ann Oncol 2011; <b>22</b> (1):110-7 doi: mdq312 [pii]	Formatted	 
10.1093/annonc/mdq312[published Online First: Epub Date]].	Formatted	
32. Kelder W, Inberg B, Schaapveld M, et al. Impact of the number of histologically examined	Formatted	
lymph nodes on prognosis in colon cancer: a population-based study in the Netherlands. Dis		
Colon Rectum 2009; <b>52</b> (2):260-7 doi: 10.1007/DCR.0b013e3181979164	Formatted	
00003453-200902000-00013 [pii][published Online First: Epub Date]].	Formatted	
83. Vather R, Sammour T, Kahokehr A, et al. Lymph node evaluation and long-term survival in	Formatted	
Stage II and Stage III colon cancer: a national study. Ann Surg Oncol 2009; <b>16</b> (3):585-93 doi:	Formatted	
10.1245/s10434-008-0265-8[published Online First: Epub Date]].	Formatted	
	Formatted	[]
	Formatted	[]

84. Lindebjerg J, Spindler KL, Ploen J, et al. The prognostic value of lymph node metastases and		ont: 12 pt, Danish, Do not che
tumour regression grade in rectal cancer patients treated with long-course preoperative	spelling or gram	ımar
chemoradiotherapy. Colorectal Dis 2009;11(3):264-9 doi: CDI1599 [pii]		ont: 12 pt, Do not check spelli
10.1111/j.1463-1318.2008.01599.x[published Online First: Epub Date]].	or grammar	
85. Choi HK, Law WL, Poon JT. The optimal number of lymph nodes examined in stage II	spelling or gram	ont: 12 pt, Bold, Do not check
colorectal cancer and its impact of on outcomes. BMC Cancer 2010;10:267 doi: 1471-2407-	Formatted	
<u>10-267 [pii]</u>		[1
10.1186/1471-2407-10-267[published Online First: Epub Date]].	Formatted	[1
86. Nelson H, Petrelli N, Carlin A, et al. Guidelines 2000 for colon and rectal cancer surgery. J Natl	Formatted	( [1
Cancer Inst 2001; <b>93</b> (8):583-96	Formatted	[ [1
87. Smith AJ, Driman DK, Spithoff K, et al. Guideline for optimization of colorectal cancer surgery	Formatted	[
and pathology. J Surg Oncol 2010;101(1):5-12 doi: 10.1002/jso.21395[published Online First:	Formatted	[[
Epub Date]].	Formatted	 [ [
88. Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and	Formatted	
leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin		[[
Oncol 2009; <b>27</b> (19):3109-16 doi: JCO.2008.20.6771 [pii]	Formatted	[[
10.1200/JCO.2008.20.6771[published Online First: Epub Date]].	Formatted	[ [
89. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon	Formatted	[
cancer. N Engl J Med 2005;352(26):2696-704 doi: 352/26/2696 [pii]	Formatted	
10.1056/NEJMoa043116[published Online First: Epub Date]].	Formatted	
90. Van Cutsem E, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly	Formatted	
infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage	Formatted	
III colon cancer: PETACC-3. J Clin Oncol 2009;27(19):3117-25 doi: JCO.2008.21.6663 [pii]	Formatted	 
10.1200/JCO.2008.21.6663[published Online First: Epub Date]	Formatted	
91. Sobrero A. Lower GI. In: ESMO, ed. ESMO HIghlights 2010, 2010.	Formatted	(
92. Des Guetz G, Nicolas P, Perret GY, et al. Does delaying adjuvant chemotherapy after curative		()
surgery for colorectal cancer impair survival? A meta-analysis. Eur J Cancer	Formatted	
<u>2010;46(6):1049-55 doi: S0959-8049(10)00039-0 [pii]</u>	Formatted	
10.1016/j.ejca.2010.01.020[published Online First: Epub Date]].	Formatted	
93. Dienstmann R, Vilar E, Tabernero J. Molecular predictors of response to chemotherapy in	Formatted	( )
colorectal cancer. Cancer J 2011;17(2):114-26 doi: 10.1097/PPO.0b013e318212f844	Formatted	
00130404-201103000-00007 [pii][published Online First: Epub Date]].	Formatted	
94. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for	Formatted	
metastatic colorectal cancer. N Engl J Med 2009;360(14):1408-17 doi: 360/14/1408 [pii]	Formatted	()
10.1056/NEJMoa0805019[published Online First: Epub Date]].	Formatted	
95. Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and BRAF	Formatted	
mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin		(]
<u>Oncol 2011;<b>29</b>(10):1261-70 doi: JCO.2010.30.1366 [pii]</u>	Formatted	[]
10.1200/JCO.2010.30.1366[published Online First: Epub Date]].	Formatted	
96. Van Cutsem E, Nordlinger B, Cervantes A. Advanced colorectal cancer: ESMO Clinical	Formatted	(
Practice Guidelines for treatment. Ann Oncol 2010;21(suppl. 5):v93-v97	Formatted	
97. Glimelius B, Holm T, Blomqvist L. Chemotherapy in addition to preoperative radiotherapy in	Formatted	
locally advanced rectal cancer - a systematic overview. Rev Recent Clin Trials 2008;3(3):204-	Formatted	
<u>11</u>	/// Formatted	
98. Glimelius B, Pahlman L, Cervantes A. Rectal cancer: ESMO Clinical Practice Guidelines for	W / Formatted	
diagnosis, treatment and follow-up. Ann Oncol 2010;21(suppl. 5):v82-v86	Formatted	
99. Landheer ML, Therasse P, van de Velde CJ. The importance of quality assurance in surgical	Formatted	(
oncology in the treatment of colorectal cancer. Surg Oncol Clin N Am 2001;10(4):885-914, x		<u> </u>
100. Wagner G. Tumor-Lokalisationsschlüssel. International Classification of Diseases for	Formatted	()
Oncology ICD-O, 2. Topographischer Teil, 5th ed. Berlin: Springer-Verlag, 1993.	Formatted	
	Formatted	[

Page 67 o	f 79 4/30/2013 3:52:00 PM	BMJ Open
1	4/30/2013 3:52:00 PM	
ngar		
4	4/30/2013 3:52:00 PM	
5		
6 7	4/30/2013 2:46:00 PM	
8		
<u>9</u> 10	4/30/2013 2:46:00 PM	
11	.,,	
12	4/30/2013 2:46:00 PM	
	4/30/2013 2.40.00 PM	
14	4/20/2012 2:46:00 PM	
16	4/30/2013 2:46:00 PM	
17 18		
18 19	4/30/2013 2:46:00 PM	
20		
21 22	4/30/2013 2:46:00 PM	
23		
24		
25 26		
27		
28		
29 30		
31		
32		
33 34		
35		
36 27		
37 38		
39		
40		
41 42		
43		
44 45		
45 46		
47		
48 40		
49 50		
51		
52 53		
53 54		
55		
56 57		
57 58		
50		

4/30/2013	2:46:00 PM

4	4/30/2013 2:46:00 PM
1 2	
3	4/30/2013 2:46:00 PM
4	
5 6	4/30/2013 2:46:00 PM
6 7	
8	4/20/2012 2-46 00 211
9	4/30/2013 2:46:00 PM
10 11	
12	4/30/2013 2:46:00 PM
13	
14 15	4/30/2013 2:46:00 PM
16	
17	4/30/2013 2:46:00 PM
18	
19 20	4/30/2013 2:46:00 PM
21	4/30/2013 2:46:00 PM 4/30/2013 2:46:00 PM
22	
23 24	
25	
26	
27 28	
28 29	
30	
31	
32 33	
34	
35	
36	
37 38	
39	
40	
41 42	
42	
44	
45	
46 47	
48	
49	
50 51	
51 52	
53	
54	
55 56	
57	
58	
59 60	
00	

nmar Page 69 of 79 4/30/2013 3:52:00 PM

	4/30/2013 3.32.00 PM
nmar	
1	4/30/2013 3:52:00 PM
2 3	
3	4/30/2013 3:52:00 PM
5	.,,
6	4/20/2012 2.52.00 81
7 8	4/30/2013 3:52:00 PM
9	
10	4/30/2013 2:46:00 PM
11 12	
12	4/30/2013 2:46:00 PM
14	
15	4/30/2013 2:46:00 PM
<del>16</del> 17	
18	4/30/2013 2:46:00 PM
19	7/30/2013 2.40.00 PM
20 21	
21	4/30/2013 2:46:00 PM
23	
24 25	
25 26	
27	
28	
29 30	
31	
32	
33 34	
34 35	
36	
37	
38 39	
40	
41	
42 43	
43 44	
45	
46	
47 48	
40	
50	
51	
52 53	
54	
55	
56	
57 59	

4/30/2013	2:46:00 PM

1	4/30/2013 2:46:00 PM
2	
3	4/30/2013 2:46:00 PM
4	
5 6	4/30/2013 2:46:00 PM
7	
8	4/30/2013 2:46:00 PM
9	7/ JU/ 2013 2:40:00 FM
10 11	
12	4/30/2013 2:46:00 PM
13	
14	4/30/2013 2:46:00 PM
15 16	
17	4/30/2013 2:46:00 PM
18	
19	A /20 /2012 2.46 00 PM
20 21	4/30/2013 2:46:00 PM
21	4/30/2013 2:46:00 PM 4/30/2013 2:46:00 PM
23	
24	
25 26	
20 27	
28	
29	
30 31	
32	
33	
34	
35	
36 37	
38	
39	
40	
41 42	
43	
44	
45	
46 47	
48	
49	
50	
51 52	
52	
54	
55	
56 57	
58	
59	
60	

Page 71 of 79 4/30/2013 2:46:00 PM	BMJ Open
1 4/30/2013 2:46:00 PM	
2 3	
4 4/30/2013 2:46:00 PM	
5	
6 7 <b>4/30/2013 2:46:00 PM</b>	
8	
9 10 <b>4/30/2013 3:52:00 PM</b>	
10 4/30/2013 3:52:00 PM	
12	
12 4/30/2013 3:52:00 PM	
14 15	
4/30/2013 2:46:00 PM	
17	
18 <b>4/30/2013 3:52:00 PM</b> 19	
20	
21 4/30/2013 2:46:00 PM	
22 23	
23	
25	
26	
27 28	
29	
30	
31	
32 33	
34	
35	
36 37	
38	
39	
40 41	
41 42	
43	
44	
45 46	
47	
48	
49 50	
51	
52	
53 54	
55	
56	
57	
58 59	
60	

4/30/2013	2:46:00 PM

	4/30/2013 2:46:00 PM	
1		
2	4/20/2012 2.46-00 PM	
3	4/30/2013 2:46:00 PM	
4 5		
5 6	4/30/2013 2:46:00 PM	
7		
8		
9	4/30/2013 2:46:00 PM	
10		
11	4/30/2013 2:46:00 PM	
12		
13		
14 15	4/30/2013 2:46:00 PM	
15 16		
17	4/30/2013 2:46:00 PM	
18	1/00/2010 21TUIOU FI'I	
19		
20	4/30/2013 2:46:00 PM	
21		
22		
23		
24 25		
25 26		
26 27		
28		
29		
30		
31		
32		
33		
34		
35 36		
36 37		
37 38		
39		
40		
41		
42		
43		
44 45		
45 46		
40 47		
48		
49		
50		
51		
52		
53		
54		
55 50		
56 57		
57 58		
58 59		
60		
00		

Page 73 of 79 4/30/2013 2:46:00 PM	BMJ Open
<sup>1</sup> 4/30/2013 3:52:00 PM	
2	
3 4 <b>4/30/2013 3:52:00 PM</b>	
5	
6	
7 4/30/2013 2:46:00 PM 8	
9	
10 4/30/2013 2:46:00 PM	
11 12	
13 4/30/2013 2:46:00 PM	
14	
15 4/30/2013 3:52:00 PM	
17	
<sup>18</sup> 4/30/2013 2:46:00 PM	
19 20	
20 21 <b>4/30/2013 3:52:00 PM</b>	
22	
23 24	
25	
26	
27	
28 29	
30	
31	
32 33	
34	
35	
36 37	
38	
39	
40 41	
42	
43	
44 45	
46	
47	
48 49	
50	
51	
52 53	
54	
55	
56 57	
58	
59	
60	

4/30/2013	2:46:00 PM

1	4/30/2013 2:46:00 PM
2	
3	4/30/2013 2:46:00 PM
4	
5 6	4/30/2013 2:46:00 PM
7	
8	4/30/2013 3:52:00 PM
9	4/ JU/ 2013 3:32:00 PM
10	
11 12	4/30/2013 2:46:00 PM
13	
14	4/30/2013 2:46:00 PM
15 16	
16	4/30/2013 2:46:00 PM
18	
19	
20	4/30/2013 2:46:00 PM
21 22	4/30/2013 2:46:00 PM 4/30/2013 2:46:00 PM
23	
24	
25	
26 27	
28	
29	
30	
31 32	
33	
34	
35	
36 27	
37 38	
39	
40	
41 42	
42 43	
44	
45	
46	
47 48	
49	
50	
51	
52 53	
53 54	
55	
56	
57 58	
59	
60	
00	

Page 75 of 79 4/30/201	3 3:52:00 PM	BMJ Open
1 4/30/201 2	3 2:46:00 PM	
3		
4 4/30/201 5	3 2:46:00 PM	
6		
	3 2:46:00 PM	
8 9		
10 <b>4/30/201</b>	3 3:52:00 PM	
måf 12		
<u>13</u> 4/30/201	3 2:46:00 PM	
14 15		
15 <b>4/30/201</b>	3 2:46:00 PM	
17		
18 <b>4/30/201</b> 19	3 2:46:00 PM	
20		
21 <b>4/30/201</b> 22	3 2:46:00 PM	
22		
24		
25 26		
27		
28 29		
30		
31		
32 33		
34		
35 36		
37		
38		
39 40		
41		
42 43		
44		
45 46		
40 47		
48		
49 50		
51		
52 53		
54		
55 56		
56 57		
58		
59 60		
00		

4/30/2013 2:46	:00 PM

	4/30/2013 2:46:00 PM
1	
2	
3	4/30/2013 3:52:00 PM
4	
5	4/30/2013 2:46:00 PM
6 7	4/50/2010 2000 111
8	
9	4/30/2013 2:46:00 PM
10	
11	4/20/2012 2:46:00 DM
12	4/30/2013 2:46:00 PM
13	
14	4/30/2013 3:52:00 PM
15	
16	
17 18	4/30/2013 2:46:00 PM
18 19	
20	4/30/2013 2:46:00 PM
21	
22	
23	
24	
25	
26	
27	
28	
29 20	
30 31	
32	
33	
34	
35	
36	
37	
38	
39 40	
40 41	
41	
43	
44	
45	
46	
47	
48	
49 50	
50 51	
52	
53	
54	
55	
56	
57	
58	
59 60	

Page 77 of	79 4/30/2013 2:46:00 PM	BMJ Open
1	4/30/2013 2:46:00 PM	
2	4/30/2013 2:40:00 PM	
3	4/20/2012 2.52.00 DM	
	4/30/2013 3:52:00 PM	
mar 7	4/20/2012 2-52-00 PM	
	4/30/2013 3:52:00 PM	
g <sup>9</sup> ammar	4/20/2012 2-52-00 PM	
<u>10</u> måf	4/30/2013 3:52:00 PM	
12		
13	4/30/2013 2:46:00 PM	
14 15		
16	4/30/2013 3:52:00 PM	
nnpar 19		
18 19	4/30/2013 3:52:00 PM	
or <sub>2</sub> grammar		
21 22	4/30/2013 3:52:00 PM	
23		
24		
25 26		
27		
28		
29 30		
31		
32 33		
34		
35		
36 37		
38		
39 40		
40		
41 42		
43 44		
45		
46 47		
48		
49		
50 51		
52		
53 54		
54 55		
56 57		
57		

